[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 100 of about 4185
1. Ng WF, Miller A, Bowman SJ, Price EJ, Kitas GD, Pease C, Emery P, Lanyon P, Hunter J, Gupta M, Giles I, Isenberg D, McLaren J, Regan M, Cooper A, Young-Min SA, McHugh N, Vadivelu S, Moots RJ, Coady D, MacKay K, Dasgupta B, Sutcliffe N, Bombardieri M, Pitzalis C, Griffiths B, Mitchell S, Miyamoto ST, Trenell M, UK Primary Sjögren’s Syndrome Registry: Physical activity but not sedentary activity is reduced in primary Sjögren's syndrome. Rheumatol Int; 2017 Apr;37(4):623-631
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • To this cross-sectional study, self-reported levels of physical activity from 273 PSS patients were measured using the International Physical Activity Questionnaire-short form (IPAQ-SF) and were compared with healthy controls matched for age, sex and body mass index.
  • Clinical care teams should explore the clinical utility of targeting low levels of physical activity in PSS.

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Ann Rheum Dis. 2012 Dec;71(12 ):1973-9 [22562982.001]
  • [Cites] Brain Behav Immun. 2011 Oct;25(7):1482-90 [21693185.001]
  • [Cites] Sleep. 1991 Dec;14(6):540-5 [1798888.001]
  • [Cites] Med Sci Sports Exerc. 2007 Aug;39(8):1423-34 [17762377.001]
  • [Cites] Ann Rheum Dis. 2014 Jul;73(7):1362-8 [23761688.001]
  • [Cites] Ann Rheum Dis. 2002 Jun;61(6):554-8 [12006334.001]
  • [Cites] Health Qual Life Outcomes. 2009 May 27;7:46 [19473510.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2011 Jan;20(1):123-33 [21051654.001]
  • [Cites] J Rheumatol. 2003 Nov;30(11):2406-12 [14677185.001]
  • [Cites] Rheumatology (Oxford). 2011 Jan;50(1):32-9 [20693261.001]
  • [Cites] Arthritis Rheum. 2007 Aug 15;57(6):943-52 [17665488.001]
  • [Cites] Rheumatology (Oxford). 2004 Jun;43(6):758-64 [15039495.001]
  • [Cites] Int J Crit Illn Inj Sci. 2011 Jul;1(2):104-9 [22229132.001]
  • [Cites] Acta Psychiatr Scand. 1983 Jun;67(6):361-70 [6880820.001]
  • [Cites] Sports Med. 2010 Jul 1;40(7):565-600 [20545381.001]
  • [Cites] Rheumatology (Oxford). 2012 Feb;51(2):262-9 [21705778.001]
  • [Cites] Ann Rheum Dis. 2010 Jun;69(6):1103-9 [19561361.001]
  • [Cites] Am J Prev Med. 2008 Jun;34(6):486-94 [18471584.001]
  • [Cites] Acta Neurol Scand. 2012 Apr;125(4):272-8 [21651503.001]
  • [Cites] Health Policy. 1990 Dec;16(3):199-208 [10109801.001]
  • [Cites] Mayo Clin Proc. 2005 Mar;80(3):330-4 [15757013.001]
  • [Cites] Ann Rheum Dis. 2011 Jun;70(6):968-72 [21345815.001]
  • [Cites] Ann Rheum Dis. 2012 May;71(5):668-73 [22121127.001]
  • [Cites] Int J Obes (Lond). 2007 Apr;31(4):663-8 [16953254.001]
  • [Cites] Int J Behav Nutr Phys Act. 2009 Mar 31;6:21 [19335883.001]
  • [Cites] J Clin Nurs. 2010 Nov;19(21-22):3006-15 [21040007.001]
  • [Cites] Med Sci Sports Exerc. 2007 Sep;39(9):1502-8 [17805081.001]
  • [Cites] Rheumatology (Oxford). 2010 Jun;49(6):1177-83 [20308122.001]
  • [Cites] Qual Life Res. 2014 Dec;23(10):2673-80 [24952110.001]
  • [Cites] Neurology. 1999 Feb;52(3):523-8 [10025781.001]
  • [Cites] Diabetes Care. 2008 Apr;31(4):661-6 [18252901.001]
  • [Cites] Sleep Med. 2012 Sep;13(8):1066-70 [22841036.001]
  • [Cites] Arthritis Rheum. 2003 Oct 15;49(5):681-8 [14558054.001]
  • [Cites] Diabetes Care. 2008 Feb;31(2):369-71 [18000181.001]
  • [Cites] JAMA. 1995 Feb 1;273(5):402-7 [7823386.001]
  • [Cites] BMC Public Health. 2012 Aug 07;12:624 [22871153.001]
  • [Cites] Med Sci Sports Exerc. 2003 Aug;35(8):1381-95 [12900694.001]
  • [Cites] Arthritis Care Res (Hoboken). 2012 Nov;64(11):1760-4 [23111856.001]
  • [Cites] Rheumatology (Oxford). 2007 May;46(5):868-71 [17308315.001]
  • [Cites] CMAJ. 2006 Mar 14;174(6):801-9 [16534088.001]
  • [Cites] Scand J Med Sci Sports. 2009 Jun;19(3):300-12 [19895380.001]
  • (PMID = 28013357.001).
  • [ISSN] 1437-160X
  • [Journal-full-title] Rheumatology international
  • [ISO-abbreviation] Rheumatol. Int.
  • [Language] eng
  • [Grant] United Kingdom / Alzheimer's Society / / 189; United Kingdom / Department of Health / / SRF-2011-04-017; United Kingdom / Medical Research Council / / G0700718; United Kingdom / Medical Research Council / / G0800629; United Kingdom / Medical Research Council / / MR/L016354/1
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  • [Keywords] NOTNLM ; Fatigue / Patient registry / Patient-reported outcomes / Physical activity / Primary Sjögren’s syndrome
  • [Investigator] Hall F; Bacabac EC; Moots R; Chakravarty K; Lamabadusuriya S; Bombardieri M; Pitzalis C; Sutcliffe N; Gendi N; Adeniba R; Hamburger J; Richards A; Rauz S; Brailsford S; Logan J; Mulherin D; Andrews J; Emery P; McManus A; Pease C; Booth A; Regan M; Dimitroulas T; Kadiki L; Kaur D; Kitas G; Lloyd M; Moore L; Gordon E; Lawson C; Gupta M; Hunter J; Stirton L; Ortiz G; Price E; Clunie G; Rose G; Cuckow S; Knight S; Symmons D; Jones B; Al-Ali S; Carr A; Collins K; Corbett I; Downie C; Edgar S; Carrozzo M; Figuereido F; Foggo H; James K; Lendrem D; Macleod I; Mawson P; Mitchell S; Natasari A; Stocks P; Tarn J; Jones A; Lanyon P; Muir A; White P; Young-Min S; Pugmire S; Vadivelu S; Cooper A; Watkins M; Field A; Kaye S; Mewar D; Medcalf P; Tomlinson P; Whiteside D; McHugh N; Pauling J; James J; Olaitan N; Akil M; McDermott J; Godia O; Coady D; Kidd E; Palmer L; Dasgupta B; Katsande V; Long P; Li C; Chandra U; MacKay K; Fedele S; Ferenkeh-Koroma A; Giles I; Isenberg D; Maconnell H; Porter S; Allcoat P; McLaren J
  •  go-up   go-down


2. Foldager CB, Bendtsen M, Berg LC, Brinchmann JE, Brittberg M, Bunger C, Canseco J, Chen L, Christensen BB, Colombier P, Deleuran BW, Edwards J, Elmengaard B, Farr J, Gatenholm B, Gomoll AH, Hui JH, Jakobsen RB, Joergensen NL, Kassem M, Koch T, Kold S, Krogsgaard MR, Lauridsen H, Le D, Le Visage C, Lind M, Nygaard JV, Olesen ML, Pedersen M, Rathcke M, Richardson JB, Roberts S, Rölfing JH, Sakai D, Toh WS, Urban J, Spector M: Aarhus Regenerative Orthopaedics Symposium (AROS). Acta Orthop; 2016 Dec;87(sup363):1-5
MedlinePlus Health Information. consumer health - Seniors' Health.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • In this position paper, we review our contemporary understanding of societal, patient-related, and basic science-related challenges in order to provide a reasoned roadmap for the future to deal with this compelling and urgent healthcare problem.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Health Technol Assess. 2005 Dec;9(47):iii-iv, ix-x, 1-82 [16336842.001]
  • [Cites] Biomed Mater. 2016 Feb 02;11(1):014110 [26836246.001]
  • [Cites] Eur J Trauma Emerg Surg. 2017 Feb;43(1):113-119 [26260068.001]
  • [Cites] Science. 1965 Nov 12;150(3698):893-9 [5319761.001]
  • [Cites] China Economic J. 2012;5(2-3):131-149 [24443653.001]
  • [Cites] Tissue Eng Part B Rev. 2008 Jun;14(2):179-86 [18544015.001]
  • [Cites] J Clin Invest. 2001 Jan;107(1):35-44 [11134178.001]
  • [Cites] Circulation. 1999 Jan 19;99(2):237-42 [9892589.001]
  • [Cites] Am J Sports Med. 2010 Jun;38(6):1110-6 [20392971.001]
  • [Cites] Stem Cell Rev. 2014 Oct;10(5):686-96 [24869958.001]
  • [Cites] N Engl J Med. 1994 Oct 6;331(14):889-95 [8078550.001]
  • [Cites] Clin Orthop Relat Res. 2004 Aug;(425):2-3 [15292781.001]
  • [Cites] Arthroscopy. 2013 Dec;29(12):2020-8 [24286801.001]
  • [Cites] Neurobiol Aging. 1999 Mar-Apr;20(2):105-10 [10537019.001]
  • [Cites] Science. 1988 Dec 16;242(4885):1528-34 [3201241.001]
  • [Cites] Biomed Res Int. 2014;2014:921905 [25143954.001]
  • [Cites] Spine (Phila Pa 1976). 2011 Mar 15;36(6):E373-9 [21372649.001]
  • [Cites] Am J Geriatr Pharmacother. 2007 Dec;5(4):345-51 [18179993.001]
  • [Cites] Nat Neurosci. 2006 Jun;9(6):715-7 [16732197.001]
  • [Cites] Am J Public Health. 2008 Jul;98(7):1198-200 [18511722.001]
  • [Cites] Med Care. 1992 Jul;30(7):646-58 [1614233.001]
  • [Cites] Cartilage. 2015 Jul;6(3):166-73 [26175862.001]
  • [Cites] Cartilage. 2010 Oct;1(4):312-9 [26069562.001]
  • [Cites] Am J Sports Med. 2009 Nov;37 Suppl 1:167S-76S [19861696.001]
  • [Cites] J Orthop Sci. 2006 May;11(3):318-25 [16721538.001]
  • [Cites] Arthritis Rheum. 1988 Apr;31(4):561-5 [3358814.001]
  • [Cites] J Biol Chem. 1989 Aug 15;264(23):13377-80 [2547759.001]
  • [Cites] Soc Sci Med. 2005 Feb;60(4):833-43 [15571900.001]
  • [Cites] Osteoarthritis Cartilage. 2007 Sep;15(9):1061-9 [17470400.001]
  • [Cites] Cartilage. 2016 Apr;7(2):140-8 [27047636.001]
  • (PMID = 28271925.001).
  • [ISSN] 1745-3682
  • [Journal-full-title] Acta orthopaedica
  • [ISO-abbreviation] Acta Orthop
  • [Language] eng
  • [Grant] United Kingdom / Arthritis Research UK / / 20631
  • [Publication-type] Congresses
  • [Publication-country] England
  •  go-up   go-down


3. Bonsang-Kitzis H, Mouttet-Boizat D, Guillot E, Feron JG, Fourchotte V, Alran S, Pierga JY, Cottu P, Lerebours F, Stevens D, Vincent-Salomon A, Sigal-Zafrani B, Campana F, Rouzier R, Reyal F: Medico-economic impact of MSKCC non-sentinel node prediction nomogram for ER-positive HER2-negative breast cancers. PLoS One; 2017;12(2):e0169962
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • PURPOSE: The aim of this study is to simulate the medico-economic impact of the routine use of the MSKCC non-sentinel node (NSN) prediction nomogram for ER+ HER2- breast cancer patients.
  • METHODS: We studied 1036 ER+ HER2- breast cancer patients with a metastatic SNB.
  • For each patient, we calculated the probability of the NSN positivity using the MSKCC nomogram.
  • After validation of this nomogram in the population, we described how the patients' characteristics spread as the threshold value changed.
  • Then, we performed an economic simulation study to estimate the total cost of caring for patients treated according to the MSKCC predictive nomogram results.
  • RESULTS: A 0.3 threshold discriminate the type of sentinel node (SN) metastases: 98.8% of patients with pN0(i+) and 91.6% of patients with pN1(mic) had a MSKCC score under 0.3 (false negative rate = 6.4%).
  • If we use the 0.3 threshold for economic simulation, 43% of ALND could be avoided, reducing the costs of caring by 1 051 980 EUROS among the 1036 patients.
  • CONCLUSION: We demonstrated the cost-effectiveness of using the MSKCC NSN prediction nomogram by avoiding ALND for the pN0(i+) or pN1(mic) ER+ HER2- breast cancer patients with a MSKCC score of less than or equal to 0.3.

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 28241044.001).
  • [ISSN] 1932-6203
  • [Journal-full-title] PloS one
  • [ISO-abbreviation] PLoS ONE
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


Advertisement
4. Gramatzki D, Kickingereder P, Hentschel B, Felsberg J, Herrlinger U, Schackert G, Tonn JC, Westphal M, Sabel M, Schlegel U, Wick W, Pietsch T, Reifenberger G, Loeffler M, Bendszus M, Weller M: Limited role for extended maintenance temozolomide for newly diagnosed glioblastoma. Neurology; 2017 Apr 11;88(15):1422-1430

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • OBJECTIVE: To explore an association with survival of modifying the current standard of care for patients with newly diagnosed glioblastoma of surgery followed by radiotherapy plus concurrent and 6 cycles of maintenance temozolomide chemotherapy (TMZ/RT → TMZ) by extending TMZ beyond 6 cycles.
  • METHODS: The German Glioma Network cohort was screened for patients with newly diagnosed glioblastoma who received TMZ/RT → TMZ and completed ≥6 cycles of maintenance chemotherapy without progression.
  • Associations of clinical patient characteristics, molecular markers, and residual tumor determined by magnetic resonance imaging after 6 cycles of TMZ with progression-free survival (PFS) and overall survival (OS) were analyzed with the log-rank test.
  • RESULTS: Sixty-one of 142 identified patients received at least 7 maintenance TMZ cycles (median 11, range 7-20).
  • Patients with extended maintenance TMZ treatment had better PFS (20.5 months, 95% confidence interval [CI] 17.7-23.3, vs 17.2 months, 95% CI 10.2-24.2, <i>p</i> = 0.035) but not OS (32.6 months, 95% CI 28.9-36.4, vs 33.2 months, 95% CI 25.3-41.0, <i>p</i> = 0.126).
  • CLASSIFICATION OF EVIDENCE: This study provides Class III evidence that in patients with newly diagnosed glioblastoma, prolonged TMZ chemotherapy does not significantly increase PFS or OS.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] © 2017 American Academy of Neurology.
  • (PMID = 28298550.001).
  • [ISSN] 1526-632X
  • [Journal-full-title] Neurology
  • [ISO-abbreviation] Neurology
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


5. Caruana M, Apers S, Kovacs AH, Luyckx K, Thomet C, Budts W, Sluman M, Eriksen K, Dellborg M, Berghammer M, Johansson B, Soufi A, Callus E, Moons P, Grech V, APPROACH-IS consortium and the International Society for Adult Congenital Heart Disease (ISACHD): Red Flags for Maltese Adults with Congenital Heart Disease: Poorer Dental Care and Less Sports Participation Compared to Other European Patients-An APPROACH-IS Substudy. Pediatr Cardiol; 2017 Mar 24;

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Red Flags for Maltese Adults with Congenital Heart Disease: Poorer Dental Care and Less Sports Participation Compared to Other European Patients-An APPROACH-IS Substudy.
  • Studies in recent years have explored lifestyle habits and health-risk behaviours in adult congenital heart disease (ACHD) patients when compared to controls.
  • The aim of this study was to investigate differences in lifestyle habits between Maltese and other European ACHD patients.
  • Data on alcohol consumption, cigarette smoking, substance misuse, dental care and physical activity collected in 2013-2015 during "Assessment of Patterns of Patient-Reported Outcomes in Adults with Congenital Heart disease-International Study" (APPROACH-IS) were analysed.
  • Significantly fewer Maltese patients with simple (Maltese 84.1% vs.
  • Maltese patients with simple (Maltese 31.8% vs. European 56.1%, p = 0.002) and moderately complex lesions (Maltese 30.0% vs.
  • Comparison by country showed Maltese patients to have significantly poorer tooth brushing and sports participation than patients from any other participating country.
  • Alcohol consumption, cigarette smoking and substance misuse were not significantly different.
  • This study highlights lifestyle aspects that Maltese ACHD patients need to improve on, which might not be evident upon comparing patients to non-CHD controls.
  • These findings should also caution researchers against considering behaviours among patients in one country as necessarily representative of patients on the larger scale.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 28341902.001).
  • [ISSN] 1432-1971
  • [Journal-full-title] Pediatric cardiology
  • [ISO-abbreviation] Pediatr Cardiol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Keywords] NOTNLM ; Congenital heart disease / Health behaviour / Lifestyle / Risk factors
  • [Investigator] Alday L; Maisuls H; Vega B; Menahem S; Eaton S; Larion R; Wang QF; Budts W; Van Deyk K; Apers S; Goossens E; Rassart J; Luyckx K; Moons P; Rempel G; Mackie A; Ballantyne R; Rankin K; Norris C; Taylor D; Vondermuhll I; Windram J; Heggie P; Lasiuk G; Khairy P; Proietti A; Dore A; Mercier LA; Mongeon FP; Marcotte F; Ibrahim R; Mondésert B; Côté MC; Kovacs A; Oechslin E; Bandyopadhyay M; Soufi A; Filippo SD; Sassolas F; Bozio A; Chidambarathanu S; Farzana F; Lakshmi N; Callus E; Quadri E; Chessa M; Campioni G; Giamberti A; Enomoto J; Mizuno Y; Caruana M; Grech V; Vella S; Mifsud A; Borg N; Chircop D; Mercieca Balbi M; Vella Critien R; Farrugia J; Gatt Y; Muscat D; Eriksen K; Estensen ME; Dellborg M; Berghammer M; Mattson E; Strandberg A; Karlström-Hallberg P; Johansson B; Kronhamn AK; Schwerzmann M; Thomet C; Huber M; Wang JK; Lu CW; Yang HL; Hua YC; Mulder B; Sluman M; Post M; Pieper E; Peels K; Waskowsky M; Veldtman G; Faust M; Lozier C; Reed C; Hilfer J; Daniels C; Jackson J; Kutty S; Chamberlain C; Cook S; Hindes M; Cedars A; White K; Rompfh A; Fernandes S; MacMillen K
  •  go-up   go-down


6. Wagenaar BH, Gimbel S, Hoek R, Pfeiffer J, Michel C, Cuembelo F, Quembo T, Afonso P, Gloyd S, Lambdin BH, Micek MA, Porthé V, Sherr K: Wait and consult times for primary healthcare services in central Mozambique: a time-motion study. Glob Health Action; 2016 Jan;9(1):31980

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Design We observed 8,102 patient arrivals and departures from clinical service areas across 12 public-sector clinics in Sofala and Manica Provinces between January and April 2011.
  • Over 70% (884/1,248) of patients arrived at the clinic to begin queuing for general reception prior to 10:30 am.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 28157004.001).
  • [ISSN] 1654-9880
  • [Journal-full-title] Global health action
  • [ISO-abbreviation] Glob Health Action
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Keywords] NOTNLM ; health professionals / health services research / healthcare allocation / maternal and child health / maternity services / primary health care / priority setting
  •  go-up   go-down


7. Kashiura M, Hamabe Y, Akashi A, Sakurai A, Tahara Y, Yonemoto N, Nagao K, Yaguchi A, Morimura N, SOS-KANTO 2012 Study Group: Association between cardiopulmonary resuscitation duration and one-month neurological outcomes for out-of-hospital cardiac arrest: a prospective cohort study. BMC Anesthesiol; 2017 Apr 21;17(1):59

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • METHODS: Data were utilized from a prospective multi-center cohort study of out-of-hospital cardiac arrest patients transported to 67 emergency hospitals between January 2012 and March 2013 in the Kanto area of Japan.
  • A total of 3,353 patients with out-of-hospital cardiac arrest (age ≥18 years) who underwent CPR by emergency medical service personnel and achieved the return of spontaneous circulation in a pre- or in-hospital setting were analyzed.
  • The CPR duration required to achieve return of spontaneous circulation in >99% of out-of-hospital cardiac arrest patients with a 1-month favorable neurological outcome was 45 min, considering both pre- and in-hospital settings.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Circulation. 2015 Nov 3;132(18 Suppl 2):S465-82 [26472996.001]
  • [Cites] Crit Care. 2014 Sep 26;18(5):535 [25255842.001]
  • [Cites] Crit Care Med. 1985 Nov;13(11):930-1 [4053643.001]
  • [Cites] Circulation. 1991 Aug;84(2):960-75 [1860248.001]
  • [Cites] Circulation. 2015 Nov 3;132(18 Suppl 2):S383-96 [26472991.001]
  • [Cites] Crit Care. 2015 Sep 10;19:322 [26353809.001]
  • [Cites] Resuscitation. 2007 Jun;73(3):394-9 [17289244.001]
  • [Cites] Resuscitation. 2014 Dec;85(12):1779-89 [25438253.001]
  • [Cites] Resuscitation. 2013 Jan;84(1):54-9 [22705831.001]
  • [Cites] Am J Emerg Med. 2015 May;33(5):677-81 [25753293.001]
  • [Cites] Resuscitation. 2015 Nov;96:323-7 [25986336.001]
  • [Cites] J Am Heart Assoc. 2016 Mar 18;5(3):e002819 [26994129.001]
  • [Cites] Circulation. 2013 Dec 3;128(23):2488-94 [24243885.001]
  • [Cites] Resuscitation. 2010 Nov;81(11):1479-87 [20828914.001]
  • [Cites] Resuscitation. 2015 Oct;95:302-11 [26477419.001]
  • [Cites] Resuscitation. 2008 Sep;78(3):355-8 [18573588.001]
  • [Cites] Emerg Med J. 2014 Jul;31(7):549-555 [23639589.001]
  • [Cites] Resuscitation. 2016 Apr;101:50-6 [26851705.001]
  • [Cites] N Engl J Med. 2010 Mar 18;362(11):994-1004 [20237345.001]
  • [Cites] Circulation. 2010 Nov 2;122(18 Suppl 3):S665-75 [20956219.001]
  • [Cites] Circ Cardiovasc Qual Outcomes. 2010 Jan;3(1):63-81 [20123673.001]
  • [Cites] Resuscitation. 2007 Mar;72(3):394-403 [17161519.001]
  • [Cites] Resuscitation. 2015 Nov;96:328-40 [25438254.001]
  • [Cites] Crit Care. 2016 Mar 01;20:49 [26926006.001]
  • [Cites] Circulation. 2013 Dec 3;128(23):2465-7 [24135072.001]
  • [Cites] Perfusion. 2016 Apr;31(3):200-6 [26081930.001]
  • [Cites] J Thorac Dis. 2016 Oct;8(10 ):E1435-E1437 [27867652.001]
  • [Cites] Resuscitation. 2016 Mar;100:25-31 [26774172.001]
  • [Cites] Lancet. 2008 Aug 16;372(9638):554-61 [18603291.001]
  • (PMID = 28431508.001).
  • [ISSN] 1471-2253
  • [Journal-full-title] BMC anesthesiology
  • [ISO-abbreviation] BMC Anesthesiol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Keywords] NOTNLM ; Cardiopulmonary resuscitation / Emergency medical services / Out-of-hospital cardiac arrest / Patient outcome assessment
  • [Investigator] Inokuchi S; Masui Y; Miura K; Tsutsumi H; Takuma K; Atsushi I; Nakano M; Tanaka H; Ikegami K; Arai T; Yaguchi A; Kitamura N; Oda S; Kobayashi K; Suda T; Ono K; Morimura N; Furuya R; Koido Y; Iwase F; Nagao K; Kanesaka S; Okada Y; Unemoto K; Sadahiro T; Iyanaga M; Muraoka A; Hayashi M; Ishimatsu S; Miyake Y; Yokokawa H; Koyama Y; Tsuchiya A; Kashiyama T; Hayashi M; Oshima K; Kiyota K; Hamabe Y; Yokota H; Hori S; Inaba S; Sakamoto T; Harada N; Kimura A; Kanai M; Otomo Y; Sugita M; Kinoshita K; Sakurai T; Kitano M; Matsuda K; Tanaka K; Yoshihara K; Yoh K; Suzuki J; Toyoda H; Mashiko K; Shimizu N; Muguruma T; Shimada T; Kobe Y; Nakanishi K; Shiga T; Yamamoto T; Sekine K; Izuka S
  •  go-up   go-down


8. Moghnieh RA, Abdallah DI, Fawaz IA, Hamandi T, Kassem M, El-Rajab N, Jisr T, Mugharbil A, Droubi N, Al Tabah S, Sinno L, Ziade F, Daoud Z, Ibrahim A: Prescription Patterns for Tigecycline in Severely Ill Patients for Non-FDA Approved Indications in a Developing Country: A Compromised Outcome. Front Microbiol; 2017;8:497

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prescription Patterns for Tigecycline in Severely Ill Patients for Non-FDA Approved Indications in a Developing Country: A Compromised Outcome.
  • <b>Materials and Methods:</b> This is a retrospective chart review evaluating a 2-year experience of tigecycline use for > 72 h in 153 adult patients inside and outside critical care unit from January 2012 to December 2013 in a Lebanese tertiary-care hospital.
  • <b>Results:</b> Tigecycline was mostly used in off-label indications (81%) and prescribed inside the critical care area, where the number of tigecycline cycles was 16/1,000 patient days.
  • Clinical success was achieved in 43.4% of the patients.
  • In the critically ill group, it was significantly higher in patients with a SOFA score <7 using multivariate analysis (Odds Ratio (OR) = 12.51 [4.29-36.51], <i>P</i> < 0.0001).
  • Microbiological success was achieved in 43.3% of patients.
  • Yet, the univariate and adjusted multivariate models failed to show a significant difference in this outcome between patients inside vs. outside critical care area, those with SOFA score <7 vs. ≥ 7, and in FDA-approved vs. off-label indications.
  • It was significantly higher in critically ill patients with SOFA score ≥7 (OR = 5.17 [2.43-11.01], <i>P</i> < 0.0001) and in off-label indications (OR = 4.00 [1.30-12.31], <i>P</i> = 0.01) using an adjusted multivariate model.
  • <b>Conclusion:</b> In our series, tigecycline has been mostly used in off-label indications, specifically in severely ill patients.
  • The outcome of such infections was not inferior to that of FDA-approved indications, especially inside critical care area.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Curr Opin Crit Care. 2015 Oct;21(5):402-11 [26263298.001]
  • [Cites] Clin Infect Dis. 2005 Sep 1;41 Suppl 5:S341-53 [16080072.001]
  • [Cites] Int J Antimicrob Agents. 2013 Jun;41(6):527-35 [23590898.001]
  • [Cites] BMC Infect Dis. 2010 Sep 29;10:287 [20920273.001]
  • [Cites] Diagn Microbiol Infect Dis. 2015 Oct;83(2):183-6 [26164275.001]
  • [Cites] Eur J Clin Microbiol Infect Dis. 2014 Oct;33(10):1675-85 [24832022.001]
  • [Cites] Surg Infect (Larchmt). 2011 Dec;12(6):465-7 [22136488.001]
  • [Cites] New Microbiol. 2015 Apr;38(2):121-36 [25915055.001]
  • [Cites] Clin Infect Dis. 2001 Sep 15;33 Suppl 3:S147-56 [11524712.001]
  • [Cites] Intensive Care Med. 2013 Feb;39(2):165-228 [23361625.001]
  • [Cites] Int J Antimicrob Agents. 2009 Jul;34(1):101-2 [19278835.001]
  • [Cites] Ann Clin Microbiol Antimicrob. 2015 May 10;14:27 [25958201.001]
  • [Cites] J Microbiol Immunol Infect. 2011 Feb;44(1):45-51 [21531352.001]
  • [Cites] Clin Infect Dis. 2007 Mar 1;44 Suppl 2:S27-72 [17278083.001]
  • [Cites] Am J Infect Control. 1988 Jun;16(3):128-40 [2841893.001]
  • [Cites] Int J Antimicrob Agents. 2014 Feb;43(2):170-8 [24315313.001]
  • [Cites] Antimicrob Agents Chemother. 2005 Jan;49(1):220-9 [15616299.001]
  • [Cites] Antimicrob Agents Chemother. 2015 Mar;59(3):1650-5 [25547356.001]
  • [Cites] J Clin Microbiol. 2007 Jan;45(1):227-30 [17093026.001]
  • [Cites] Int J Antimicrob Agents. 2014 Apr;43(4):378-82 [24613422.001]
  • [Cites] J Antimicrob Chemother. 2008 Feb;61(2):235-7 [18065413.001]
  • [Cites] Diagn Microbiol Infect Dis. 2008 Jul;61(3):329-38 [18508226.001]
  • [Cites] J Antibiot (Tokyo). 2010 Jan;63(1):29-31 [19911030.001]
  • [Cites] Clin Microbiol Infect. 2012 Mar;18(3):268-81 [21793988.001]
  • [Cites] Clin Infect Dis. 2005 Sep 1;41 Suppl 5:S354-67 [16080073.001]
  • [Cites] Int J Antimicrob Agents. 2014 Nov;44(5):396-401 [25442358.001]
  • [Cites] Intensive Care Med. 2014 Jul;40(7):988-97 [24871500.001]
  • [Cites] Clin Infect Dis. 2009 Jan 1;48(1):1-12 [19035777.001]
  • [Cites] Diagn Microbiol Infect Dis. 2010 Nov;68(3):307-11 [20955916.001]
  • (PMID = 28396656.001).
  • [Journal-full-title] Frontiers in microbiology
  • [ISO-abbreviation] Front Microbiol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Switzerland
  • [Keywords] NOTNLM ; Acinetobacter baumannii / antibiotic resistance / antibiotic stewardship / critically ill / off-label indications / tigecycline
  •  go-up   go-down


9. Holt TA, Dalton A, Marshall T, Fay M, Qureshi N, Kirkpatrick S, Hislop J, Lasserson D, Kearley K, Mollison J, Yu LM, Hobbs FD, Fitzmaurice D: Automated Software System to Promote Anticoagulation and Reduce Stroke Risk: Cluster-Randomized Controlled Trial. Stroke; 2017 Mar;48(3):787-790
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We investigated the effectiveness of a software tool (AURAS-AF [Automated Risk Assessment for Stroke in Atrial Fibrillation]) designed to identify such individuals during routine care through a cluster-randomized trial.
  • METHODS: Screen reminders appeared each time the electronic health records of an eligible patient was accessed until a decision had been taken over OAC treatment.
  • Control practices continued usual care.
  • Incidence of recorded transient ischemic attack was higher in the intervention practices (median 10.0 versus 2.3 per 1000 patients with atrial fibrillation; <i>P</i>=0.027), but at 12 months, we found a lower incidence of both all cause stroke (<i>P</i>=0.06) and hemorrhage (<i>P</i>=0.054).

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] © 2017 American Heart Association, Inc.
  • [Cites] Trials. 2013 Nov 13;14:385 [24220602.001]
  • [Cites] Br J Gen Pract. 2012 Oct;62(603):e710-7 [23265231.001]
  • [Cites] Lancet. 2014 Mar 15;383(9921):955-62 [24315724.001]
  • [Cites] Am J Med. 2010 Jul;123(7):638-645.e4 [20609686.001]
  • [Cites] Cochrane Database Syst Rev. 2009 Jul 08;(3):CD001096 [19588323.001]
  • [Cites] Stroke. 1991 Aug;22(8):983-8 [1866765.001]
  • [Cites] Thromb Res. 2006;118(3):321-33 [16198396.001]
  • (PMID = 28119433.001).
  • [ISSN] 1524-4628
  • [Journal-full-title] Stroke
  • [ISO-abbreviation] Stroke
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Keywords] NOTNLM ; anticoagulants / atrial fibrillation / electronic health records / reminder systems / stroke
  •  go-up   go-down


10. Dargazanli C, Consoli A, Gory B, Blanc R, Labreuche J, Preda C, Bourdain F, Decroix JP, Redjem H, Ciccio G, Mazighi M, Smajda S, Desilles JP, Riva R, Labeyrie PE, Coskun O, Rodesch G, Turjman F, Piotin M, Lapergue B: Is Reperfusion Useful in Ischaemic Stroke Patients Presenting with a Low National Institutes of Health Stroke Scale and a Proximal Large Vessel Occlusion of the Anterior Circulation? Cerebrovasc Dis; 2017 Apr 07;43(5-6):305-312
figshare. supplemental materials - Supporting Data and Materials for the article .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Is Reperfusion Useful in Ischaemic Stroke Patients Presenting with a Low National Institutes of Health Stroke Scale and a Proximal Large Vessel Occlusion of the Anterior Circulation?
  • BACKGROUND: In population-based studies, patients presenting with minor or mild stroke symptoms represent about two-thirds of stroke patients, and almost one-third of these patients are unable to ambulate independently at the time of discharge.
  • Although mechanical thrombectomy (MT) has become the standard of care for acute ischaemic stroke with proximal large vessel occlusion (LVO) in the anterior circulation, the management of patients harbouring proximal occlusion and minor-to-mild stroke symptoms has not yet been determined by recent trials.
  • The purpose of this study was to evaluate the impact of reperfusion on clinical outcome in low National Institutes of Health Stroke Scale (NIHSS) patients treated with MT.
  • METHODS: We analysed 138 consecutive patients with acute LVO of the anterior circulation (middle cerebral artery M1 or M2 segment, internal carotid artery or tandem occlusion) with NIHSS <8, having undergone MT in 3 different centres.
  • RESULTS: Successful reperfusion was achieved in 81.2% of patients (TICI 2B, n = 47; TICI 3, n = 65).
  • Excellent outcome (mRs 0-1) was achieved in 69 patients (65.0%) and favourable outcome (mRs ≤2) in 108 (78.3%).
  • Excellent outcome increased with reperfusion grades, with a rate of 34.6% in patients with failed/poor reperfusion, 61.7% in patients with TICI 2B reperfusion, and 78.5% in patients with TICI 3 reperfusion (p < 0.001).
  • In multivariate analysis adjusted for patient characteristics associated with excellent outcome, the reperfusion grade remained significantly associated with an increase in excellent outcome; the OR (95% CI) was 3.09 (1.06-9.03) for TICI 2B and 6.66 (2.27-19.48) for TICI 3, using the failed/poor reperfusion grade as reference.
  • CONCLUSION: Successful reperfusion is strongly associated with better functional outcome among patients with proximal LVO in the anterior circulation and minor-to-mild stroke symptoms.
  • Randomized controlled studies are mandatory to assess the benefit of MT compared with optimal medical management in this subset of patients.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] © 2017 S. Karger AG, Basel.
  • (PMID = 28384632.001).
  • [ISSN] 1421-9786
  • [Journal-full-title] Cerebrovascular diseases (Basel, Switzerland)
  • [ISO-abbreviation] Cerebrovasc. Dis.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Switzerland
  •  go-up   go-down


11. Evangelidis N, Tong A, Manns B, Hemmelgarn B, Wheeler DC, Tugwell P, Crowe S, Harris T, Van Biesen W, Winkelmayer WC, Sautenet B, O'Donoghue D, Tam-Tham H, Youssouf S, Mandayam S, Ju A, Hawley C, Pollock C, Harris DC, Johnson DW, Rifkin DE, Tentori F, Agar J, Polkinghorne KR, Gallagher M, Kerr PG, McDonald SP, Howard K, Howell M, Craig JC, Standardized Outcomes in Nephrology–Hemodialysis (SONG-HD) Initiative: Developing a Set of Core Outcomes for Trials in Hemodialysis: An International Delphi Survey. Am J Kidney Dis; 2017 Feb 23;
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: Survival and quality of life for patients on hemodialysis therapy remain poor despite substantial research efforts.
  • Existing trials often report surrogate outcomes that may not be relevant to patients and clinicians.
  • SETTING & PARTICIPANTS: 1,181 participants (202 [17%] patients/caregivers, 979 health professionals) from 73 countries completed round 1, with 838 (71%) completing round 3.
  • OUTCOMES & MEASUREMENTS: Outcomes included in the potential core outcome set met the following criteria for both patients/caregivers and health professionals: median score ≥ 8, mean score ≥ 7.5, proportion rating the outcome as critically important ≥ 75%, and median score in the forced ranking question < 10.
  • RESULTS: Patients/caregivers rated 4 outcomes higher than health professionals: ability to travel, dialysis-free time, dialysis adequacy, and washed out after dialysis (mean differences of 0.9, 0.5, 0.3, and 0.2, respectively).
  • CONCLUSIONS: Patients/caregivers gave higher priority to lifestyle-related outcomes than health professionals.

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright © 2017 National Kidney Foundation, Inc. Published by Elsevier Inc. All rights reserved.
  • (PMID = 28238554.001).
  • [ISSN] 1523-6838
  • [Journal-full-title] American journal of kidney diseases : the official journal of the National Kidney Foundation
  • [ISO-abbreviation] Am. J. Kidney Dis.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Keywords] NOTNLM ; Delphi survey / Hemodialysis (HD) / Standardized Outcomes in Nephrology-Hemodialysis (SONG-HD) / biochemical end point / cardiovascular disease (CVD) / core outcome set / dialysis adequacy / lifestyle-related outcomes / mortality / outcome domains / outcomes / patient-centered care / quality of life / research priorities / surrogate end points / trials / vascular access problems / well-being
  •  go-up   go-down


12. Grubbs SS, Go RS, Berger MZ, Gonzalez M, Thompson MA, Enos R, St Germain DC, Denicoff A, Servididio C, Bearden JD, Zaren H, Wilkinson K, Krasna M, McCaskill-Stevens W, Bell M, Freeman RK, Miesfeldt S, Ravikumar TS, Nair SG, Bashey A: Early success in narrowing age, gender, and racial disparities in clinical trial accrual: Targeted screening efforts through the National Cancer Institute Community Cancer Centers Program (NCCCP). J Clin Oncol; 2011 May 20;29(15_suppl):6110

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The data included patient demographics, trial eligibility, trial enrollment, and reasons for non-enrollment.
  • This abstract addresses patient demographics.
  • RESULTS: Of the 1,589 patients screened during this period, 359 were enrolled, for an overall accrual rate of 23%.
  • No disparity based on gender, ethnicity, or race between Whites and African Americans (P value for the latter comparison 0.59) was found and the disparity gap between the young and elderly appears narrowed when compared to historical data (3-fold difference; Murthy VH, et al JAMA 2004).

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 28022513.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


13. Chersich MF, Takkinen J, Charlier C, Leclercq A, Adams PE, Godbole G, Altmeyer U, Friesema IH, Labbé Sandelin L, Jenkin L, Fontana L, Aldigeri R, Venter F, Luchters SM, Lecuit M, Cimino L: Diagnosis and Treatment of Listeria monocytogenes Endophthalmitis: A Systematic Review. Ocul Immunol Inflamm; 2017 Feb 01;:1-10
figshare. supplemental materials - Supporting Data and Materials for the article .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • PURPOSE: Describe patient characteristics, treatment, and vision outcomes of Listeria monocytogenes endophthalmitis, an exceedingly rare form of listeriosis.
  • Patients were a median 61 years, 57% male (24/42) and half were immunosuppressed.
  • Median days from entering care to diagnosis was 8 (IQR = 5-17).
  • Older patients had poorer outcomes.

  • HIV InSite. treatment guidelines - Ophthalmic Manifestations of HIV .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 28145786.001).
  • [ISSN] 1744-5078
  • [Journal-full-title] Ocular immunology and inflammation
  • [ISO-abbreviation] Ocul. Immunol. Inflamm.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Keywords] NOTNLM ; Endophthalmitis / Listeria monocytogenes / ocular inflammation / systematic review
  •  go-up   go-down


14. Beukelman T, Kimura Y, Ilowite NT, Mieszkalski K, Natter MD, Burrell G, Best B, Jones J, Schanberg LE, CARRA Registry Investigators: The new Childhood Arthritis and Rheumatology Research Alliance (CARRA) registry: design, rationale, and characteristics of patients enrolled in the first 12 months. Pediatr Rheumatol Online J; 2017 Apr 17;15(1):30

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The new Childhood Arthritis and Rheumatology Research Alliance (CARRA) registry: design, rationale, and characteristics of patients enrolled in the first 12 months.
  • BACKGROUND: Herein we describe the history, design, and rationale of the new Childhood Arthritis and Rheumatology Research Alliance (CARRA) Registry and present the characteristics of patients with juvenile idiopathic arthritis (JIA) enrolled in the first 12 months of operation.
  • Data are collected every 6 months and include clinical assessments, detailed medication use, patient-reported outcomes, and safety events.
  • RESULTS: As of July 2016, 1192 patients with JIA were enrolled in the CARRA Registry at 49 clinical sites.
  • Owing to preferential enrollment, patients with systemic JIA (13%) and with a polyarticular course (75%) were over-represented compared to patients in typical clinical practice.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Arthritis Rheum. 2008 Apr;58(4):919-28 [18383377.001]
  • [Cites] Arthritis Care Res (Hoboken). 2014 Mar;66(3):404-10 [23983017.001]
  • [Cites] Arthritis Care Res (Hoboken). 2012 Apr;64(4):546-53 [22076847.001]
  • [Cites] Arthritis Rheum. 1997 Jul;40(7):1202-9 [9214419.001]
  • [Cites] Arthritis Rheum. 2009 May 15;61(5):658-66 [19405003.001]
  • [Cites] J Rheumatol. 2012 Dec;39(12):2341-51 [23070991.001]
  • [Cites] Arthritis Care Res (Hoboken). 2014 Jul;66(7):1063-72 [24339215.001]
  • [Cites] Am J Epidemiol. 2003 Nov 1;158(9):915-20 [14585769.001]
  • [Cites] J Am Med Inform Assoc. 2013 Jan 1;20(1):172-9 [22733975.001]
  • [Cites] Arthritis Care Res (Hoboken). 2013 May;65(5):745-52 [23139240.001]
  • [Cites] Pediatrics. 2013 Nov;132(5):e1384-94 [24144710.001]
  • [Cites] J Rheumatol. 2013 Dec;40(12):2088-96 [24187099.001]
  • [Cites] Pediatr Rheumatol Online J. 2016 Mar 10;14 (1):14 [26965173.001]
  • [Cites] J Rheumatol. 2016 Sep;43(9):1755-62 [27307527.001]
  • [Cites] J Rheumatol. 2016 Apr;43(4):799-803 [26879356.001]
  • [Cites] J Rheumatol. 2013 Jun;40(6):936-42 [23588937.001]
  • [Cites] Lupus. 2016 Jun;25(7):749-53 [26980741.001]
  • [Cites] Arthritis Care Res (Hoboken). 2012 Aug;64(8):1175-85 [22505322.001]
  • [Cites] Arthritis Care Res (Hoboken). 2012 Mar;64(3):375-83 [22162255.001]
  • [Cites] Pediatr Rheumatol Online J. 2016 Feb 16;14 (1):9 [26879972.001]
  • [Cites] Am Heart J. 2011 Nov;162(5):844-51 [22093200.001]
  • [Cites] J Rheumatol. 2004 Feb;31(2):390-2 [14760812.001]
  • [Cites] Lupus. 2014 Aug;23(9):898-904 [24729278.001]
  • [Cites] Arthritis Care Res (Hoboken). 2012 Jul;64(7):1001-10 [22290637.001]
  • [Cites] J Rheumatol. 2012 Sep;39(9):1867-74 [22859354.001]
  • [Cites] J Rheumatol. 2002 May;29(5):1058-64 [12022323.001]
  • [Cites] Ann Rheum Dis. 2013 Dec;72(12):1983-8 [23256951.001]
  • [Cites] Pediatr Clin North Am. 2012 Apr;59(2):301-27 [22560572.001]
  • [Cites] J Am Heart Assoc. 2014 Feb 07;3(1):e000523 [24510115.001]
  • [Cites] Arthritis Care Res (Hoboken). 2011 Jul;63(7):929-36 [21717596.001]
  • (PMID = 28416023.001).
  • [ISSN] 1546-0096
  • [Journal-full-title] Pediatric rheumatology online journal
  • [ISO-abbreviation] Pediatr Rheumatol Online J
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Investigator] Abramson L; Akoghlanian S; Anderson E; Andrew M; Baszis K; Becker M; Bell-Brunson H; Benham H; Birmingham J; Blier P; Brunner H; Chalom E; Chang J; Charpentier P; Chowdhury N; Dean J; Dedeoglu F; Dionizovik-Dimanovski M; Feldman B; Ferguson P; Fox M; Francis K; Franco L; Gervasini M; Goh I; Goldsmith D; Graham TB; Griffin T; Helfrich D; Hickey K; Hoeltzel M; Holtschlag S; Hsu J; Huber A; Huttenlocher A; Imundo L; Inman C; Jaquith J; Jerath R; Jones S; Kahn P; Kingsbury D; Klein K; Klein-Gitelman M; Kramer S; Kunkel A; Lapidus S; Latham D; Lehman T; Lindsley C; Linehan S; Lorenzo J; Malla B; Martyniuk A; Mason T; McConnell K; McCurdy D; McKibben K; McMullen-Jackson C; Milojevic D; Mims K; Moniz C; Morgan S; Murray E; Nicely K; O'Neil K; Onel K; Orange J; Ponder L; Prahalad S; Punaro M; Rabinovich CE; Rakestraw A; Rauch S; Reichley L; Rhea A; Ringold S; Riordan ME; Roberson S; Robinson A; Rosenkranz M; Ross K; Rothman D; Ruas Y; Ruth N; Sanders R; Schikler K; Singer N; Smith C; Stapp H; Swann S; Syed R; Tangarone A; Thatayatikom A; Trejo D; Tress J; Vehe R; von Scheven E; Watts A; Weiss J; Weiss P; Woo J; Yalcindag A; Zeft A; Zemel L; Zhu A
  •  go-up   go-down


15. Erb S, Letang E, Glass TR, Natamatungiro A, Mnzava D, Mapesi H, Haschke M, Duthaler U, Berger B, Muri L, Bader J, Marzolini C, Elzi L, Klimkait T, Langewitz W, Battegay M, Kilombero Ulanga Antiretroviral Cohort (KIULARCO) study group: Health care provider communication training in rural Tanzania empowers HIV-infected patients on antiretroviral therapy to discuss adherence problems. HIV Med; 2017 Mar 13;
HIV InSite. treatment guidelines - Adherence to HIV Antiretroviral Therapy .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Health care provider communication training in rural Tanzania empowers HIV-infected patients on antiretroviral therapy to discuss adherence problems.
  • OBJECTIVES: Self-reported adherence assessment in HIV-infected patients on antiretroviral therapy (ART) is challenging and may overestimate adherence.
  • The aim of this study was to improve the ability of health care providers to elicit patients' reports of nonadherence using a "patient-centred" approach in a rural sub-Saharan African setting.
  • METHODS: A prospective interventional cohort study of HIV-infected patients on ART for ≥ 6 months attending an HIV clinic in rural Tanzania was carried out.
  • The intervention consisted of a 2-day workshop for health care providers on patient-centred communication and the provision of an adherence assessment checklist for use in the consultations.
  • Patients' self-reports of nonadherence (≥ 1 missed ART dose/4 weeks), subtherapeutic plasma ART concentrations (< 2.5th percentile of published population-based pharmacokinetic models), and virological and immunological failure according to the World Health Organization definition were assessed before and after (1-3 and 6-9 months after) the intervention.
  • RESULTS: Before the intervention, only 3.3% of 299 patients included in the study reported nonadherence.
  • Subtherapeutic plasma ART drug concentrations and virological and immunological failure were recorded in 6.5%, 7.7% and 14.5% of the patients, respectively.
  • Two months after the intervention, health care providers detected significantly more patients reporting nonadherence compared with baseline (10.7 vs. 3.3%, respectively; P < 0.001), decreasing to 5.7% after 6-9 months.
  • CONCLUSIONS: Patient-centred communication can successfully be implemented with a simple intervention in rural Africa.
  • It increases the likelihood of HIV-infected patients reporting problems with adherence to ART; however, sustainability remains a challenge.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] © 2017 The Authors HIV Medicine published by John Wiley & Sons Ltd on behalf of British HIV Association.
  • (PMID = 28296019.001).
  • [ISSN] 1468-1293
  • [Journal-full-title] HIV medicine
  • [ISO-abbreviation] HIV Med.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Keywords] NOTNLM ; HIV / antiretroviral therapy / patient-centred communication / self-reported adherence / sub-Saharan Africa / therapeutic drug monitoring
  • [Investigator] Asantiel A; Chale A; Faini D; Felger I; Francis G; Furrer H; Gamell A; Glass T; Hatz C; Hatz S; Kasuga B; Kalinjuma AV; Kimera N; Kisunga Y; Luhombero A; Luwanda LB; Mbwile L; Mkulila M; Mkumbo J; Mkusa M; Mossad G; Mpundunga D; Msami D; Mtandanguo A; Mwamelo KD; Myeya S; Nahota S; Ndaki R; Ngulukila A; Ntamatungiro AJ; Samson L; Sikalengo G; Tanner M; Vanobberghen F
  •  go-up   go-down


16. Dreyer RP, Dharmarajan K, Kennedy KF, Jones PG, Vaccarino V, Murugiah K, Nuti SV, Smolderen KG, Buchanan DM, Spertus JA, Krumholz HM: Sex Differences in 1-Year All-Cause Rehospitalization in Patients After Acute Myocardial Infarction: A Prospective Observational Study. Circulation; 2017 Feb 07;135(6):521-531
Faculty of 1000. commentaries/discussion - See the articles recommended by F1000Prime's Faculty of more than 8,000 leading experts in Biology and Medicine. (subscription/membership/fee required).

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Sex Differences in 1-Year All-Cause Rehospitalization in Patients After Acute Myocardial Infarction: A Prospective Observational Study.
  • METHODS: We recruited 3536 patients (33% women) ≥18 years of age hospitalized with AMI from 24 US centers into the TRIUMPH study (Translational Research Investigating Underlying Disparities in Acute Myocardial Infarction Patients' Health Status).
  • Data were obtained by medical record abstraction and patient interviews, and a physician panel adjudicated hospitalizations within the first year after AMI.
  • [MeSH-minor] Acute Disease. Female. Humans. Male. Middle Aged. Patient Readmission. Prospective Studies. Sex Factors

  • Genetic Alliance. consumer health - Myocardial infarction 1.
  • MedlinePlus Health Information. consumer health - Heart Attack.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] © 2017 American Heart Association, Inc.
  • [Cites] J Gen Intern Med. 2001 Sep;16(9):606-13 [11556941.001]
  • [Cites] Circulation. 2015 Jul 21;132(3):158-66 [26085455.001]
  • [Cites] Heart. 2009 Jan;95(1):20-6 [18463200.001]
  • [Cites] Stat Methods Med Res. 2013 Jun;22(3):278-95 [21220355.001]
  • [Cites] Circ Cardiovasc Qual Outcomes. 2011 Jul;4(4):467-76 [21772003.001]
  • [Cites] J Health Soc Behav. 1983 Dec;24(4):385-96 [6668417.001]
  • [Cites] Psychosom Med. 2005 Nov-Dec;67(6):879-88 [16314592.001]
  • [Cites] Am Heart J. 2006 Mar;151(3):589-97 [16504619.001]
  • [Cites] Am Heart J. 2008 Feb;155(2):375-81 [18215611.001]
  • [Cites] N Engl J Med. 2013 Jan 10;368(2):100-2 [23301730.001]
  • [Cites] JAMA. 2003 Jul 9;290(2):215-21 [12851276.001]
  • [Cites] Ann Intern Med. 2001 Feb 6;134(3):173-81 [11177329.001]
  • [Cites] PLoS Med. 2014 Sep 30;11(9):e1001737 [25268126.001]
  • [Cites] Circ Cardiovasc Qual Outcomes. 2009 Jan;2(1):33-40 [20031810.001]
  • [Cites] Am J Cardiol. 1994 Dec 15;74(12):1240-4 [7977097.001]
  • [Cites] JAMA Intern Med. 2013 Jun 10;173(11):997-1004 [23471421.001]
  • [Cites] J Am Heart Assoc. 2016 Jan 25;5(1):null [26811163.001]
  • [Cites] JAMA. 2009 Nov 18;302(19):2095-103 [19918088.001]
  • [Cites] Psychosom Med. 2005 Nov-Dec;67(6):869-78 [16314591.001]
  • [Cites] Heart. 2004 May;90(5):523-7 [15084550.001]
  • [Cites] J Am Coll Cardiol. 1995 Feb;25(2):333-41 [7829785.001]
  • [Cites] J Am Coll Cardiol. 2005 Nov 15;46(10):1838-44 [16286168.001]
  • [Cites] J Am Coll Cardiol. 2005 Nov 15;46(10):1845-51 [16286169.001]
  • [Cites] Am Heart J. 2000 Jan;139(1 Pt 1):1-9 [10618555.001]
  • [Cites] N Engl J Med. 1999 Jul 22;341(4):217-25 [10413733.001]
  • [Cites] Circ Cardiovasc Qual Outcomes. 2010 Mar;3(2):143-50 [20160162.001]
  • [Cites] Med Care. 1996 Mar;34(3):220-33 [8628042.001]
  • [Cites] Circulation. 2015 Jun 2;131(22):1971-80 [25862743.001]
  • [Cites] Am J Cardiol. 2006 Aug 1;98(3):282-8 [16860010.001]
  • [Cites] Health Qual Life Outcomes. 2004 May 13;2:24 [15142277.001]
  • [Cites] Arch Intern Med. 2006 Apr 24;166(8):876-83 [16636213.001]
  • [Cites] J Am Heart Assoc. 2015 Nov 03;4(11):null [26534862.001]
  • [Cites] Circ Cardiovasc Qual Outcomes. 2009 Sep;2(5):500-7 [20031883.001]
  • [Cites] Circ Cardiovasc Qual Outcomes. 2014 Jan;7(1):2-4 [24425704.001]
  • [Cites] Qual Life Res. 2005 Mar;14(2):285-95 [15892420.001]
  • [Cites] Circ Cardiovasc Qual Outcomes. 2009 Jan;2(1):25-32 [20031809.001]
  • [Cites] Stat Med. 1999 Apr 15;18(7):855-88 [10327531.001]
  • [Cites] JAMA. 2008 Nov 26;300(20):2379-88 [19033588.001]
  • [Cites] BMJ. 2015 Feb 05;350:h411 [25656852.001]
  • (PMID = 28153989.001).
  • [ISSN] 1524-4539
  • [Journal-full-title] Circulation
  • [ISO-abbreviation] Circulation
  • [Language] eng
  • [Grant] United States / NCATS NIH HHS / TR / UL1 TR001863; United States / NIA NIH HHS / AG / P30 AG021342; United States / NHLBI NIH HHS / HL / U01 HL105270; United States / NHLBI NIH HHS / HL / P50 HL077113; United States / NIA NIH HHS / AG / K23 AG048331
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Keywords] NOTNLM ; acute myocardial infarction / readmission / sex differences / women
  •  go-up   go-down


17. Jaruseviciene L, Orozco M, Ibarra M, Cordova Ossio F, Vega B, Auquilla N, Medina J, Gorter AC, Decat P, De Meyer S, Temmerman M, Edmonds AB, Valius L, Lazarus JV: Primary healthcare providers' views on improving sexual and reproductive healthcare for adolescents in Bolivia, Ecuador, and Nicaragua. Glob Health Action; 2013 Jan;6(1):20444

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • : Objectives To elicit the views of primary healthcare providers from Bolivia, Ecuador, and Nicaragua on how adolescent sexual and reproductive health (ASRH) care in their communities can be improved.
  • Results Study participants emphasized managerial issues such as the prioritization of adolescents as a patient group and increased healthcare providers' awareness about adolescent-friendly approaches.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 28140871.001).
  • [ISSN] 1654-9880
  • [Journal-full-title] Global health action
  • [ISO-abbreviation] Glob Health Action
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Keywords] NOTNLM ; Latin America / adolescents / healthcare personnel / primary healthcare / reproductive health services
  •  go-up   go-down


18. Dawes TJW, de Marvao A, Shi W, Fletcher T, Watson GMJ, Wharton J, Rhodes CJ, Howard LSGE, Gibbs JSR, Rueckert D, Cook SA, Wilkins MR, O'Regan DP: Machine Learning of Three-dimensional Right Ventricular Motion Enables Outcome Prediction in Pulmonary Hypertension: A Cardiac MR Imaging Study. Radiology; 2017 May;283(2):381-390
MedlinePlus Health Information. consumer health - Pulmonary Hypertension.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Purpose To determine if patient survival and mechanisms of right ventricular failure in pulmonary hypertension could be predicted by using supervised machine learning of three-dimensional patterns of systolic cardiac motion.
  • Two hundred fifty-six patients (143 women; mean age ± standard deviation, 63 years ± 17) with newly diagnosed pulmonary hypertension underwent cardiac magnetic resonance (MR) imaging, right-sided heart catheterization, and 6-minute walk testing with a median follow-up of 4.0 years.
  • Results At the end of follow-up, 36% of patients (93 of 256) died, and one underwent lung transplantation.
  • Conclusion A machine-learning survival model that uses three-dimensional cardiac motion predicts outcome independent of conventional risk factors in patients with newly diagnosed pulmonary hypertension.

  • Genetic Alliance. consumer health - Pulmonary Hypertension.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Am J Respir Crit Care Med. 2006 Nov 1;174(9):1034-41 [16888289.001]
  • [Cites] Circulation. 2013 Jan 15;127(2):197-206 [23224059.001]
  • [Cites] J Cardiovasc Magn Reson. 2014 Feb 03;16:16 [24490638.001]
  • [Cites] J Am Coll Cardiol. 2011 Dec 6;58(24):2511-9 [22133851.001]
  • [Cites] Am J Respir Crit Care Med. 2002 Jul 1;166(1):111-7 [12091180.001]
  • [Cites] IEEE Trans Med Imaging. 2016 Sep 13;:null [28113656.001]
  • [Cites] Circ Res. 2015 Mar 27;116(7):1115-9 [25814682.001]
  • [Cites] PLoS Biol. 2004 Apr;2(4):E108 [15094809.001]
  • [Cites] Interface Focus. 2016 Apr 6;6(2):20150083 [27051509.001]
  • [Cites] J Cardiovasc Magn Reson. 2012 Jan 11;14:4 [22236389.001]
  • [Cites] J Cardiovasc Magn Reson. 2013 May 01;15:35 [23634753.001]
  • [Cites] J Thorac Cardiovasc Surg. 2008 Sep;136(3):578-89, 589.e1-11 [18805255.001]
  • [Cites] Neuroimage. 2009 Jul 1;46(3):726-38 [19245840.001]
  • [Cites] Bioinformatics. 2011 Aug 15;27(16):2288-95 [21737439.001]
  • [Cites] Med Image Comput Comput Assist Interv. 2014;17(Pt 1):348-55 [25333137.001]
  • [Cites] J Am Coll Cardiol. 2013 Dec 24;62(25 Suppl):D22-33 [24355638.001]
  • [Cites] PLoS One. 2014 Oct 31;9(10):e110243 [25360520.001]
  • [Cites] J Cardiovasc Magn Reson. 2013 Oct 08;15:91 [24103764.001]
  • [Cites] Circulation. 2010 Jul 13;122(2):164-72 [20585012.001]
  • [Cites] J Cardiovasc Magn Reson. 2014 Jul 30;16:56 [25160814.001]
  • [Cites] Brief Bioinform. 2011 May;12(3):203-14 [21324971.001]
  • [Cites] Eur Respir J. 2015 Oct;46(4):903-75 [26318161.001]
  • [Cites] J Cardiovasc Magn Reson. 2010 Jun 04;12:35 [20525337.001]
  • [Cites] Med Image Anal. 2015 Dec;26(1):133-45 [26387054.001]
  • [Cites] Phys Med Biol. 2001 Mar;46(3):R1-45 [11277237.001]
  • [Cites] J Am Coll Cardiol. 2007 Jun 26;49(25):2450-6 [17599609.001]
  • [Cites] Med Image Anal. 2012 Jan;16(1):201-15 [21920797.001]
  • [Cites] Eur Respir J. 2015 Jan;45(1):33-5 [25552736.001]
  • [Cites] Nature. 2015 May 28;521(7553):436-44 [26017442.001]
  • [Cites] Med Image Anal. 2015 Jan;19(1):187-202 [25461337.001]
  • [Cites] Circulation. 2015 Nov 17;132(20):1920-30 [26572668.001]
  • [Cites] Biometrics. 2000 Jun;56(2):337-44 [10877287.001]
  • (PMID = 28092203.001).
  • [ISSN] 1527-1315
  • [Journal-full-title] Radiology
  • [ISO-abbreviation] Radiology
  • [Language] eng
  • [Grant] United Kingdom / Wellcome Trust / /
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


19. Fogel MA, Li C, Elci OU, Pawlowski T, Schwab PJ, Wilson F, Nicolson SC, Montenegro LM, Diaz L, Spray TL, Gaynor JW, Fuller S, Mascio C, Keller MS, Harris MA, Whitehead KK, Bethel J, Vossough A, Licht DJ: Neurological Injury and Cerebral Blood Flow in Single Ventricles Throughout Staged Surgical Reconstruction. Circulation; 2017 Feb 14;135(7):671-682
ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: Patients with a single ventricle experience a high rate of brain injury and adverse neurodevelopmental outcome; however, the incidence of brain abnormalities throughout surgical reconstruction and their relationship with cerebral blood flow, oxygen delivery, and carbon dioxide reactivity remain unknown.
  • METHODS: Patients with a single ventricle were studied with magnetic resonance imaging scans immediately prior to bidirectional Glenn (pre-BDG), before Fontan (BDG), and then 3 to 9 months after Fontan reconstruction.
  • Nonacute ischemic white matter changes on T2-weighted imaging, focal tissue loss, and ventriculomegaly were all more commonly detected in BDG and Fontan compared with pre-BDG patients (<i>P</i><0.05).
  • BDG patients had significantly higher cerebral blood flow than did Fontan patients.
  • The odds of discovering brain injury with adjustment for surgical stage as well as ≥2 coexisting lesions within a patient decreased (63%-75% and 44%, respectively) with increasing amount of cerebral blood flow (<i>P</i><0.05).
  • In general, there was no association of oxygen delivery (except for ventriculomegaly in the BDG group) or carbon dioxide reactivity with neurological injury.
  • CONCLUSIONS: Significant brain abnormalities are commonly present in patients with a single ventricle, and detection of these lesions increases as children progress through staged surgical reconstruction, with multiple coexisting lesions more common earlier than later.
  • In addition, this study demonstrated that BDG patients had greater cerebral blood flow than did Fontan patients and that an inverse association exists of various indexes of cerebral blood flow with these brain lesions.
  • However, CO<sub>2</sub> reactivity and oxygen delivery (with 1 exception) were not associated with brain lesion development.

  • MedlinePlus Health Information. consumer health - Neurologic Diseases.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] © 2016 American Heart Association, Inc.
  • [Cites] J Pediatr. 2013 Feb;162(2):250-6.e2 [22939929.001]
  • [Cites] Magn Reson Med. 1995 Sep;34(3):293-301 [7500865.001]
  • [Cites] Pediatrics. 2007 Sep;120(3):584-93 [17766532.001]
  • [Cites] Ann Thorac Surg. 2014 Jul;98 (1):125-32 [24820395.001]
  • [Cites] Pediatrics. 2006 Jan;117(1):1-8 [16396853.001]
  • [Cites] J Thorac Cardiovasc Surg. 2004 Mar;127(3):692-704 [15001897.001]
  • [Cites] J Thorac Cardiovasc Surg. 2009 Mar;137(3):529-36; discussion 536-7 [19258059.001]
  • [Cites] J Thorac Cardiovasc Surg. 2006 Jan;131(1):190-7 [16399311.001]
  • [Cites] Early Hum Dev. 2009 May;85(5):279-84 [19141366.001]
  • [Cites] Arch Dis Child Fetal Neonatal Ed. 2005 May;90(3):F257-61 [15846019.001]
  • [Cites] Magn Reson Imaging. 1994;12(8):1205-25 [7854027.001]
  • [Cites] Neuroradiology. 2003 Apr;45(4):253-8 [12687311.001]
  • [Cites] Gerontology. 1994;40(5):279-85 [7959085.001]
  • [Cites] Ann Neurol. 1983 Feb;13(2):155-9 [6830175.001]
  • [Cites] J Thorac Cardiovasc Surg. 2004 Dec;128(6):841-9 [15573068.001]
  • [Cites] J Thorac Cardiovasc Surg. 2010 Mar;139(3):543-56 [19909994.001]
  • [Cites] Intern Med. 2015 ;54(9):1027-33 [25948342.001]
  • [Cites] Circulation. 2000 Aug 22;102(8):883-9 [10952957.001]
  • [Cites] Brain Dev. 2008 Oct;30(9):589-94 [18367356.001]
  • [Cites] Circulation. 2013 Mar 5;127(9):971-9 [23371931.001]
  • [Cites] Heart. 2015 Aug;101(16):1325-31 [26048877.001]
  • [Cites] Magn Reson Med. 2002 Aug;48(2):242-54 [12210932.001]
  • [Cites] J Thorac Cardiovasc Surg. 2014 Apr;147(4):1312-8 [23879933.001]
  • [Cites] Circulation. 2002 Sep 24;106(12 Suppl 1):I95-102 [12354716.001]
  • [Cites] J Pediatr. 2004 Nov;145(5):588-92 [15520755.001]
  • [Cites] Acta Paediatr. 2008 Oct;97(10):1426-32 [18624991.001]
  • [Cites] Circulation. 2002 Sep 24;106(12 Suppl 1):I109-14 [12354718.001]
  • [Cites] Ultrasound Obstet Gynecol. 2010 Aug;36(2):178-85 [20503251.001]
  • [Cites] N Engl J Med. 2007 Nov 8;357(19):1928-38 [17989385.001]
  • [Cites] Blood. 1990 Nov 1;76(9):1680-97 [2224118.001]
  • [Cites] Stroke. 2007 Feb;38(2 Suppl):736-41 [17261728.001]
  • [Cites] Pediatrics. 2000 May;105(5):1082-9 [10790466.001]
  • [Cites] Acta Paediatr Scand Suppl. 1989;360:72-82 [2484464.001]
  • [Cites] N Engl J Med. 2010 May 27;362(21):1980-92 [20505177.001]
  • [Cites] BMC Neurol. 2014 Mar 06;14 :43 [24602446.001]
  • [Cites] Ann Thorac Surg. 2014 Nov;98(5):1693-8 [25149046.001]
  • [Cites] J Thorac Cardiovasc Surg. 2010 Sep;140(3):550-7 [20434174.001]
  • [Cites] Circulation. 2008 Jan 1;117(1):85-92 [18071068.001]
  • [Cites] Pediatr Neurol. 1985 Mar-Apr;1(2):85-90 [3880396.001]
  • [Cites] Ultrasound Obstet Gynecol. 2008 Dec;32(7):894-9 [19035538.001]
  • [Cites] Chest. 2008 Jun;133(6 Suppl):887S-968S [18574281.001]
  • (PMID = 28031423.001).
  • [ISSN] 1524-4539
  • [Journal-full-title] Circulation
  • [ISO-abbreviation] Circulation
  • [Language] eng
  • [Databank-accession-numbers] ClinicalTrials.gov/ NCT02135081
  • [Grant] United States / NHLBI NIH HHS / HL / R01 HL090615; United States / NINDS NIH HHS / NS / R01 NS060653; United States / NINDS NIH HHS / NS / R01 NS072338; United States / NICHD NIH HHS / HD / U01 HD087180
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Keywords] NOTNLM ; Fontan procedure / cerebral infarction / cerebrovascular circulation / heart ventricles / magnetic resonance imaging
  •  go-up   go-down


20. Nesbitt M, Kennerley K, Lacoursiere L, Frechette C, Flaherty S, Catalano PJ, Fuller F, Thiele J, Gilchrist H, Kostka J, Buswell LA: Standardizing chemotherapy education for quality improvement. J Clin Oncol; 2013 Nov;31(31_suppl):136

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • : 136 Background: Variation of chemotherapy teaching at three affiliated regional oncology centers was associated with a low patient satisfaction PS; Press Ganey Survey for Adult Oncology score of 83.7% in understanding what to expect during chemotherapy treatment and 72.9% in how to manage chemotherapy side effects.
  • Nursing staff collaborated to standardize content to improve PS and quality of care.
  • 1) A standardized teaching checklist, 2) electronic patient calendars, 3) 3 weeks later a patient education assessment survey (EAS).
  • 2) calendars listing (clinic appointments, symptoms requiring MD/NP notification, how to contact providers); and 3) ES assessed patient's level of comprehension.
  • Staff reported high satisfaction, highlighting its benefit to patients.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 28136415.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


21. Mintegi S, Azkunaga B, Prego J, Qureshi N, Dalziel SR, Arana-Arri E, Acedo Y, Martinez-Indart L, Urkaregi A, Salmon N, Benito J, Kuppermann N, Pediatric Emergency Research Networks (PERN) Poisoning Working Group: International Epidemiological Differences in Acute Poisonings in Pediatric Emergency Departments. Pediatr Emerg Care; 2017 01 24;

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • No patient died.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 28121975.001).
  • [ISSN] 1535-1815
  • [Journal-full-title] Pediatric emergency care
  • [ISO-abbreviation] Pediatr Emerg Care
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Investigator] Kuppermann N; Benito J; Waisman Y; Osmond M; Johnson D; Chamberlain J; Macias CG; Kharbanda A; Babl FE; Dalziel S; Sutter M; Cohen D; Lloyd J; Duffy E; Mahajan P; Wang GS; Bradin SA; Ramirez J; Stephenson S; Carison A; Babl FE; Craig S; Graudins A; Cheek J; Dalziel SR; Bonish M; Van de Voorde P; Hachimi-Idrissi S; Petrovska A; Mercier JC; Morin L; Cheron G; Szabo E; Nagy R; Bognar Z; Simon G; Balla G; Juhász E; Martin C; Koshy R; Mc Namara R; Waisman Y; Amir L; Da Dalt L; Moretti C; Norbedo S; Salvatore R; Debbia C; Arrighini A; Botarelli P; Pisani M; Ponticiello E; Tipo E; Moll H; Bilhota X; Garrido A; Gata L; Mação P; Costa Lima S; Araújo e Sá G; Almeida S; Gafencu M; Babeu A; Moldovan D; Mitrofan DM; Humayor Yanez FJ; Andrés Andrés AG; del Campo Muñoz T; Mendivil R; Olomi IB; Fábrega i Sabaté J; Iturralde-Orive I; Roca A; Fernández R; Jorda-Lope A; Canduela V; Mesa S; García-Vao Bel C; Bar A; Herrero L; Campos Calleja C; Molina JC; Herrero MAG; Canduela C; Bello-Gutiérrez P; Velasco R; Martínez Sánchez L; Martínez Mengual L; Rodríguez Suárez J; Mintegi S; Salmon N; Muñoz-Bernal JA; López-Ávila J; Vázquez López P; May E; Cozar-Olmo J; López-Corominas V; Tallón-García M; Crespo-Rupérez E; Pérez Sáez A; Sancosmed Ron M; Velasco-Puyó P; Mesa J; Pociello N; Galán-Mercado M; Seiler M; Rey-Bellet Gasser C; Pittet A; Gervaix A; Manzano S; Ulas Saz E; Yurtseven A; Anil M; Oguz S; Tekin D; Kurt F; Ryan M; Hoyle A; Lyttle MD; Potter S; Babakhanlou R; Cagnasia S; Berzel H; Cargnel E; Gordillo E; Gait N; Méndez MM; Has AI; Quevedo MG; Parot Varela MM; Regnando M; Bonifacio Rino P; Torres-Cerino V; Tobares H; Bruno F; Godoy L; Pavlicich V; Casella W; Giachetto-Larraz GA; Ferreira MI; Pedemoti A; Antúnez E; Dall’Orso P; Más M; Torello P; Parodi V; Pandolfo S; Prego J; García-Gariglio L; Arreseigor E; Gugliemone H; Yemini L; Qureshi N; Fayyaz J
  •  go-up   go-down


22. Subbe CP, Kellett J, Barach P, Chaloner C, Cleaver H, Cooksley T, Korsten E, Croke E, Davis E, De Bie AJ, Durham L, Hancock C, Hartin J, Savijn T, Welch J, Crisis Checklist Collaborative: Crisis checklists for in-hospital emergencies: expert consensus, simulation testing and recommendations for a template determined by a multi-institutional and multi-disciplinary learning collaborative. BMC Health Serv Res; 2017 May 08;17(1):334
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: 'Failure to rescue' of hospitalized patients with deteriorating physiology on general wards is caused by a complex array of organisational, technical and cultural failures including a lack of standardized team and individual expected responses and actions.
  • The aim of this study using a learning collaborative method was to develop consensus recomendations on the utility and effectiveness of checklists as training and operational tools to assist in improving the skills of general ward staff on the effective rescue of patients with abnormal physiology.
  • We sought to achieve a consensus on procedures and clinical simulation technology to determine the requirements, develop and test a safe using a checklist template that is rapidly accessible to assist in emergency management of common events for general ward use.
  • RESULTS: Safety considerations about deteriorating patients were agreed upon and summarized.
  • 'Stop & Think'), and, a list of items required for the safe "handover" of patients that remain on the general ward (i.e. 'Check Out').
  • Simulation usability assessment of the template demonstrated feasibility for clinical management of deteriorating patients.
  • CONCLUSIONS: Emergency checklists custom-designed for general ward patients have the potential to guide the treatment speed and reliability of responses for emergency management of patients with abnormal physiology while minimizing the risk of adverse events.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Acute Med. 2014;13(2):56-60 [24940567.001]
  • [Cites] N Engl J Med. 2010 Nov 11;363(20):1928-37 [21067384.001]
  • [Cites] Emerg Med J. 2011 Jun;28(6):507-12 [21036796.001]
  • [Cites] Surg Neurol Int. 2012;3:2 [22347672.001]
  • [Cites] BMJ Qual Saf. 2013 Jun;22(6):507-14 [23457361.001]
  • [Cites] BMJ Qual Saf. 2015 Jul;24(7):428-31 [25969512.001]
  • [Cites] J Nurs Care Qual. 2012 Jan-Mar;27(1):43-50 [21849908.001]
  • [Cites] Med Care. 1992 Jul;30(7):615-29 [1614231.001]
  • [Cites] Clin Med (Lond). 2012 Dec;12 (6):501-3 [23342400.001]
  • [Cites] Implement Sci. 2011 Apr 16;6:39 [21496276.001]
  • [Cites] Qual Saf Health Care. 2005 Oct;14(5):326-31 [16195564.001]
  • [Cites] Ann Surg. 2014 Apr;259(4):807-13 [24096751.001]
  • [Cites] Qual Saf Health Care. 2010 Oct;19(5):e44 [20538629.001]
  • [Cites] J Am Coll Surg. 2011 Aug;213(2):212-217.e10 [21658974.001]
  • [Cites] Crit Care Med. 2004 Oct;32(10):2014-20 [15483409.001]
  • [Cites] Jt Comm J Qual Patient Saf. 2015 May;41(5):212-20 [25977248.001]
  • [Cites] Ann Surg. 2003 Jun;237(6):844-51; discussion 851-2 [12796581.001]
  • [Cites] N Engl J Med. 2014 Mar 13;370(11):1029-38 [24620866.001]
  • [Cites] Lancet. 2009 Aug 8;374(9688):444-5 [19681190.001]
  • [Cites] Ann Surg. 2012 Dec;256(6):925-33 [22968074.001]
  • [Cites] Crit Care Med. 2011 Nov;39(11):2401-6 [21705896.001]
  • [Cites] Crit Care. 2006 Feb;10(1):R30 [16507153.001]
  • [Cites] Intensive Care Med. 2010 Jan;36(1):100-6 [19760206.001]
  • [Cites] Ann Intern Med. 2005 May 3;142(9):756-64 [15867408.001]
  • [Cites] Crit Care. 2005;9(6):R808-15 [16356230.001]
  • [Cites] Jt Comm J Qual Patient Saf. 2005 May;31(5):243-8 [15960014.001]
  • [Cites] Resuscitation. 2011 Jul;82(7):810-4 [21497982.001]
  • [Cites] BMJ Qual Saf. 2015 Sep;24(9):545-9 [26089207.001]
  • [Cites] Resuscitation. 2010 Nov;81(11):1509-15 [20673606.001]
  • [Cites] QJM. 2001 Oct;94(10 ):521-6 [11588210.001]
  • [Cites] BMJ Qual Saf. 2012 Sep;21(9):737-45 [22927487.001]
  • [Cites] N Engl J Med. 2009 Jan 29;360(5):491-9 [19144931.001]
  • [Cites] N Engl J Med. 2013 Jan 17;368(3):246-53 [23323901.001]
  • [Cites] Anaesth Intensive Care. 1995 Apr;23(2):183-6 [7793590.001]
  • [Cites] Implement Sci. 2013 Jun 20;8:70 [23786847.001]
  • [Cites] BMJ Qual Saf. 2011 Jan;20(1):102-7 [21228082.001]
  • [Cites] Hum Factors. 2008 Jun;50(3):442-8 [18689051.001]
  • (PMID = 28482890.001).
  • [ISSN] 1472-6963
  • [Journal-full-title] BMC health services research
  • [ISO-abbreviation] BMC Health Serv Res
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Keywords] NOTNLM ; Crisis / Learning Collaborative / Patient safety / Rapid response teams / Reliability / Simulation
  • [Investigator] Barach P; Beaugrand H; Breen D; Byrne D; Chalmers C; Cleaver H; Cooksley T; Croke E; Davis E; De Bie A; Donnelly P; Dunne E; Durham L; Ellis B; Goel R; Hancock C; Hartin J; Hinge D; Holland M; Hueske-Kraus D; Kellett J; Kennelly S; Korsten E; Lighthall G; Lunn R; Müller M; O'Dwyer C; O'Mahony K; Paice N; Roberts L; Savijn T; Subbe CP; Thomas D; Walsh R; Weber F; Welch J; Woodworth S
  •  go-up   go-down


23. Carrieri MP, Protopopescu C, Younossi Z, Vilotitch A, Fontaine H, Petrov-Sanchez V, Marcellin F, Carrat F, Hézode C, Bourlière M, CUPIC Study Group: Health-Related Quality of Life in Chronic HCV-Infected Patients Switching to Pegylated-Interferon-Free Regimens (ANRS CO20 CUPIC Cohort Study and SIRIUS Trial). Patient; 2017 Mar 28;

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Health-Related Quality of Life in Chronic HCV-Infected Patients Switching to Pegylated-Interferon-Free Regimens (ANRS CO20 CUPIC Cohort Study and SIRIUS Trial).
  • OBJECTIVE: We aimed to compare health-related quality of life (HRQL) during and after hepatitis C virus (HCV) treatment in patients receiving pegylated-interferon (PEG-IFN)-containing therapy (including boceprevir or telaprevir-ANRS CO20 CUPIC cohort) who subsequently switched to PEG-IFN-free regimens (sofosbuvir + ledipasvir with or without ribavirin [RBV]-SIRIUS trial).
  • RESULTS: Among patients enrolled successively in both studies, 43 (corresponding to 212 HRQL assessments) and 43 (82 HRQL assessments) were eligible for the 'during' and 'post' treatment analyses, respectively.
  • This suggests that in the PEG-IFN-free regimens era, screening and comprehensive care of comorbidities and residual somatic symptoms during treatment, and especially after HCV clearance, are still needed to improve patient outcomes.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 28353221.001).
  • [ISSN] 1178-1661
  • [Journal-full-title] The patient
  • [ISO-abbreviation] Patient
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] New Zealand
  • [Investigator] Poncin E; Botta-Friedland D; Fontanges T; Arpurt JP; Bacq Y; Calès P; Delasalle P; Ouzan D; Nousbaum JB; Sylvain C; Ribard D; Gatineau-Sailliant G; de Montigny-Lenhardt S; Renard P; Pilette C; Denis J; Lascoux-Combe C; Abel L; Albert M; Chazouillères O; Dubuisson J; Negro F; Pageaux GP; Paradis V; Spire B; Taburet AM; Trinchet JC; Yazdanpanah Y; Dufour C; Fréhaut C; Pirot M; Lesel A; Zahraa N; Chau F
  •  go-up   go-down


24. Mayanja BN, Kasamba I, Levin J, Namakoola I, Kazooba P, Were J, Kaleebu P, Munderi P, CoLTART study team: COHORT PROFILE: The Complications of Long-Term Antiretroviral Therapy study in Uganda (CoLTART), a prospective clinical cohort. AIDS Res Ther; 2017 May 04;14(1):26

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • There were no differences in renal dysfunction between patients on Tenofovir and Non-Tenofovir containing ART regimens.
  • Patients on PI regimens had higher total cholesterol, lower high density lipoprotein, higher low density lipoprotein, higher triglycerides, and a high atherogenic index for plasma than the non-PI regimen, p = 0.001 or < 0.001.
  • Patients on Non-PI regimens had higher mean diastolic hypertension than patients on PI regimens, p < 0.001.
  • CONCLUSIONS: Our finding of no differences in renal dysfunction between patients on Tenofovir and those on Non-Tenofovir containing ART regimens means that Tenofovir based first line ART can safely be initiated even in settings without routine renal function monitoring.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Clin Infect Dis. 2006 Jan 15;42(2):283-90 [16355343.001]
  • [Cites] AIDS. 2007 Jun 19;21(10):1273-81 [17545703.001]
  • [Cites] PLoS One. 2015 Aug 24;10(8):e0135188 [26301416.001]
  • [Cites] Biomed Pharmacother. 2008 Jan;62(1):6-11 [17574807.001]
  • [Cites] PLoS One. 2009;4(3):e4724 [19266092.001]
  • [Cites] Lancet. 2010 Jan 9;375(9709):123-31 [20004464.001]
  • [Cites] HIV Med. 2011 Oct;12(9):553-61 [21535347.001]
  • [Cites] Bioinformatics. 2009 May 1;25(9):1197-8 [19304876.001]
  • [Cites] AIDS. 2011 Mar 13;25(5):671-8 [21252634.001]
  • [Cites] AIDS Patient Care STDS. 2008 Feb;22(2):99-103 [18260800.001]
  • [Cites] J Hypertens. 2011 Jun;29(6):1061-8 [21505357.001]
  • [Cites] AIDS. 2009 Mar 27;23(6):689-96 [19262355.001]
  • [Cites] Expert Opin Drug Metab Toxicol. 2006 Jun;2(3):429-45 [16863444.001]
  • [Cites] Int J Epidemiol. 2013 Feb;42(1):129-41 [23364209.001]
  • [Cites] Curr Med Chem. 2006;13(26):3121-32 [17168701.001]
  • [Cites] Diabetes Obes Metab. 2008 Jun;10(6):441-50 [17825081.001]
  • [Cites] J Trop Med. 2011;2011:598341 [21845196.001]
  • [Cites] J Infect Dis. 2013 May 1;207(9):1359-69 [23382571.001]
  • [Cites] AIDS. 2004 Apr 30;18(7):1074-6 [15096814.001]
  • [Cites] Afr Health Sci. 2009 Sep;9(3):143-6 [20589141.001]
  • [Cites] J Infect Dis. 2008 Jun 1;197(11):1490-2 [18422454.001]
  • [Cites] Popul Health Metr. 2011 Aug 04;9:36 [21816100.001]
  • [Cites] CMAJ. 2004 Jan 20;170(2):229-38 [14734438.001]
  • [Cites] Trop Med Int Health. 2010 Jun;15(6):697-705 [20406428.001]
  • [Cites] Clin Infect Dis. 2013 Feb;56(4):567-75 [23143096.001]
  • [Cites] Afr Health Sci. 2006 Sep;6(3):139-44 [17140334.001]
  • [Cites] AIDS. 1997 Apr;11(5):633-40 [9108945.001]
  • [Cites] Clin Infect Dis. 2006 May 15;42(10):1488-95 [16619164.001]
  • [Cites] PLoS One. 2015 May 14;10(5):e0126166 [25974077.001]
  • [Cites] Curr Opin Infect Dis. 2009 Feb;22(1):43-8 [19106702.001]
  • [Cites] AIDS. 2008 Oct 18;22(16):2155-63 [18832879.001]
  • [Cites] Lancet. 2000 Jun 17;355(9221):2106-11 [10902624.001]
  • [Cites] AIDS. 2005 Aug 12;19(12):1332-3 [16052093.001]
  • [Cites] Int J STD AIDS. 2001 Sep;12(9):555-62; quiz 563-4 [11516363.001]
  • [Cites] J Acquir Immune Defic Syndr. 2013 Apr 1;62(4):388-95 [23254151.001]
  • (PMID = 28473001.001).
  • [ISSN] 1742-6405
  • [Journal-full-title] AIDS research and therapy
  • [ISO-abbreviation] AIDS Res Ther
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Keywords] NOTNLM ; Antiretroviral therapy / Cohort profile / HIV / Metabolic abnormalities / Renal complications / Uganda
  • [Investigator] Mayanja BN; Nalwadda J; Nakibuuka G; Namugenyi H; Kazooba P; Lubega R; Mugisha A; Tereka A; Kalyebara A; Namara A; Nakitto D; Wangi D; Nume F; Ssemwanga G; Nabulime G; Nassuna G; Lubega G; Namakoola I; Lutaakome J; Generous L; Matama L; Massa R; Tino S; Nakahima W; Kapaata AA; Magambo B; Parry C; Lyagoba F; Nazziwa J; Nannyonjo M; Muhigirwa E; Wamalugu F; Kabajuma F; Nakazibwe HG; Were J; Bwandinga J; Bukenya J; Kamushaaga MZ; Hughes P; Nkurunziza P; Balungi PA; Mukasa S; Nassimbwa S; Vudriko T; Senyonga W; Ochola W; Nakimbugwe A; Nampewo C; Nambuba D; Naphtali E; Barigye G; Nakamanya I; Kasamba I; Levin J; Kahwa J; Matovu JN; Namayirira L; Lubega RN; Nabalayo S; Kaddu S; Munderi P
  •  go-up   go-down


25. Chen TH, Yen AM, Fann JC, Gordon P, Chen SL, Chiu SY, Hsu CY, Chang KJ, Lee WC, Yeoh KG, Saito H, Promthet S, Hamashima C, Maidin A, Robinson F, Zhao LZ: Clarifying the debate on population-based screening for breast cancer with mammography: A systematic review of randomized controlled trials on mammography with Bayesian meta-analysis and causal model. Medicine (Baltimore); 2017 Jan;96(3):e5684
MedlinePlus Health Information. consumer health - Mammography.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [MeSH-minor] Humans. Medical Overuse. Patient Acceptance of Health Care. Randomized Controlled Trials as Topic. Sensitivity and Specificity

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Lancet. 1999 Jun 5;353(9168):1903-8 [10371567.001]
  • [Cites] J Natl Cancer Inst. 1988 Sep 21;80(14 ):1125-32 [3411625.001]
  • [Cites] Cancer. 1997 Dec 1;80(11):2091-9 [9392331.001]
  • [Cites] Diabetes Care. 2003 Nov;26(11):3093-101 [14578245.001]
  • [Cites] J Epidemiol Community Health. 1985 Dec;39(4):364-6 [4086970.001]
  • [Cites] BMJ. 1988 Oct 15;297(6654):943-8 [3142562.001]
  • [Cites] Lancet. 2012 Nov 17;380(9855):1778-86 [23117178.001]
  • [Cites] BMJ. 2014 Feb 11;348:g366 [24519768.001]
  • [Cites] Lancet. 1990 Feb 3;335(8684):241-6 [1967717.001]
  • [Cites] Ann Intern Med. 1994 Feb 15;120(4):326-34 [8291826.001]
  • [Cites] Breast J. 2015 Jan-Feb;21(1):13-20 [25413699.001]
  • [Cites] Lancet. 2000 Jan 8;355(9198):129-34 [10675181.001]
  • [Cites] Am J Epidemiol. 1983 Dec;118(6):865-86 [6650488.001]
  • [Cites] J Natl Cancer Inst Monogr. 1997;(22):27-30 [9709271.001]
  • [Cites] Lancet. 1985 Apr 13;1(8433):829-32 [2858707.001]
  • [Cites] Radiology. 2011 Sep;260(3):658-63 [21712474.001]
  • [Cites] BMJ. 2010 Mar 23;340:c332 [20332509.001]
  • [Cites] Breast Cancer Res Treat. 1997 Sep;45(3):263-70 [9386870.001]
  • [Cites] Breast Cancer Res Treat. 1987;9(3):219-25 [3663958.001]
  • [Cites] Lancet. 2006 Dec 9;368(9552):2053-60 [17161727.001]
  • [Cites] Control Clin Trials. 1996 Feb;17(1):1-12 [8721797.001]
  • [Cites] CMAJ. 1992 Nov 15;147(10 ):1459-76 [1423087.001]
  • [Cites] J Natl Cancer Inst. 1982 Aug;69(2):349-55 [6955542.001]
  • [Cites] Am J Prev Med. 1998 Oct;15(3):206-11 [9791638.001]
  • [Cites] J Natl Cancer Inst. 2000 Sep 20;92 (18):1490-9 [10995804.001]
  • [Cites] Cancer. 2003 May 15;97(10):2387-96 [12733136.001]
  • [Cites] Br J Cancer. 2013 Feb 19;108(3):542-8 [23322203.001]
  • [Cites] Am J Epidemiol. 1974 Nov;100(5):357-66 [4417355.001]
  • [Cites] Ann Intern Med. 2002 Sep 3;137(5 Part 1):305-12 [12204013.001]
  • [Cites] CMAJ. 1992 Nov 15;147(10 ):1477-88 [1423088.001]
  • [Cites] Radiol Clin North Am. 2004 Sep;42(5):793-806, v [15337416.001]
  • [Cites] Ann Epidemiol. 2007 Jul;17(7):564-8 [17329122.001]
  • [Cites] AJR Am J Roentgenol. 1992 Aug;159(2):287-94 [1632342.001]
  • [Cites] Lancet. 1993 Apr 17;341(8851):973-8 [8096941.001]
  • [Cites] PLoS Med. 2009 Jul 21;6(7):e1000097 [19621072.001]
  • (PMID = 28099330.001).
  • [ISSN] 1536-5964
  • [Journal-full-title] Medicine
  • [ISO-abbreviation] Medicine (Baltimore)
  • [Language] eng
  • [Publication-type] Journal Article; Meta-Analysis; Review
  • [Publication-country] United States
  •  go-up   go-down


26. Koami H, Sakamoto Y, Sakurai R, Ohta M, Imahase H, Yahata M, Umeka M, Miike T, Nagashima F, Iwamura T, Yamada KC, Inoue S: Thromboelastometric analysis of the risk factors for return of spontaneous circulation in adult patients with out-of-hospital cardiac arrest. PLoS One; 2017;12(4):e0175257

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Thromboelastometric analysis of the risk factors for return of spontaneous circulation in adult patients with out-of-hospital cardiac arrest.
  • It is well known that coagulopathy is observed in patients with out-of-hospital cardiac arrest (OHCA).
  • Thrombolytic therapy for those patients has been controversial until now.
  • The purpose of this study was to identify a significant predictor for return of spontaneous circulation (ROSC) of OHCA patients in the emergency department (ED) using whole blood viscoelastic testing.
  • Adult non-trauma OHCA patients transported to our hospital that underwent thromboelastometry (ROTEM) during cardiopulmonary resuscitation between January 2013 and December 2015 were enrolled in this study.
  • We divided patients into two groups based on the presence or absence of ROSC, and performed statistical analysis utilizing patient characteristics, prehospital data, laboratory data, and ROTEM data.
  • Seventy-five patients were enrolled.
  • The ROSC group and non-ROSC group included 23 and 52 patients, respectively.
  • We defined a positive prediction for ROSC if the patient presented lower lactate level (<12.0 mmol/L) and higher A30 of EXTEM (≥48.0 mm) with high specificity (94.7%) and accuracy (75.0%).
  • The present study showed that lactate level and ROTEM parameter of clot firmness were reliable predictors of ROSC in the ED for adult patients with OHCA.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Br J Anaesth. 2015 Jan;114(1):91-102 [25303988.001]
  • [Cites] Resuscitation. 2006 Jul;70(1):31-6 [16762481.001]
  • [Cites] N Engl J Med. 2002 May 16;346(20):1522-8 [12015391.001]
  • [Cites] Resuscitation. 2007 May;73(2):189-201 [17239516.001]
  • [Cites] Transplant Proc. 2013;45(10):3637-9 [24314981.001]
  • [Cites] Crit Care. 2010;14(2):R55 [20374650.001]
  • [Cites] Resuscitation. 2001 Jul;50(1):71-6 [11719132.001]
  • [Cites] Arch Intern Med. 2000 May 22;160(10):1529-35 [10826469.001]
  • [Cites] J Intern Med. 1991 Apr;229(4):331-5 [2026986.001]
  • [Cites] Resuscitation. 2006 Jun;69(3):399-406 [16563599.001]
  • [Cites] Medicine (Baltimore). 2016 Aug;95(31):e4514 [27495106.001]
  • [Cites] Circulation. 1995 Nov 1;92(9):2572-8 [7586359.001]
  • [Cites] Resuscitation. 2013 Apr;84(4):454-9 [22922072.001]
  • [Cites] Thromb Res. 1999 Oct 15;96(2):107-13 [10574588.001]
  • [Cites] Crit Care Med. 2011 Dec;39(12):2652-8 [21765358.001]
  • [Cites] Resuscitation. 2003 Apr;57(1):49-55 [12668299.001]
  • [Cites] J Cardiothorac Vasc Anesth. 2014 Apr;28(2):210-6 [24630470.001]
  • [Cites] N Engl J Med. 2008 Dec 18;359(25):2651-62 [19092151.001]
  • [Cites] Resuscitation. 2012 Dec;83(12):1451-5 [22634432.001]
  • (PMID = 28380019.001).
  • [ISSN] 1932-6203
  • [Journal-full-title] PloS one
  • [ISO-abbreviation] PLoS ONE
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


27. Weilburg JB, Sistrom CL, Rosenthal DI, Stout MB, Dreyer KJ, Rockett HR, Baron JM, Ferris TG, Thrall JH: Utilization Management of High-Cost Imaging in an Outpatient Setting in a Large Stable Patient and Provider Cohort over 7 Years. Radiology; 2017 Apr 21;:160968

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Utilization Management of High-Cost Imaging in an Outpatient Setting in a Large Stable Patient and Provider Cohort over 7 Years.
  • Materials and Methods This retrospective, 7-year cohort study included all patients regularly seen by primary care physicians (PCPs) at an urban academic medical center.
  • The main outcome was the number of outpatient high-cost imaging examinations per patient per year ordered by the patient's PCP or by any specialist.
  • The authors determined the probability of a patient undergoing any high-cost imaging procedure during a study year and the number of examinations per patient per year (intensity) in patients who underwent high-cost imaging.
  • Results The patient cohort steadily increased in size from 88 959 in 2007 to 109 823 in 2013.
  • Conclusion Analysis of high-cost imaging utilization in a stable cohort of patients cared for by PCPs during a 7-year period showed that comprehensive UM can produce a significant and sustained reduction in risk-adjusted per-patient year outpatient high-cost imaging volume.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 28430557.001).
  • [ISSN] 1527-1315
  • [Journal-full-title] Radiology
  • [ISO-abbreviation] Radiology
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


28. McClurg D, Goodman K, Hagen S, Harris F, Treweek S, Emmanuel A, Norton C, Coggrave M, Doran S, Norrie J, Donnan P, Mason H, Manoukian S: Abdominal massage for neurogenic bowel dysfunction in people with multiple sclerosis (AMBER - Abdominal Massage for Bowel Dysfunction Effectiveness Research): study protocol for a randomised controlled trial. Trials; 2017 Mar 29;18(1):150

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Neurogenic bowel dysfunction (NBD) occurs in 50-80% of these patients and is the term used to describe constipation and faecal incontinence, which often co-exist.
  • METHODS/DESIGN: This is a multi-centred patient randomised superiority trial comparing an experimental strategy of once daily abdominal massage for 6 weeks against a control strategy of no massage in people with MS who have stated that their constipation is bothersome.
  • Both groups will receive optimised advice plus the MS Society booklet on bowel management in MS, and will continue to receive usual care.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Mult Scler. 2011 Feb;17(2):223-33 [20940182.001]
  • [Cites] Clin Radiol. 2008 Dec;63(12 ):1326-31 [18996262.001]
  • [Cites] Dis Colon Rectum. 1996 Jun;39(6):681-5 [8646957.001]
  • [Cites] Spinal Cord. 2006 Oct;44(10):625-31 [16344850.001]
  • [Cites] J Clin Epidemiol. 2010 Aug;63(8):e1-37 [20346624.001]
  • [Cites] BMC Med. 2010 Mar 24;8:18 [20334633.001]
  • [Cites] Cochrane Database Syst Rev. 2006 Apr 19;(2):CD002115 [16625555.001]
  • [Cites] J Urol. 2008 Dec;180(6):2592-8 [18950816.001]
  • [Cites] Qual Life Res. 2005 Feb;14(1):95-105 [15789944.001]
  • [Cites] BMJ. 2008 Sep 29;337:a1655 [18824488.001]
  • [Cites] Spinal Cord. 2009 Apr;47(4):323-30; quiz 331-3 [19015665.001]
  • [Cites] J Neurol Neurosurg Psychiatry. 2014 Jan;85(1):76-84 [24052635.001]
  • [Cites] Am J Gastroenterol. 2005 Jul;100(7):1605-15 [15984989.001]
  • [Cites] Colorectal Dis. 2007 May;9(4):344-51 [17432988.001]
  • [Cites] Lancet. 1996 Jun 15;347(9016):1651-3 [8642958.001]
  • [Cites] Scand J Gastroenterol. 1997 Sep;32(9):920-4 [9299672.001]
  • (PMID = 28356133.001).
  • [ISSN] 1745-6215
  • [Journal-full-title] Trials
  • [ISO-abbreviation] Trials
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Keywords] NOTNLM ; Abdominal massage / Constipation / Multiple sclerosis / Randomised controlled trial
  •  go-up   go-down


29. Biegstraaten M, Cox TM, Belmatoug N, Berger MG, Collin-Histed T, Vom Dahl S, Di Rocco M, Fraga C, Giona F, Giraldo P, Hasanhodzic M, Hughes DA, Iversen PO, Kiewiet AI, Lukina E, Machaczka M, Marinakis T, Mengel E, Pastores GM, Plöckinger U, Rosenbaum H, Serratrice C, Symeonidis A, Szer J, Timmerman J, Tylki-Szymańska A, Weisz Hubshman M, Zafeiriou DI, Zimran A, Hollak CE: Management goals for type 1 Gaucher disease: An expert consensus document from the European working group on Gaucher disease. Blood Cells Mol Dis; 2016 Oct 24;

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Therapy improves the principal manifestations of the condition and, as a consequence, many patients show a modified phenotype which reflects manifestations of their disease that are refractory to treatment.
  • More generally, it is increasingly recognised that information as to how a patient feels and functions [obtained by patient- reported outcome measurements (PROMs)] is critical to any comprehensive evaluation of treatment.
  • Based on a literature review and with input from patients, 65 potential goals were formulated as statements.
  • When applying this set of goals in medical practice, the clinical status of the individual patient should be taken into account.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright © 2016. Published by Elsevier Inc.
  • (PMID = 28274788.001).
  • [ISSN] 1096-0961
  • [Journal-full-title] Blood cells, molecules & diseases
  • [ISO-abbreviation] Blood Cells Mol. Dis.
  • [Language] eng
  • [Grant] United Kingdom / Medical Research Council / / MR/K015338/1; United Kingdom / Medical Research Council / / MR/K025570/1
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Keywords] NOTNLM ; Delphi study / Gaucher disease / Management goals / PROMs / Therapy
  •  go-up   go-down


30. Duma A, Pal S, Johnston J, Helwani MA, Bhat A, Gill B, Rosenkvist J, Cartmill C, Brown F, Miller JP, Scott MG, Sanchez-Conde F, Jarvis M, Farber NB, Zorumski CF, Conway C, Nagele P: High-sensitivity Cardiac Troponin Elevation after Electroconvulsive Therapy: A Prospective, Observational Cohort Study. Anesthesiology; 2017 Apr;126(4):643-652

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • METHODS: This was a prospective cohort study in adult patients undergoing electroconvulsive therapy in a single academic center (up to three electroconvulsive therapy treatments per patient).
  • Twelve-lead electrocardiogram and high-sensitivity cardiac troponin I values were obtained before and 15 to 30 min after electroconvulsive therapy; in a subset of patients, an additional 2-h high-sensitivity cardiac troponin I value was obtained.
  • RESULTS: The final study population was 100 patients and a total of 245 electroconvulsive therapy treatment sessions.
  • Eight patients (8 of 100; 8%) experienced new high-sensitivity cardiac troponin I elevation after electroconvulsive therapy with a cumulative incidence of 3.7% (9 of 245 treatments; one patient had two high-sensitivity cardiac troponin I elevations), two of whom had a non-ST-elevation myocardial infarction (incidence 2 of 245; 0.8%).
  • CONCLUSIONS: Electroconvulsive therapy appears safe from a cardiac standpoint in a large majority of patients.
  • A small subset of patients with preexisting cardiovascular risk factors, however, may develop new cardiac troponin elevation after electroconvulsive therapy, the clinical relevance of which is unclear in the absence of signs of myocardial ischemia.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Clin Anesth. 1990 Jan-Feb;2(1):37-41 [2310579.001]
  • [Cites] Am Heart J. 2013 Aug;166(2):325-332.e1 [23895816.001]
  • [Cites] J ECT. 2008 Dec;24(4):277-80 [18955900.001]
  • [Cites] Circulation. 2012 Oct 16;126(16):2020-35 [22923432.001]
  • [Cites] J ECT. 2014 Dec;30(4):263-4 [25166734.001]
  • [Cites] Circulation. 2011 Jul 12;124(2):136-45 [21709058.001]
  • [Cites] JAMA. 1985 May 3;253(17):2525-9 [3981780.001]
  • [Cites] Am J Med. 2011 Nov;124(11):e11; author reply e13 [21722866.001]
  • [Cites] Br J Anaesth. 2014 Jul;113(1):43-51 [24942714.001]
  • [Cites] Eur Heart J Acute Cardiovasc Care. 2015 Oct;4(5):419-28 [25505224.001]
  • [Cites] Clin Biochem. 2015 Mar;48(4-5):218-22 [25218832.001]
  • [Cites] Clin Chem. 2010 Apr;56(4):642-50 [20167697.001]
  • [Cites] Anesth Analg. 1992 Oct;75(4):511-4 [1530163.001]
  • [Cites] Arch Intern Med. 1983 Sep;143(9):1786-7 [6615101.001]
  • [Cites] Clin Chem. 2009 Nov;55(11):2057-9 [19729470.001]
  • [Cites] Am J Med. 2014 Feb;127(2):105-8 [24462011.001]
  • [Cites] Anesth Analg. 1996 Jan;82(1):143-7 [8712391.001]
  • [Cites] Br J Anaesth. 1999 Aug;83(2):271-4 [10618942.001]
  • [Cites] Am J Med. 2016 Apr;129(4):354-65 [26743351.001]
  • [Cites] Am J Psychiatry. 1995 Nov;152(11):1697-8 [7485653.001]
  • [Cites] J ECT. 2009 Jun;25(2):117-20 [19225404.001]
  • [Cites] J ECT. 2011 Sep;27(3):221-3 [21673587.001]
  • [Cites] N Engl J Med. 2009 Apr 2;360(14):1437-44 [19339723.001]
  • [Cites] Psychosomatics. 2010 Sep-Oct;51(5):432-6 [20833943.001]
  • [Cites] Clin Chem. 2011 Jul;57(7):1080-1 [21519039.001]
  • [Cites] Anesth Analg. 2016 Jul;123(1):5-7 [27192474.001]
  • [Cites] Am J Geriatr Psychiatry. 2005 Apr;13(4):268-81 [15845752.001]
  • [Cites] Eur Heart J Acute Cardiovasc Care. 2014 Dec;3(4):313-6 [25009249.001]
  • [Cites] Clin Chem. 2016 Feb;62(2):360-6 [26546635.001]
  • [Cites] Clin Chem Lab Med. 2014 Nov;52(11):1657-65 [24897400.001]
  • [Cites] Biol Psychiatry. 1990 Nov 1;28(9):758-66 [2257285.001]
  • [Cites] JAMA Cardiol. 2016 Jun 1;1(3):247-8 [27438099.001]
  • [Cites] Anesthesiology. 1993 Aug;79(2):383-8 [8342848.001]
  • [Cites] Am J Med. 2011 Mar;124(3):229-34 [21396506.001]
  • (PMID = 28166110.001).
  • [ISSN] 1528-1175
  • [Journal-full-title] Anesthesiology
  • [ISO-abbreviation] Anesthesiology
  • [Language] eng
  • [Grant] United States / NHLBI NIH HHS / HL / R01 HL126892; United States / NIMH NIH HHS / MH / R21 MH108901; United States / NCRR NIH HHS / RR / UL1 RR024992; United States / NCATS NIH HHS / TR / UL1 TR000448
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


31. Volkers EJ, Greving JP, Hendrikse J, Algra A, Kappelle LJ, Becquemin JP, Bonati LH, Brott TG, Bulbulia R, Calvet D, Eckstein HH, Fraedrich G, Gregson J, Halliday A, Howard G, Jansen O, Roubin GS, Brown MM, Mas JL, Ringleb PA, Carotid Stenosis Trialists' Collaboration: Body mass index and outcome after revascularization for symptomatic carotid artery stenosis. Neurology; 2017 Apr 26;

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • OBJECTIVE: To determine whether the obesity paradox exists in patients who undergo carotid artery stenting (CAS) or carotid endarterectomy (CEA) for symptomatic carotid artery stenosis.
  • METHODS: We combined individual patient data from 2 randomized trials (Endarterectomy vs Angioplasty in Patients with Symptomatic Severe Carotid Stenosis and Stent-Protected Angioplasty vs Carotid Endarterectomy) and 3 centers in a third trial (International Carotid Stenting Study).
  • Baseline body mass index (BMI) was available for 1,969 patients and classified into 4 groups: <20, 20-<25, 25-<30, and ≥30 kg/m<sup>2</sup>.
  • This outcome was compared between different BMI strata in CAS and CEA patients separately, and in the total group.
  • Stroke or death occurred in 159 patients in the periprocedural (cumulative risk 8.1%) and in 270 patients in the postprocedural period (rate 4.8/100 person-years).
  • BMI did not affect periprocedural risk of stroke or death for patients assigned to CAS (<i>p</i><sub>trend</sub> = 0.39) or CEA (<i>p</i><sub>trend</sub> = 0.77) or for the total group (<i>p</i><sub>trend</sub> = 0.48).
  • Within the total group, patients with BMI 25-<30 had lower postprocedural risk of stroke or death than patients with BMI 20-<25 (BMI 25-<30 vs BMI 20-<25; hazard ratio 0.72; 95% confidence interval 0.55-0.94).

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] © 2017 American Academy of Neurology.
  • (PMID = 28446644.001).
  • [ISSN] 1526-632X
  • [Journal-full-title] Neurology
  • [ISO-abbreviation] Neurology
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Investigator] Algra A Prof; Becquemin JP Prof; Calvet D; Mas JL Prof; Bonati LH; Brown MM Prof; Hendrikse J Prof; Eckstein HH Prof; Fraedrich G Prof; Jansen O Prof; Ringleb PA Prof; Brott TG Prof; Howard G Prof; Roubin GS Prof; Bulbulia R; Halliday A; Radcliffe J; Gregson J
  •  go-up   go-down


32. Schober A, Sterz F, Herkner H, Wallmueller C, Weiser C, Hubner P, Testori C: Emergency extracorporeal life support and ongoing resuscitation: a retrospective comparison for refractory out-of-hospital cardiac arrest. Emerg Med J; 2017 May;34(5):277-281

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Extracorporeal cardiopulmonary resuscitation (ECPR) is an option for certain patients with cardiac arrest.
  • The aim of this study was to evaluate characteristics of patients selected for ECPR.
  • METHODS: Anonymised data of adult patients suffering refractory cardiac arrest, transported with ongoing CPR to an ED of a tertiary care centre between 2002 and 2012 were analysed.
  • RESULTS: Overall, 239 patients fulfilled the inclusion criteria.
  • ECPR was initiated in seven patients.
  • Patients treated with ECPR were younger (46 vs 60 years; p=0.04), had shorter intervals before CPR was started (0 vs 1 min; p=0.013), faster admissions at the ED (38 vs 56 min; p=0.31) and lower blood glucose levels on admission (14 vs 21 mmol/L; p=0.018).
  • Survival to discharge in good neurological condition was achieved in 14 (6%) of all patients.
  • One patient in the ECPR group survived in excellent neurological condition.
  • CONCLUSIONS: Emergency extracorporeal life support was used for a highly selected group of patients in refractory cardiac arrest.
  • The patient selection resulting in a survival of one patient out of seven treated seems reasonable.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] © Article author(s) (or their employer(s) unless otherwise stated in the text of the article) 2017. All rights reserved. No commercial use is permitted unless otherwise expressly granted.
  • (PMID = 28213587.001).
  • [ISSN] 1472-0213
  • [Journal-full-title] Emergency medicine journal : EMJ
  • [ISO-abbreviation] Emerg Med J
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Keywords] NOTNLM ; Cardiac arrest / ECLS / ECPR / Extracorporeal life support / Resuscitation / Ventricular fibrillation
  •  go-up   go-down


33. Ferguson S, Ahmad S, Chen Y, Ferreira C, Islam M, Keeling V, Lau A, Jin H: SU-F-T-143: Implementation of a Correction-Based Output Model for a Compact Passively Scattered Proton Therapy System. Med Phys; 2016 Jun;43(6):3494-3495

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • METHODS: A previously published output prediction model (Sahoo et al, Med Phys, 35, 5088-5097, 2008) was commissioned for our Mevion S250 proton therapy system.
  • To minimize fluence perturbation, scattered dose from range compensator and patient was not considered.
  • However, great care should be taken when the field-size is less than 5×5 cm<sup>2</sup> where a direct output measurement is required due to substantial output change by irregular block shape.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] © 2016 American Association of Physicists in Medicine.
  • (PMID = 28047467.001).
  • [ISSN] 2473-4209
  • [Journal-full-title] Medical physics
  • [ISO-abbreviation] Med Phys
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Keywords] NOTNLM ; Computer modeling / Interpolation / Proton therapy
  •  go-up   go-down


34. Tursi A, Di Mario F, Franceschi M, De Bastiani R, Elisei W, Baldassarre G, Ferronato A, Grillo S, Landi S, Zamparella M, De Polo M, Boscariolo L, Picchio M: New bismuth-containing quadruple therapy in patients infected with Helicobacter pylori: A first Italian experience in clinical practice. Helicobacter; 2017 Jun;22(3)

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] New bismuth-containing quadruple therapy in patients infected with Helicobacter pylori: A first Italian experience in clinical practice.
  • AIMS: To test the efficacy and safety of the new bismuth-containing quadruple therapy in patients infected with Helicobacter pylori.
  • MATERIAL AND METHODS: Consecutive H. pylori-positive dyspeptic patients were enrolled, either naïve or with previous failure treatment.
  • Patients were treated with Pylera<sup>®</sup> (three-in-one capsules containing bismuth subcitrate potassium 140 mg, metronidazole 125 mg, and tetracycline 125 mg) three capsules q.i.d. plus omeprazole 20 mg or esomeprazole 40 mg b.i.d. for 10 days.
  • RESULTS: One hundred and thirty-one patients were included in the study: 42% of patients were naïve, and 58%, with previous failure treatment. H. pylori eradication was achieved in 124 patients (94.7%, 95% confidence intervals (CIs) 89.3-97.8) in ITT population.
  • No difference in eradication rate was found either between naïve and previously treated patients (92.7% vs 96.0%, P=.383), or smoking and nonsmoking ones, or in patients taking omeprazole or esomeprazole.
  • Treatment-emergent adverse events occurred in 35 patients (26.7%, 95% CIs 19.9-34.9).
  • They were mild in all cases except in four, who discontinued the study due to diarrhea (three patients) and diffuse urticarial rush (one patient).

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] © 2017 John Wiley & Sons Ltd.
  • (PMID = 28125857.001).
  • [ISSN] 1523-5378
  • [Journal-full-title] Helicobacter
  • [ISO-abbreviation] Helicobacter
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Keywords] NOTNLM ; Helicobacter pylori / antibiotics / bismuth-containing therapy / treatment
  •  go-up   go-down


35. Vesterhus M, Holm A, Hov JR, Nygård S, Schrumpf E, Melum E, Thorbjørnsen LW, Paulsen V, Lundin K, Dale I, Gilja OH, Zweers SJ, Vatn M, Schaap FG, Jansen PL, Ueland T, Røsjø H, Moum B, Ponsioen CY, Boberg KM, Färkkilä M, Karlsen TH, Lund-Johansen F: Novel serum and bile protein markers predict primary sclerosing cholangitis disease severity and prognosis. J Hepatol; 2017 Feb 02;
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND & AIMS: Prognostic biomarkers are lacking in primary sclerosing cholangitis, hampering patient care and the development of therapy.
  • RESULTS: In the bile derivation panel, the levels of 14 proteins were different between PSC patients and controls (p<0.05); all were confirmed in the validation panel.
  • Twenty-four proteins in the bile derivation panel were significantly (p<0.05) different between PSC patients with mild compared to severe cholangiographic changes (modified Amsterdam criteria); this was replicated for 18 proteins in the validation panel.
  • Stratifying PSC patients according to tertiles of serum IL-8, but not MMP9/LCN2 and S100A12, provided excellent discrimination for transplant-free survival both in the serum derivation and validation cohort.
  • LAY SUMMARY: Prognostic biomarkers are lacking in primary sclerosing cholangitis, hampering patient care and the development of therapy.
  • We have identified inflammatory proteins including calprotectin and IL-8 as important indicators of disease severity and prognosis in bile and serum from patients with primary sclerosing cholangitis.

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright © 2017 European Association for the Study of the Liver. Published by Elsevier B.V. All rights reserved.
  • (PMID = 28161472.001).
  • [ISSN] 1600-0641
  • [Journal-full-title] Journal of hepatology
  • [ISO-abbreviation] J. Hepatol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Netherlands
  • [Keywords] NOTNLM ; Biomarker / Calprotectin / IL-8 / PSC / Prognosis
  •  go-up   go-down


36. Ji L, Bonnet F, Charbonnel B, Gomes MB, Kosiborod M, Khunti K, Nicolucci A, Pocock S, Rathmann W, Shestakova MV, Shimomura I, Watada H, Fenici P, Hammar N, Hashigami K, Macaraeg G, Surmont F, Medina J: Towards an improved global understanding of treatment and outcomes in people with type 2 diabetes: Rationale and methods of the DISCOVER observational study program. J Diabetes Complications; 2017 Apr 05;

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The global DISCOVER study program aims to describe the disease management patterns and a broad range of associated outcomes in patients with type 2 diabetes initiating a second-line glucose-lowering therapy in routine clinical practice.
  • METHODS: The DISCOVER program comprises two longitudinal observational studies involving more than 15,000 patients in 38 countries across six continents.
  • RESULTS: The DISCOVER program will record patient, healthcare provider, and healthcare system characteristics, treatment patterns, and factors influencing changes in therapy.
  • Microvascular and macrovascular complications, incidence of hypoglycemic events, and patient-reported outcomes will also be captured.
  • CONCLUSIONS: The DISCOVER program will provide insights into the current management of patients with type 2 diabetes worldwide, which will contribute to informing future clinical guidelines and improving patient care.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright © 2017 The Authors. Published by Elsevier Inc. All rights reserved.
  • (PMID = 28499961.001).
  • [ISSN] 1873-460X
  • [Journal-full-title] Journal of diabetes and its complications
  • [ISO-abbreviation] J. Diabetes Complicat.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Keywords] NOTNLM ; Longitudinal observational study / Outcomes / Real-world evidence / Second-line therapy / Treatment patterns / Type 2 diabetes
  •  go-up   go-down


37. Mehta S, Burns KE, Machado FR, Fox-Robichaud AE, Cook DJ, Calfee CS, Ware LB, Burnham EL, Kissoon N, Marshall JC, Mancebo J, Finfer S, Hartog C, Reinhart K, Maitland K, Stapleton RD, Kwizera A, Amin P, Abroug F, Smith O, Laake JH, Shrestha GS, Herridge MS: Gender Parity in Critical Care Medicine. Am J Respir Crit Care Med; 2017 Feb 27;

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Gender Parity in Critical Care Medicine.
  • Clinical practice guidelines are systematically developed statements to assist practitioner and patient decisions about appropriate healthcare for specific clinical circumstances.
  • These documents inform and shape patient care around the world.
  • In this perspective we discuss the importance of diversity on guideline panels, the disproportionately low representation of women on critical care guideline panels, and existing initiatives to increase the representation of women in corporations, universities and government.
  • We propose five strategies to ensure gender parity within critical care medicine.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 28240961.001).
  • [ISSN] 1535-4970
  • [Journal-full-title] American journal of respiratory and critical care medicine
  • [ISO-abbreviation] Am. J. Respir. Crit. Care Med.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Keywords] NOTNLM ; diversity, gender, critical care, interprofessional
  •  go-up   go-down


38. Tan D, Xu J, Shao S, Fu Y, Sun F, Zhang Y, Hu Y, Walline J, Zhu H, Yu X: Comparison of different inspiratory triggering settings in automated ventilators during cardiopulmonary resuscitation in a porcine model. PLoS One; 2017;12(2):e0171869

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • A turned-off patient triggering or a pressure-triggering of 20 cmH2O is preferred for ventilation when an ordinary inpatient hospital ventilator is used during resuscitation.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Eur J Anaesthesiol. 2014 Jul;31(7):371-80 [24625464.001]
  • [Cites] Crit Care Med. 1998 Apr;26(4):710-6 [9559609.001]
  • [Cites] Crit Care Med. 2014 Feb;42(2):e89-95 [24158168.001]
  • [Cites] Intensive Care Med. 1995 Feb;21(2):159-68 [7775698.001]
  • [Cites] Lancet. 2010 Nov 6;376(9752):1552-7 [20951422.001]
  • [Cites] Resuscitation. 2007 Apr;73(1):123-30 [17175090.001]
  • [Cites] Circulation. 2015 Nov 3;132(18 Suppl 2):S444-64 [26472995.001]
  • [Cites] South Med J. 2005 Oct;98(10):970-6 [16295811.001]
  • [Cites] Resuscitation. 2011 Aug;82(8):1025-9 [21497007.001]
  • [Cites] Chin J Traumatol. 2012;15(5):284-7 [23069099.001]
  • [Cites] Respir Care. 1992 Sep;37(9):1056-69 [10145700.001]
  • [Cites] Crit Care Med. 1994 Nov;22(11):1827-34 [7956288.001]
  • [Cites] Resuscitation. 2008 Oct;79(1):118-24 [18586375.001]
  • [Cites] Intensive Care Med. 2006 Jun;32(6):843-51 [16715326.001]
  • [Cites] Lancet. 2004 Jul 24-30;364(9431):313-5 [15276374.001]
  • [Cites] Resuscitation. 2012 Feb;83(2):259-64 [21854734.001]
  • [Cites] Acta Paediatr. 1998 Dec;87(12):1256-60 [9894826.001]
  • [Cites] Ann Emerg Med. 1992 Sep;21(9):1094-101 [1514720.001]
  • [Cites] Eur Heart J Acute Cardiovasc Care. 2015 Feb;4(1):24-7 [24381094.001]
  • [Cites] Respir Care. 2008 Jul;53(7):862-70 [18593487.001]
  • [Cites] Acad Emerg Med. 1995 Aug;2(8):719-24 [7584751.001]
  • [Cites] Resuscitation. 2007 Apr;73(1):82-5 [17289248.001]
  • [Cites] Ann Emerg Med. 1990 Oct;19(10):1104-6 [2121075.001]
  • [Cites] Resuscitation. 2007 Jul;74(1):94-101 [17287062.001]
  • [Cites] PLoS One. 2015 May 26;10(5):e0127759 [26011525.001]
  • [Cites] Crit Care Med. 2004 Sep;32(9 Suppl):S345-51 [15508657.001]
  • [Cites] JAMA. 2005 Jan 19;293(3):305-10 [15657323.001]
  • [Cites] Circulation. 2002 Jul 16;106(3):373-8 [12119256.001]
  • [Cites] Resuscitation. 2013 Mar;84(3):298-303 [22885095.001]
  • [Cites] Circulation. 2015 Nov 3;132(18 Suppl 2):S436-43 [26472994.001]
  • [Cites] Circulation. 2004 Apr 27;109(16):1960-5 [15066941.001]
  • [Cites] Circulation. 2015 Nov 3;132(18 Suppl 2):S414-35 [26472993.001]
  • [Cites] Resuscitation. 2017 Jan;110:101-106 [27840003.001]
  • (PMID = 28187154.001).
  • [ISSN] 1932-6203
  • [Journal-full-title] PloS one
  • [ISO-abbreviation] PLoS ONE
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


39. Khan A, Coffey M, Litterer KP, Baird JD, Furtak SL, Garcia BM, Ashland MA, Calaman S, Kuzma NC, O'Toole JK, Patel A, Rosenbluth G, Destino LA, Everhart JL, Good BP, Hepps JH, Dalal AK, Lipsitz SR, Yoon CS, Zigmont KR, Srivastava R, Starmer AJ, Sectish TC, Spector ND, West DC, Landrigan CP, and the Patient and Family Centered I-PASS Study Group, Allair BK, Alminde C, Alvarado-Little W, Atsatt M, Aylor ME, Bale JF Jr, Balmer D, Barton KT, Beck C, Bismilla Z, Blankenberg RL, Chandler D, Choudhary A, Christensen E, Coghlan-McDonald S, Cole FS, Corless E, Cray S, Da Silva R, Dahale D, Dreyer B, Growdon AS, Gubler L, Guiot A, Harris R, Haskell H, Kocolas I, Kruvand E, Lane MM, Langrish K, Ledford CJ, Lewis K, Lopreiato JO, Maloney CG, Mangan A, Markle P, Mendoza F, Micalizzi DA, Mittal V, Obermeyer M, O'Donnell KA, Ottolini M, Patel SJ, Pickler R, Rogers JE, Sanders LM, Sauder K, Shah SS, Sharma M, Simpkin A, Subramony A, Thompson ED Jr, Trueman L, Trujillo T, Turmelle MP, Warnick C, Welch C, White AJ, Wien MF, Winn AS, Wintch S, Wolf M, Yin HS, Yu CE: Families as Partners in Hospital Error and Adverse Event Surveillance. JAMA Pediatr; 2017 Apr 01;171(4):372-381

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • While clinician reports are the foundation of operational hospital safety surveillance and a key component of multifaceted research surveillance, patient and family reports are not routinely gathered.
  • Design, Setting, and Participants: We conducted a prospective cohort study including the parents/caregivers of 989 hospitalized patients 17 years and younger (total 3902 patient-days) and their clinicians from December 2014 to July 2015 in 4 US pediatric centers.
  • Rates were generated using Poisson regression estimated via generalized estimating equations to account for repeated measures on the same patient.
  • Error rates with family reporting (45.9 per 1000 patient-days) were 1.2-fold (95% CI, 1.1-1.2) higher than rates without family reporting (39.7 per 1000 patient-days).
  • Adverse event rates with family reporting (28.7 per 1000 patient-days) were 1.1-fold (95% CI, 1.0-1.2; P = .006) higher than rates without (26.1 per 1000 patient-days).
  • Families and clinicians reported similar rates of errors (10.0 vs 12.8 per 1000 patient-days; relative rate, 0.8; 95% CI, .5-1.2) and AEs (8.5 vs 6.2 per 1000 patient-days; relative rate, 1.4; 95% CI, 0.8-2.2).

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 28241211.001).
  • [ISSN] 2168-6211
  • [Journal-full-title] JAMA pediatrics
  • [ISO-abbreviation] JAMA Pediatr
  • [Language] eng
  • [Grant] United States / AHRQ HHS / HS / K12 HS022986
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


40. Rossi C, Raboud J, Walmsley S, Cooper C, Antoniou T, Burchell AN, Hull M, Chia J, Hogg RS, Moodie EE, Klein MB, Canadian Observational Cohort (CANOC) Collaboration: Hepatitis C co-infection is associated with an increased risk of incident chronic kidney disease in HIV-infected patients initiating combination antiretroviral therapy. BMC Infect Dis; 2017 Apr 04;17(1):246
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Hepatitis C co-infection is associated with an increased risk of incident chronic kidney disease in HIV-infected patients initiating combination antiretroviral therapy.
  • BACKGROUND: Combination antiretroviral therapy (cART) has reduced mortality from AIDS-related illnesses and chronic comorbidities have become prevalent among HIV-infected patients.
  • We examined the association between hepatitis C virus (HCV) co-infection and chronic kidney disease (CKD) among patients initiating modern antiretroviral therapy.
  • CKD incidence rates after cART initiation were compared between HCV co-infected and HIV mono-infected patients.
  • RESULTS: We included 2595 HIV-infected patients with eGFR >60 mL/min/1.73m<sup>2</sup> at cART initiation, of which 19% were HCV co-infected.
  • One hundred and fifty patients developed CKD during 10,903 person-years of follow-up (PYFU).
  • The CKD incidence rate was higher among co-infected than HIV mono-infected patients (26.0 per 1000 PYFU vs. 10.7 per 1000 PYFU).
  • CONCLUSIONS: HCV co-infection was associated with an increased risk of incident CKD among HIV-infected patients initiating cART.
  • HCV-HIV co-infected patients should be monitored for kidney disease and may benefit from available HCV treatments.

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Acquir Immune Defic Syndr. 2012 Nov 1;61(3):302-9 [22842844.001]
  • [Cites] HIV Med. 2015 Apr;16 Suppl 1:55-63 [25711324.001]
  • [Cites] Stat Methods Med Res. 2013 Jun;22(3):278-95 [21220355.001]
  • [Cites] AIDS. 2007 Oct 1;21(15):2101-3 [17885301.001]
  • [Cites] J Viral Hepat. 2015 Nov;22(11):906-13 [25894392.001]
  • [Cites] J Acquir Immune Defic Syndr. 2010 Oct;55(2):262-70 [20700060.001]
  • [Cites] J Infect Dis. 2016 Oct 15;214(8):1212-20 [27485357.001]
  • [Cites] BMJ. 2009 Jan 26;338:a3172 [19171560.001]
  • [Cites] Medicine (Baltimore). 2011 Sep;90(5):289-95 [21857365.001]
  • [Cites] PLoS One. 2012;7(7):e40245 [22911697.001]
  • [Cites] Lancet. 2012 Jan 14;379(9811):165-80 [21840587.001]
  • [Cites] Int J Epidemiol. 2011 Feb;40(1):25-32 [20157000.001]
  • [Cites] Stat Med. 2009 Jul 10;28(15):1982-98 [19452569.001]
  • [Cites] Circulation. 2010 Feb 9;121(5):651-8 [20100969.001]
  • [Cites] Clin Infect Dis. 2005 Jun 1;40(11):1559-85 [15889353.001]
  • [Cites] AIDS. 2008 Sep 12;22(14):1799-807 [18753863.001]
  • [Cites] Ann Intern Med. 2009 May 5;150(9):604-12 [19414839.001]
  • [Cites] Hepatology. 2003 Aug;38(2):518-26 [12883497.001]
  • [Cites] J Infect Dis. 2008 Jun 1;197(11):1548-57 [18422458.001]
  • [Cites] Curr Opin HIV AIDS. 2014 Jan;9(1):41-7 [24225381.001]
  • [Cites] Epidemiology. 2015 Mar;26(2):e24-6 [25643117.001]
  • [Cites] J Gastroenterol. 2013 Jan;48(1):93-100 [22678465.001]
  • [Cites] Clin Infect Dis. 2014 Nov 1;59(9):e96-138 [25234519.001]
  • [Cites] J Infect Dis. 2016 Jan 15;213(2):257-65 [26216904.001]
  • [Cites] Gastroenterology. 2015 Nov;149(6):1345-60 [26319013.001]
  • [Cites] Lancet HIV. 2015 Mar;2(3):e92-7 [25780802.001]
  • [Cites] PLoS Med. 2015 Mar 31;12(3):e1001809 [25826420.001]
  • [Cites] Epidemiology. 1995 Jul;6(4):356-65 [7548341.001]
  • [Cites] Stat Med. 2011 Feb 20;30(4):377-99 [21225900.001]
  • [Cites] AIDS. 2012 Sep 24;26(15):1917-26 [22781222.001]
  • [Cites] AIDS. 2014 Jan 2;28(1):121-7 [24413263.001]
  • [Cites] AIDS. 2012 Sep 10;26(14):1789-94 [22739388.001]
  • [Cites] Lancet HIV. 2016 Jan;3(1):e23-32 [26762990.001]
  • [Cites] AIDS Patient Care STDS. 2011 Mar;25(3):135-41 [21309706.001]
  • [Cites] J Nephrol. 2006 May-Jun;19(3):246-58 [16874683.001]
  • [Cites] AIDS. 2016 Jun 1;30(9):1403-311 [26859371.001]
  • [Cites] MMWR Recomm Rep. 1992 Dec 18;41(RR-17):1-19 [1361652.001]
  • [Cites] Am J Kidney Dis. 2009 Jul;54(1):43-50 [19394735.001]
  • [Cites] PLoS One. 2013 Jun 12;8(6):e66223 [23776637.001]
  • [Cites] J Infect Dis. 2012 Aug 15;206(4):469-77 [22811301.001]
  • [Cites] N Engl J Med. 1993 Feb 18;328(7):465-70 [7678440.001]
  • [Cites] Curr Opin HIV AIDS. 2015 Sep;10(5):309-15 [26132342.001]
  • [Cites] Curr Opin HIV AIDS. 2015 Sep;10(5):297-302 [26248117.001]
  • [Cites] Clin Infect Dis. 2006 May 15;42(10):1488-95 [16619164.001]
  • [Cites] J Acquir Immune Defic Syndr. 2015 Apr 1;68(4):425-31 [25559601.001]
  • [Cites] J Acquir Immune Defic Syndr. 2016 Apr 15;71(5):530-7 [26627107.001]
  • [Cites] BMC Infect Dis. 2015 Jul 17;15:274 [26183704.001]
  • [Cites] Can J Infect Dis Med Microbiol. 2015 Jan-Feb;26(1):17-22 [25798149.001]
  • [Cites] AIDS. 2010 Jul 17;24(11):1667-78 [20523203.001]
  • [Cites] Liver Int. 2011 Sep;31(8):1071-80 [21745269.001]
  • [Cites] Lancet Glob Health. 2015 Mar;3(3):e169-77 [25701995.001]
  • [Cites] AIDS. 2004 Feb 20;18(3):541-6 [15090808.001]
  • [Cites] AIDS. 2014 Mar 13;28(5):727-37 [24983543.001]
  • [Cites] AIDS. 2010 Aug 24;24(13):2059-67 [20616694.001]
  • [Cites] Clin Infect Dis. 2015 Mar 15;60(6):941-9 [25409471.001]
  • [Cites] HIV Med. 2013 Jan;14(1):10-20 [22639840.001]
  • (PMID = 28376824.001).
  • [ISSN] 1471-2334
  • [Journal-full-title] BMC infectious diseases
  • [ISO-abbreviation] BMC Infect. Dis.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Keywords] NOTNLM ; Antiretroviral therapy / Chronic kidney disease / Co-infection / Glomerular filtration / HIV / Hepatitis C
  • [Investigator] Hogg R; Burchell AN; Cooper C; Kelly D; Klein M; Loutfy M; Machouf N; Montaner J; Raboud J; Tsoukas C; Sanche S; Wong A; Antoniou T; Bayoumi A; Hull M; Nosyk B; Cescon A; Cotterchio M; Goldsmith C; Guillemi S; Richard Harrigan P; Harris M; Hosein S; Johnston S; Kendall C; Liddy C; Lima V; Marsh D; Moore D; Palmer A; Patterson S; Phillips P; Rachlis A; Rourke SB; Samji H; Smieja M; Trottier B; Wainberg M; Walmsley S; Archibald C; Clement K; Crouzat F; Doolittle-Romas M; Edmiston L; Gardner S; Huskins B; Lawless J; Lee D; Masching R; Tattle S; Zahirieh A; Allen C; Calvez S; Chia J; Corsi D; Gilbert L; Gataric N; Leslie A; Light L; Pexos C; Shurgold S; Szadkowski L; Galanakis C; Sandler I; Yip B; Younger J; Zhu J
  •  go-up   go-down


41. Kimura Y, Grevich S, Beukelman T, Morgan E, Nigrovic PA, Mieszkalski K, Graham TB, Ibarra M, Ilowite N, Klein-Gitelman M, Onel K, Prahalad S, Punaro M, Ringold S, Toib D, Van Mater H, Weiss JE, Weiss PF, Schanberg LE, CARRA Registry Investigators: Pilot study comparing the Childhood Arthritis & Rheumatology Research Alliance (CARRA) systemic Juvenile Idiopathic Arthritis Consensus Treatment Plans. Pediatr Rheumatol Online J; 2017 Apr 11;15(1):23
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • METHODS: Untreated systemic JIA patients enrolled in the CARRA Registry were begun on one of 4 CTPs chosen by the treating physician and patient/family (glucocorticoid [GC] alone; methotrexate [MTX] ± GC; IL1 inhibitor [IL1i] ± GC; IL6 inhibitor [IL6i] ± GC).
  • RESULTS: Thirty patients were enrolled at 13 sites; eight patients were started on a non-biologic CTP (2 GC, 6 MTX) and 22 patients on a biologic CTP (12 IL1i, 10 IL6i) at disease onset.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Arthritis Rheum. 2013 Oct;65(10):2499-512 [24092554.001]
  • [Cites] Lancet. 2011 Jun 18;377(9783):2138-49 [21684384.001]
  • [Cites] BMC Med Res Methodol. 2010 Jan 06;10:1 [20053272.001]
  • [Cites] Arthritis Rheumatol. 2016 Dec;68(12 ):3023-3034 [27332999.001]
  • [Cites] N Engl J Med. 2012 Dec 20;367 (25):2396-406 [23252526.001]
  • [Cites] Arthritis Care Res (Hoboken). 2013 May;65(5):745-52 [23139240.001]
  • [Cites] J Rheumatol. 2011 Apr;38(4):741-6 [21285163.001]
  • [Cites] J Rheumatol. 1992 Mar;19(3):424-30 [1578458.001]
  • [Cites] Lancet. 2008 Mar 22;371(9617):998-1006 [18358927.001]
  • [Cites] J Rheumatol. 2008 Feb;35(2):343-8 [18085728.001]
  • [Cites] J Rheumatol. 2016 Sep;43(9):1755-62 [27307527.001]
  • [Cites] J Rheumatol. 2004 Nov;31(11):2290-4 [15517647.001]
  • [Cites] Arthritis Rheum. 2000 Nov;43(11):2402-9 [11083261.001]
  • [Cites] Ann Rheum Dis. 2011 May;70(5):747-54 [21173013.001]
  • [Cites] Arthritis Rheumatol. 2014 Jun;66(6):1405-13 [24623686.001]
  • [Cites] Arthritis Rheum. 2006 May;54(5):1595-601 [16645998.001]
  • [Cites] Arthritis Rheumatol. 2014 Apr;66(4):1034-43 [24757154.001]
  • [Cites] J Rheumatol. 2004 Feb;31(2):390-2 [14760812.001]
  • [Cites] Arthritis Care Res (Hoboken). 2012 Jul;64(7):1001-10 [22290637.001]
  • [Cites] Ann Intern Med. 2009 Aug 4;151(3):203-5 [19567618.001]
  • [Cites] Arthritis Care Res (Hoboken). 2014 Sep;66(9):1430-1 [24719268.001]
  • [Cites] Lifetime Data Anal. 2007 Mar;13(1):119-37 [17031496.001]
  • [Cites] N Engl J Med. 2012 Dec 20;367 (25):2385-95 [23252525.001]
  • [Cites] Arthritis Rheum. 2011 Feb;63(2):545-55 [21280009.001]
  • [Cites] Arthritis Care Res (Hoboken). 2011 Jul;63(7):929-36 [21717596.001]
  • [Cites] Arthritis Care Res (Hoboken). 2011 Apr;63(4):465-82 [21452260.001]
  • [Cites] Ann Rheum Dis. 2016 Sep;75(9):1654-60 [26644233.001]
  • (PMID = 28399931.001).
  • [ISSN] 1546-0096
  • [Journal-full-title] Pediatric rheumatology online journal
  • [ISO-abbreviation] Pediatr Rheumatol Online J
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Keywords] NOTNLM ; Biologic response modifiers / Comparative effectiveness / Pediatric rheumatology / Registries / Still’s disease / Systemic Juvenile Idiopathic Arthritis
  • [Investigator] Abramson L; Anderson E; Andrew M; Battle N; Becker M; Benham H; Beukelman T; Birmingham J; Blier P; Brown A; Brunner H; Cabrera A; Canter D; Carlton D; Caruso B; Ceracchio L; Chalom E; Chang J; Charpentier P; Clark K; Dean J; Dedeoglu F; Feldman B; Ferguson P; Fox M; Francis K; Gervasini M; Goldsmith D; Gorton G; Gottlieb B; Graham T; Griffin T; Grosbein H; Guppy S; Haftel H; Helfrich D; Higgins G; Hillard A; Hollister JR; Hsu J; Hudgins A; Hung C; Huttenlocher A; Ilowite N; Imlay A; Imundo L; Inman CJ; Jaqith J; Jerath R; Jung L; Kahn P; Kapedani A; Kingsbury D; Klein K; Klein-Gitelman M; Kunkel A; Lapidus S; Layburn S; Lehman T; Lindsley C; Macgregor-Hannah M; Malloy M; Mawhorter C; McCurdy D; Mims K; Moorthy N; Morus D; Muscal E; Natter M; Olson J; O'Neil K; Onel K; Orlando M; Palmquist J; Phillips M; Ponder L; Prahalad S; Punaro M; Puplava D; Quinn S; Quintero A; Rabinovich C; Reed A; Reed C; Ringold S; Riordan M; Roberson S; Robinson A; Rossette J; Rothman D; Russo D; Ruth N; Schikler K; Sestak A; Shaham B; Sherman Y; Simmons M; Singer N; Spalding S; Stapp H; Syed R; Thomas E; Torok K; Trejo D; Tress J; Upton W; Vehe R; von Scheven E; Walters L; Weiss JE; Weiss PF; Welnick N; White A; Woo J; Wootton J; Yalcindag A; Zapp C; Zemel L; Zhu A
  •  go-up   go-down


42. Sheedy SP, Bruining DH, Dozois EJ, Faubion WA, Fletcher JG: MR Imaging of Perianal Crohn Disease. Radiology; 2017 Mar;282(3):628-645

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Perianal fistulas are a leading cause of patient morbidity because closure often requires multimodality treatments over a prolonged period of time.
  • Different treatment modalities are selected based on fistula anatomy, patient factors, and management goals (closure versus sepsis control).
  • Radiologists can help maximize patient care by being familiar with MR imaging features of perianal Crohn disease and knowledgeable about what features may influence therapy decisions.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 28218881.001).
  • [ISSN] 1527-1315
  • [Journal-full-title] Radiology
  • [ISO-abbreviation] Radiology
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


43. Neyt M, Baeyens H, Pouppez C, Slegers P, Hulstaert F, Stordeur S, Vinck I: Introduction of high-risk medical devices: national measures that can be taken under the current European legislation to put the patient interest central. Expert Rev Med Devices; 2017 Mar;14(3):181-188

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Introduction of high-risk medical devices: national measures that can be taken under the current European legislation to put the patient interest central.
  • INTRODUCTION: High-risk medical devices may not always provide a therapeutic added value to patients.
  • In conclusion, within the framework of the (revised) European legislation, measures at national level can be taken to temporarily restrict and follow up the use of high-risk medical devices with a greater focus on the therapeutic added value for the patients.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 28128008.001).
  • [ISSN] 1745-2422
  • [Journal-full-title] Expert review of medical devices
  • [ISO-abbreviation] Expert Rev Med Devices
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Keywords] NOTNLM ; Device approval / European union / equipement and supplies / government regulation / treatment outcome
  •  go-up   go-down


44. Babiloni C, Del Percio C, Lizio R, Noce G, Cordone S, Lopez S, Soricelli A, Ferri R, Pascarelli MT, Nobili F, Arnaldi D, Aarsland D, Orzi F, Buttinelli C, Giubilei F, Onofrj M, Stocchi F, Stirpe P, Fuhr P, Gschwandtner U, Ransmayr G, Caravias G, Garn H, Sorpresi F, Pievani M, Frisoni GB, D'Antonio F, De Lena C, Güntekin B, Hanoğlu L, Başar E, Yener G, Emek-Savaş DD, Triggiani AI, Franciotti R, De Pandis MF, Bonanni L: Abnormalities of cortical neural synchronization mechanisms in patients with dementia due to Alzheimer's and Lewy body diseases: an EEG study. Neurobiol Aging; 2017 Apr 05;

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Abnormalities of cortical neural synchronization mechanisms in patients with dementia due to Alzheimer's and Lewy body diseases: an EEG study.
  • The aim of this retrospective exploratory study was that resting state eyes-closed electroencephalographic (rsEEG) rhythms might reflect brain arousal in patients with dementia due to Alzheimer's disease dementia (ADD), Parkinson's disease dementia (PDD), and dementia with Lewy body (DLB).
  • Demography, education, and Mini-Mental State Evaluation score were not different between the patient groups.
  • Furthermore, all patient groups showed lower posterior alpha 2 source activities.
  • The posterior delta and alpha sources allowed good classification accuracy (approximately 0.85-0.90) between the Nold subjects and patients, and between ADD and PDD patients.
  • In quiet wakefulness, delta and alpha sources unveiled different spatial and frequency features of the cortical neural synchronization underpinning brain arousal in ADD, PDD, and DLB patients.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright © 2017 Elsevier Inc. All rights reserved.
  • (PMID = 28454845.001).
  • [ISSN] 1558-1497
  • [Journal-full-title] Neurobiology of aging
  • [ISO-abbreviation] Neurobiol. Aging
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Keywords] NOTNLM ; Alzheimer's disease dementia (ADD) / Dementia with Lewy body (DLB) / Exact low-resolution brain electromagnetic source tomography (eLORETA) / Parkinson's disease dementia (PDD) / Resting state electroencephalographic (rsEEG) rhythms
  •  go-up   go-down


45. Pericàs JM, Messina JA, Garcia-de-la-Mària C, Park L, Sharma-Kuinkel BK, Marco F, Wray D, Kanafani ZA, Carugati M, Durante-Mangoni E, Tattevin P, Chu VH, Moreno A, Fowler VG Jr, Miró JM, International Collaboration on Endocarditis Microbiology Investigators: Influence of vancomycin minimum inhibitory concentration on the outcome of methicillin-susceptible Staphylococcus aureus left-sided infective endocarditis treated with antistaphylococcal β-lactam antibiotics: a prospective cohort study by the International Collaboration on Endocarditis. Clin Microbiol Infect; 2017 Feb 01;
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • METHODS: All patients with left-sided MSSA infective endocarditis treated with antistaphylococcal β-lactam antibiotics between 2000 and 2006 with available isolates were included.
  • No significant differences in patient demographic data or characteristics of infection were observed between patients with infective endocarditis due to high and low vancomycin MIC isolates.
  • CONCLUSIONS: In this international cohort of patients with left-sided MSSA endocarditis treated with antistaphylococcal β-lactams, vancomycin MIC phenotype was not associated with patient demographics, clinical outcome or virulence gene repertoire.

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright © 2017 European Society of Clinical Microbiology and Infectious Diseases. Published by Elsevier Ltd. All rights reserved.
  • (PMID = 28159672.001).
  • [ISSN] 1469-0691
  • [Journal-full-title] Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases
  • [ISO-abbreviation] Clin. Microbiol. Infect.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Keywords] NOTNLM ; Endocarditis / Genotype / Phenotype / Staphylococcus aureus / Vancomycin MIC
  • [Investigator] Athan E; Harris O; Korman TM; Kotsanas D; Jones P; Reinbott P; Ryan S; Fortes CQ; Garcia P; Jones SB; Barsic B; Bukovski S; Selton-Suty C; Aissa N; Doco-Lecompte T; Delahaye F; Vandenesch F; Tattevin P; Hoen B; Plesiat P; Giamarellou H; Giannitsioti E; Tarpatzi E; Durante-Mangoni E; Iossa D; Orlando S; Ursi MP; Pafundi PC; D' Amico F; Bernardo M; Cuccurullo S; Dialetto G; Covino FE; Manduca S; Della Corte A; De Feo M; Tripodi MF; Baban T; Kanafani Z; Kanj SS; Sfeir J; Yasmine M; Morris A; Murdoch DR; Premru MM; Lejko-Zupanc T; Almela M; Ambrosioni J; Azqueta M; Brunet M; Cervera C; De Lazzari E; Falces C; Fuster D; Garcia-de-la-Maria C; Garcia-Gonzalez J; Gatell JM; Marco F; Miró JM; Moreno A; Ortiz J; Ninot S; Paré JC; Pericas JM; Quintana E; Ramirez J; Sandoval E; Sitges M; Tolosana JM; Vidal B; Vila J; Bouza E; Rodríguez-Créixems M; Ramallo V; Bradley S; Wray D; Steed L; Cantey R; Peterson G; Stancoven A; Woods C; Corey GR; Reller LB; Fowler VG Jr; Chu VH; Baloch K; Chu VH; Corey GR; Dixon CC; Fowler VG Jr; Harding T; Jones-Richmond M; Pappas P; Park LP; Redick T; Stafford J; Anstrom K; Athan E; Bayer AS; Cabell CH; Chu VH; Corey GR; Fowler VG Jr; Hoen B; Karchmer AW; Miró JM; Murdoch DR; Sexton DJ; Wang A; Bayer AS; Cabell CH; Chu V; Corey GR; Durack DT; Eykyn S; Fowler VG Jr; Hoen B; Miró JM; Moreillon P; Olaison L; Raoult D; Rubinstein E; Sexton DJ
  •  go-up   go-down


46. Laurent C, Baron M, Amara N, Haioun C, Dandoit M, Maynadié M, Parrens M, Vergier B, Copie-Bergman C, Fabiani B, Traverse-Glehen A, Brousse N, Copin MC, Tas P, Petrella T, Rousselet MC, Brière J, Charlotte F, Chassagne-Clement C, Rousset T, Xerri L, Moreau A, Martin A, Damotte D, Dartigues P, Soubeyran I, Peoch M, Dechelotte P, Michiels JF, de Mascarel A, Berger F, Bossard C, Arbion F, Quintin-Roué I, Picquenot JM, Patey M, Fabre B, Sevestre H, Le Naoures C, Chenard-Neu MP, Bastien C, Thiebault S, Martin L, Delage M, Filleron T, Salles G, Molina TJ, Delsol G, Brousset P, Gaulard P: Impact of Expert Pathologic Review of Lymphoma Diagnosis: Study of Patients From the French Lymphopath Network. J Clin Oncol; 2017 May 01;:JCO2016712083

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Impact of Expert Pathologic Review of Lymphoma Diagnosis: Study of Patients From the French Lymphopath Network.
  • Materials and Methods From January 2010 to December 2013, 42,145 samples from patients with newly diagnosed or suspected lymphomas were reviewed, according to the 2008 WHO classification, in real time by experts through the Lymphopath Network.
  • Changes in diagnosis between referral and expert review were classified as major or minor according to their potential impact on patient care.
  • A diagnostic change between referral and expert review occurred in 19.7% of patients, with an estimated impact on patient care for 17.4% of patients.
  • This rate was significantly higher for patients sent with a provisional diagnosis seeking expert second opinion (37.8%) than for patients sent with a formal diagnosis (3.7%).
  • Conclusion To our knowledge, this study provides the largest ever description of the distribution of lymphoma entities in a western country and highlights how expert review significantly contributes to a precise lymphoma diagnosis and optimal clinical management in a proportion of patients.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 28459613.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


47. Funk M, Fennie KP, Stephens KE, May JL, Winkler CG, Drew BJ, PULSE Site Investigators: Association of Implementation of Practice Standards for Electrocardiographic Monitoring With Nurses' Knowledge, Quality of Care, and Patient Outcomes: Findings From the Practical Use of the Latest Standards of Electrocardiography (PULSE) Trial. Circ Cardiovasc Qual Outcomes; 2017 Feb;10(2)
ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Association of Implementation of Practice Standards for Electrocardiographic Monitoring With Nurses' Knowledge, Quality of Care, and Patient Outcomes: Findings From the Practical Use of the Latest Standards of Electrocardiography (PULSE) Trial.
  • We evaluated implementation of American Heart Association practice standards for ECG monitoring on nurses' knowledge, quality of care, and patient outcomes.
  • Nurses' knowledge (N=3013 nurses) was measured by a validated 20-item online test, quality of care related to ECG monitoring (N=4587 patients) by on-site observation, and patient outcomes (mortality, in-hospital myocardial infarction, and not surviving a cardiac arrest; N=95 884 hospital admissions) by review of administrative, laboratory, and medical record data.
  • For most measures of quality of care (accurate electrode placement, accurate rhythm interpretation, appropriate monitoring, and ST-segment monitoring when indicated), the intervention was associated with significant improvement, which was sustained 15 months later.
  • Of the 3 patient outcomes, only in-hospital myocardial infarction declined significantly after the intervention and was sustained.
  • CONCLUSIONS: Online ECG monitoring education and strategies to change practice can lead to improved nurses' knowledge, quality of care, and patient outcomes.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] © 2017 American Heart Association, Inc.
  • (PMID = 28174175.001).
  • [ISSN] 1941-7705
  • [Journal-full-title] Circulation. Cardiovascular quality and outcomes
  • [ISO-abbreviation] Circ Cardiovasc Qual Outcomes
  • [Language] eng
  • [Databank-accession-numbers] ClinicalTrials.gov/ NCT01269736
  • [Grant] United States / NHLBI NIH HHS / HL / R01 HL081642
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Keywords] NOTNLM ; electrocardiography / nursing / outcome assessment (health care) / quality of health care / randomized controlled trial
  • [Investigator] Borman B; Calcasola S; Carey M; Currie L; Davis L; Fitzpatrick E; Fleischman R; Hawkins D; Hazlewood E; Henry R; Honess C; Kalowes P; Ann Kearns S; Leeper B; Liggett J; Lusardi P; Lynn C; Man M; McCauley K; Hing M; Pang A; Parkosewich J; Phillips J; Robinson A; Salazar N; Sandau K; Piper Sandoval C; Sangkachand P; Shaffer R; Sherrard H; Smith M; Stamm R; Strang V; Tee N; Wells K; White P
  •  go-up   go-down


48. Breitenstein C, Grewe T, Flöel A, Ziegler W, Springer L, Martus P, Huber W, Willmes K, Ringelstein EB, Haeusler KG, Abel S, Glindemann R, Domahs F, Regenbrecht F, Schlenck KJ, Thomas M, Obrig H, de Langen E, Rocker R, Wigbers F, Rühmkorf C, Hempen I, List J, Baumgaertner A, FCET2EC study group: Intensive speech and language therapy in patients with chronic aphasia after stroke: a randomised, open-label, blinded-endpoint, controlled trial in a health-care setting. Lancet; 2017 Apr 15;389(10078):1528-1538

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Intensive speech and language therapy in patients with chronic aphasia after stroke: a randomised, open-label, blinded-endpoint, controlled trial in a health-care setting.
  • METHODS: In this multicentre, parallel group, superiority, open-label, blinded-endpoint, randomised controlled trial, patients aged 70 years or younger with aphasia after stroke lasting for 6 months or more were recruited from 19 inpatient or outpatient rehabilitation centres in Germany.
  • FINDINGS: We randomly assigned 158 patients between April 1, 2012, and May 31, 2014.
  • The modified intention-to-treat population comprised 156 patients (78 per group).
  • Eight patients had adverse events during therapy or treatment deferral (one car accident [in the control group], two common cold [one patient per group], three gastrointestinal or cardiac symptoms [all intervention group], two recurrent stroke [one in intervention group before initiation of treatment, and one before group assignment had occurred]); all were unrelated to study participation.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright © 2017 Elsevier Ltd. All rights reserved.
  • (PMID = 28256356.001).
  • [ISSN] 1474-547X
  • [Journal-full-title] Lancet (London, England)
  • [ISO-abbreviation] Lancet
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Investigator] Villringer A; Bley M; Jöbges M; Halm K; Schulz J; Werner C; Goldenberg G; Klingenberg G; König E; Müller F; Gröne B; Knecht S; Baake R; Knauss J; Miethe S; Steller U; Sudhoff R; Schillikowski E; Pfeiffer G; Billo K; Hoffmann H; Ferneding FJ; Runge S; Keck T; Middeldorf V; Krüger S; Wilde B; Krakow K; Berghoff C; Reinhuber F; Maser I; Hofmann W; Sous-Kulke C; Schupp W; Oertel A; Bätz D; Hamzei F; Schulz K; Meyer A; Kartmann A; Som O; Schipke SB; Bamborschke S
  •  go-up   go-down


49. Bertini E, Dessaud E, Mercuri E, Muntoni F, Kirschner J, Reid C, Lusakowska A, Comi GP, Cuisset JM, Abitbol JL, Scherrer B, Ducray PS, Buchbjerg J, Vianna E, van der Pol WL, Vuillerot C, Blaettler T, Fontoura P, Olesoxime SMA Phase 2 Study Investigators: Safety and efficacy of olesoxime in patients with type 2 or non-ambulatory type 3 spinal muscular atrophy: a randomised, double-blind, placebo-controlled phase 2 trial. Lancet Neurol; 2017 Apr 28;
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Safety and efficacy of olesoxime in patients with type 2 or non-ambulatory type 3 spinal muscular atrophy: a randomised, double-blind, placebo-controlled phase 2 trial.
  • We investigated the safety and efficacy of olesoxime in patients with type 2 or non-ambulatory type 3 SMA.
  • METHODS: This randomised, double-blind, placebo-controlled, phase 2 study was done in 22 neuromuscular care centres in Belgium, France, Germany, Italy, Netherlands, Poland, and the UK.
  • Safety and efficacy of olesoxime were assessed in patients aged 3-25 years with genetically confirmed type 2 or non-ambulatory type 3 SMA.
  • A centralised, computerised randomisation process allocated patients (2:1 with stratification by SMA type and centre) to receive olesoxime (10 mg/kg per day) in an oral liquid suspension or placebo for 24 months.
  • Patients, investigators assessing outcomes, and sponsor study personnel were masked to treatment assignment.
  • A shorter, 20-item version of the MFM, which was specifically adapted for young children, was used to assess patients younger than 6 years.
  • Of 198 patients screened, 165 were randomly assigned to olesoxime (n=108) or placebo (n=57).
  • Five patients in the olesoxime group were not included in the primary outcome analysis because of an absence of post-baseline assessments.
  • There were two patient deaths (one in each group), but these were not deemed to be related to the study treatment.
  • Although the primary endpoint was not met, secondary endpoints and sensitivity analyses suggest that olesoxime might maintain motor function in patients with type 2 or type 3 SMA over a period of 24 months.
  • Based on these results, olesoxime might provide meaningful clinical benefits for patients with SMA and, given its mode of action, might be used in combination with other drugs targeting other mechanisms of disease, although additional evidence is needed.

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright © 2017 Elsevier Ltd. All rights reserved.
  • (PMID = 28460889.001).
  • [ISSN] 1474-4465
  • [Journal-full-title] The Lancet. Neurology
  • [ISO-abbreviation] Lancet Neurol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Investigator] André C; Bruno C; Chabrol B; Deconinck N; Estournet B; Fontaine-Carbonnel S; Goemans N; Gorni K; Govoni A; Guglieri M; Lochmuller H; Magri F; Mayer M; Müller-Felber W; Rivier F; Roper H; Schara U; Scoto M; van den Berg L; Vita G; Walter MC
  •  go-up   go-down


50. Backes D, Rinkel GJE, Greving JP, Velthuis BK, Murayama Y, Takao H, Ishibashi T, Igase M, terBrugge KG, Agid R, Jääskeläinen JE, Lindgren AE, Koivisto T, von Und Zu Fraunberg M, Matsubara S, Moroi J, Wong GKC, Abrigo JM, Igase K, Matsumoto K, Wermer MJH, van Walderveen MAA, Algra A, Vergouwen MDI: ELAPSS score for prediction of risk of growth of unruptured intracranial aneurysms. Neurology; 2017 Apr 25;88(17):1600-1606
MedlinePlus Health Information. consumer health - Brain Aneurysm.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • METHODS: From 10 cohorts of patients with unruptured intracranial aneurysms and follow-up imaging, we pooled individual data on sex, population, age, hypertension, history of subarachnoid hemorrhage, and aneurysm location, size, aspect ratio, and shape but not on smoking during follow-up and family history of intracranial aneurysms in 1,507 patients with 1,909 unruptured intracranial aneurysms and used aneurysm growth as outcome.
  • RESULTS: Aneurysm growth occurred in 257 patients (17%) and 267 aneurysms (14%) during 5,782 patient-years of follow-up.
  • CONCLUSIONS: The ELAPSS score consists of 6 easily retrievable predictors and can help physicians in decision making on the need for and timing of follow-up imaging in patients with unruptured intracranial aneurysms.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] © 2017 American Academy of Neurology.
  • (PMID = 28363976.001).
  • [ISSN] 1526-632X
  • [Journal-full-title] Neurology
  • [ISO-abbreviation] Neurology
  • [Language] eng
  • [Publication-type] Journal Article; Multicenter Study
  • [Publication-country] United States
  •  go-up   go-down


51. Beckmann S, Nikolic N, Denhaerynck K, Binet I, Koller M, Boely E, De Geest S, Psychosocial Interest Group, Swiss Transplant Cohort Study: Evolution of body weight parameters up to 3 years after solid organ transplantation: The prospective Swiss Transplant Cohort Study. Clin Transplant; 2016 Dec 23;

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • After 3 years, based on their BMI categories at 6 months, normal weight and obese liver Tx patients, as well as underweight kidney, lung and heart Tx patients had the highest weight gains.
  • Judged against international Tx patient data, the majority of our Swiss Tx recipients' experienced lower post-Tx weight gain.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] © 2016 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.
  • (PMID = 28008650.001).
  • [ISSN] 1399-0012
  • [Journal-full-title] Clinical transplantation
  • [ISO-abbreviation] Clin Transplant
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Denmark
  • [Keywords] NOTNLM ; body mass index / obesity / organ transplantation / prospective study / underweight / weight gain
  • [Investigator] Berben L; Burkhalter H; Claes V; Helmy R; Kirsch M; Leppla L; Mauthner O; Struker M; Boehler A; Gerull S; Huynh-Do U; Catana E; Simcox A; Seiler A; Klaghofer R; Künzler-Heule P; Achermann R; Amico P; Aubert JD; Banz V; Beldi G; Benden C; Berger C; Bochud PY; Bucher H; Bühler L; Carell T; Chalandon Y; de Rougemont O; Dickenmann M; Duchosal M; Elkrief L; Fehr T; Ferrari-Lacraz S; Garzoni C; Soccal PG; Gaudet C; Giostra E; Golshayan D; Hadaya K; Halter J; Heim D; Hess C; Hillinger S; Hirsch HH; Hofbauer G; Immer F; Laesser B; Lehmann R; Lovis C; Manuel O; Marti HP; Martin PY; Meylan P; Mohacsi P; Morel P; Mueller U; Mueller NJ; Mueller-McKenna H; Müller A; Müller T; Müllhaupt B; Nadal D; Pascual M; Passweg J; Rick J; Roosnek E; Rosselet A; Rothlin S; Ruschitzka F; Schanz U; Schaub S; Schnyder A; Seiler C; Stampf S; Steiger J; Stirnimann G; Toso C; Van Delden C; Venetz JP; Villard J; Wick M; Wilhelm M; Yerly P
  •  go-up   go-down


52. Stott DJ, Rodondi N, Kearney PM, Ford I, Westendorp RG, Mooijaart SP, Sattar N, Aubert CE, Aujesky D, Bauer DC, Baumgartner C, Blum MR, Browne JP, Byrne S, Collet TH, Dekkers OM, den Elzen WP, Du Puy RS, Ellis G, Feller M, Floriani C, Hendry K, Hurley C, Jukema JW, Kean S, Kelly M, Krebs D, Langhorne P, McCarthy G, McCarthy V, McConnachie A, McDade M, Messow M, O'Flynn A, O'Riordan D, Poortvliet RK, Quinn TJ, Russell A, Sinnott C, Smit JW, Van Dorland HA, Walsh KA, Walsh EK, Watt T, Wilson R, Gussekloo J, TRUST Study Group: Thyroid Hormone Therapy for Older Adults with Subclinical Hypothyroidism. N Engl J Med; 2017 Apr 03;

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • A total of 368 patients were assigned to receive levothyroxine (at a starting dose of 50 μg daily, or 25 μg if the body weight was <50 kg or the patient had coronary heart disease), with dose adjustment according to the thyrotropin level; 369 patients were assigned to receive placebo with mock dose adjustment.
  • Results The mean age of the patients was 74.4 years, and 396 patients (53.7%) were women.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 28402245.001).
  • [ISSN] 1533-4406
  • [Journal-full-title] The New England journal of medicine
  • [ISO-abbreviation] N. Engl. J. Med.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


53. Bourgeois H, Grudé F, Solal-Céligny P, Dupuis O, Voog E, Ganem G, Denis F, Zinger M, Juhel-Voog L, Lafond C, Maillart P, Capitain O, Delva R, Soulié P, Abadie-Lacourtoisie S, Guérin-Meyer V, Morin-Meschin ME, Commer JM, Gangler A, d'Aillières B, Zannetti A, Bourbouloux E, Berton-Rigault D, Lebouvier-Sadot S, Kaassis M, Baudon J, Lam YH, Bizieux A, Marcq M, Edeline J, Le Du F, Lefeuvre C, Deguiral P, Delecroix V, Blot E, Egreteau J, Goudier MJ, Lamy R, Ferec M, Artignan X, Corbinais S, Morel H, Hardy-Bessard AC, Alleaume C, Naudeix E, Cojocarasu O, Metges JP, Riché C, Déniel-Lagadec D, Marhuenda F, Ingrand P, Douillard JY: Clinical validation of a prognostic tool in a population of outpatients treated for incurable cancer undergoing anti-cancer therapy: PRONOPALL study. Ann Oncol; 2017 May 04;
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Background: In 2008, a study of the characteristics of hospitalised patients led to the development of a prognostic tool that distinguished three populations with significantly different two-month survival rates.
  • Patients and Methods: : PRONOPALL is a multicentre study of current care.
  • 302 adult patients who met one or more of the following criteria: life expectancy under six months, performance status ≥ 2, disease progression during the previous chemotherapy regimen, were included across 16 institutions between October 2009 and October 2010.
  • Afterwards, in order to validate the prognostic tool, the score was ciphered and correlated to patient survival.
  • Results: 262 patients (87%) were evaluable (27 patients excluded and 13 unknown score).
  • 32% of patients presented one metastatic site, 35% had two, and 31% had more than two.
  • According to the PRONOPALL prognostic tool, the two-month survival rate was 92% and the median survival rate was 301 days [209-348] for the 130 patients in population C, 66% and 79 days [71-114] for the 111 patients in population B, and 24% and 35 days for [14-56] the 21 patients in population A.

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 28472235.001).
  • [ISSN] 1569-8041
  • [Journal-full-title] Annals of oncology : official journal of the European Society for Medical Oncology
  • [ISO-abbreviation] Ann. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Keywords] NOTNLM ; Lactate DeHydrogenase / Perfomans Status (PS ECOG) / Prognostic tool / palliative care / serum albumin / survival at 2 months
  •  go-up   go-down


54. Denis F, Lethrosne C, Pourel N, Molinier O, Pointreau Y, Domont J, Bourgeois H, Senellart H, Trémolières P, Lizée T, Bennouna J, Urban T, El Khouri C, Charron A, Septans AL, Balavoine M, Landry S, Solal-Céligny P, Letellier C: Randomized Trial Comparing a Web-Mediated Follow-up With Routine Surveillance in Lung Cancer Patients. J Natl Cancer Inst; 2017 Sep 01;109(9)
MedlinePlus Health Information. consumer health - Lung Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Randomized Trial Comparing a Web-Mediated Follow-up With Routine Surveillance in Lung Cancer Patients.
  • Background: The use of web-based monitoring for lung cancer patients is growing in interest because of promising recent results suggesting improvement in cancer and resource utilization outcomes.
  • It remains an open question whether the overall survival (OS) in these patients could be improved by using a web-mediated follow-up rather than classical scheduled follow-up and imaging.
  • Methods: Advanced-stage lung cancer patients without evidence of disease progression after or during initial treatment were randomly assigned in a multicenter phase III trial to compare a web-mediated follow-up algorithm (experimental arm), based on weekly self-scored patient symptoms, with routine follow-up with CT scans scheduled every three to six months according to the disease stage (control arm).
  • Results: From June 2014 to January 2016, 133 patients were enrolled and 121 were retained in the intent-to-treat analysis; 12 deemed ineligible after random assignment were not subsequently followed.
  • Most of the patients (95.1%) had stage III or IV disease.
  • The performance status at first detected relapse was 0 to 1 for 75.9% of the patients in the experimental arm and for 32.5% of those in the control arm (two-sided P < .001).
  • Optimal treatment was initiated in 72.4% of the patients in the experimental arm and in 32.5% of those in the control arm (two-sided P < .001).
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Chi-Square Distribution. Diagnostic Self Evaluation. Female. Follow-Up Studies. Humans. Kaplan-Meier Estimate. Male. Middle Aged. Neoplasm Staging. Outcome Assessment (Health Care) / methods. Outcome Assessment (Health Care) / statistics & numerical data. Prospective Studies. Quality of Life. Time Factors

  • Genetic Alliance. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 28423407.001).
  • [ISSN] 1460-2105
  • [Journal-full-title] Journal of the National Cancer Institute
  • [ISO-abbreviation] J. Natl. Cancer Inst.
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase III; Comparative Study; Journal Article; Multicenter Study; Randomized Controlled Trial
  • [Publication-country] United States
  •  go-up   go-down


55. Strandberg AY, Khanfir H, Mäkimattila S, Saukkonen T, Strandberg TE, Hoti F: Insulins NPH, glargine, and detemir, and risk of severe hypoglycemia among working-age adults. Ann Med; 2017 Jun;49(4):357-364

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Risk of severe hypoglycemia requiring hospital care was compared between insulin types.
  • RESULTS: A total of 16,985 persons initiated basal insulin treatment (5586, 7499, and 3900 patients started NPH, glargine, and detemir, respectively) during follow-up.
  • Absolute rate (per 1000 patient-years) was 20.6 (95% CI 17.9, 23.8), 17.8 (15.6, 20.3), and 12.4 (9.9, 15.5) for NPH, glargine, and detemir initiators, respectively.
  • Large reductions in the incidence of severe hypoglycemia were seen among real-life patients who started insulin detemir, as compared to patients who initiated glargine or especially NPH insulin.
  • Given the large amount of patients using insulin, these findings may have considerable clinical consequences at the population level.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 28042719.001).
  • [ISSN] 1365-2060
  • [Journal-full-title] Annals of medicine
  • [ISO-abbreviation] Ann. Med.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Keywords] NOTNLM ; Hypoglycemia / NPH insulin / basal insulin therapy / insulin detemir / insulin glargine / working-age population
  •  go-up   go-down


56. Tan J, You Y, Guo F, Xu J, Dai H, Bie P: Association of elevated risk of pancreatic cancer in diabetic patients: A systematic review and meta-analysis. Oncol Lett; 2017 Mar;13(3):1247-1255

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Association of elevated risk of pancreatic cancer in diabetic patients: A systematic review and meta-analysis.
  • PubMed, EMBASE, Scholar, Web of Science and Scopus databases were searched to identify clinical and patient oriented studies that examined the incidence of diabetes in pancreatic cancer patients and vice versa, over the last 10 years.
  • Parameters analyzed included, the Incidence of diabetes in pancreatic cancer patients; duration history of T2D in pancreatic cancer patients; influence of insulin therapy in T2D patients on pancreatic cancer incidence.
  • Eleven studies with a total of 14,399 patients, of whom 4,080 were T2D-positive and 9,721 were non-diabetic were included in this meta-analysis.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Gastroenterology. 2008 Jan;134(1):95-101 [18061176.001]
  • [Cites] J Clin Endocrinol Metab. 2013 Sep;98(9):3550-4 [23861463.001]
  • [Cites] Cancer Res. 2015 Aug 15;75(16):3355-64 [26113084.001]
  • [Cites] Pancreas. 2011 Aug;40(6):931-7 [21747317.001]
  • [Cites] Pancreas. 2013 Mar;42(2):202-8 [23000889.001]
  • [Cites] Ann Surg Oncol. 2014 Apr;21(4):1082-9 [24322532.001]
  • [Cites] Eur J Cancer. 2012 Jul;48(10):1434-42 [22119354.001]
  • [Cites] Proc Natl Acad Sci U S A. 2010 Sep 14;107(37):16009-12 [20798346.001]
  • [Cites] J Natl Cancer Inst. 2013 Jul 17;105(14):1027-35 [23847240.001]
  • [Cites] CA Cancer J Clin. 2006 Mar-Apr;56(2):106-30 [16514137.001]
  • [Cites] Proc Natl Acad Sci U S A. 2013 Mar 5;110(10 ):3919-24 [23407165.001]
  • [Cites] J Gastroenterol. 2013 Feb;48(2):238-46 [22735942.001]
  • [Cites] BMC Public Health. 2014 Oct 10;14:1058 [25300498.001]
  • [Cites] World J Surg Oncol. 2012 Aug 24;10:171 [22920886.001]
  • [Cites] Am J Cancer Res. 2015 Sep 15;5(10):3260-9 [26693076.001]
  • [Cites] Biochim Biophys Acta. 2015 Jan;1855(1):61-82 [25489989.001]
  • [Cites] JOP. 2014 Jul 28;15(4):319-21 [25076332.001]
  • [Cites] Sci Rep. 2015 Nov 24;5:17102 [26598798.001]
  • [Cites] Cancer Res Treat. 2016 Jan;48(1):171-9 [25779362.001]
  • [Cites] Cancer Med. 2012 Dec;1(3):357-62 [23342285.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2006 Aug;15(8):1458-63 [16896032.001]
  • [Cites] Acta Oncol. 2015 Jul;54(7):986-92 [25734801.001]
  • [Cites] Cancer Causes Control. 2011 Feb;22(2):189-97 [21104117.001]
  • [Cites] Int J Cancer. 2007 May 1;120(9):1986-92 [17230509.001]
  • [Cites] Br J Cancer. 2015 Dec 1;113(11):1607-14 [26575601.001]
  • [Cites] Diabetes Care. 2012 Nov;35(11):2402-11 [23093685.001]
  • [Cites] Eur J Cancer. 2011 Jan;47(2):248-54 [20709528.001]
  • [Cites] Korean J Gastroenterol. 2016 Apr 25;67(4):168-77 [27112242.001]
  • [Cites] Urol Ann. 2012 May;4(2):98-101 [22629005.001]
  • [Cites] Lancet. 2005 Apr 9-15;365(9467):1333-46 [15823385.001]
  • [Cites] HPB (Oxford). 2012 Apr;14(4):228-35 [22404260.001]
  • [Cites] Ann Oncol. 2014 Oct;25(10):2065-72 [25057164.001]
  • (PMID = 28454242.001).
  • [ISSN] 1792-1074
  • [Journal-full-title] Oncology letters
  • [ISO-abbreviation] Oncol Lett
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Greece
  • [Keywords] NOTNLM ; HbA1c / carbohydrate antigen 19-9 / insulin therapy / overall survival / pancreatic cancer / type 2 diabetes
  •  go-up   go-down


57. Cox H, Dickson-Hall L, Ndjeka N, Van't Hoog A, Grant A, Cobelens F, Stevens W, Nicol M: Delays and loss to follow-up before treatment of drug-resistant tuberculosis following implementation of Xpert MTB/RIF in South Africa: A retrospective cohort study. PLoS Med; 2017 Feb;14(2):e1002238

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: South Africa has a large burden of rifampicin-resistant tuberculosis (RR-TB), with 18,734 patients diagnosed in 2014.
  • The number of diagnosed patients has increased substantially with the introduction of the Xpert MTB/RIF test, used for tuberculosis (TB) diagnosis for all patients with presumptive TB.
  • Routine aggregate data suggest a large treatment gap (pre-treatment loss to follow-up) between the numbers of patients with laboratory-confirmed RR-TB and those reported to have started second-line treatment.
  • METHODS AND FINDINGS: A nationwide retrospective cohort study was conducted to assess second-line treatment initiation and treatment delay among laboratory-diagnosed RR-TB patients.
  • Cohorts, including approximately 300 sequentially diagnosed RR-TB patients per South African province, were drawn from the years 2011 and 2013, i.e., before and after Xpert implementation.
  • Patients with prior laboratory RR-TB diagnoses within 6 mo and currently treated patients were excluded.
  • Treatment initiation was determined through data linkage with national and local treatment registers, medical record review, interviews with health care staff, and direct contact with patients or household members.
  • National estimates of the percentage of patients who initiated treatment and time to treatment were weighted to account for the sampling design.
  • There were 2,508 and 2,528 eligible patients in the 2011 and 2013 cohorts, respectively; 92% were newly diagnosed with RR-TB (no prior RR-TB diagnoses).
  • Nationally, among the 2,340 and 2,311 new RR-TB patients in the 2011 and 2013 cohorts, 55% (95% CI 53%-57%) and 63% (95% CI 61%-65%), respectively, started treatment within 6 mo of laboratory receipt of their diagnostic specimen (p < 0.001).
  • However, in 2013, there was no difference in the percentage of patients who initiated treatment at 6 mo between the 1,368 new RR-TB patients diagnosed by Xpert (62%, 95% CI 59%-65%) and the 943 diagnosed by other methods (64%, 95% CI 61%-67%) (p = 0.39).
  • In 2013, across the nine provinces, there were substantial variations in both treatment initiation (range 51%-73% by 6 mo) and median time to treatment (range 15-36 d, n = 1,450), and only 53% of the 1,448 new RR-TB patients who received treatment were recorded in the national RR-TB register.
  • Other limitations include the use of names and dates of birth to locate patient-level data, potentially resulting in missed treatment initiation among some patients.
  • However, given improved case detection with Xpert, a larger proportion of RR-TB patients overall have received treatment, with reduced delays.
  • Nonetheless, strategies to further improve linkage to treatment for all diagnosed RR-TB patients are urgently required.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 28222095.001).
  • [ISSN] 1549-1676
  • [Journal-full-title] PLoS medicine
  • [ISO-abbreviation] PLoS Med.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


58. Dugas M, Trottier MÈ, Chipenda Dansokho S, Vaisson G, Provencher T, Colquhoun H, Dogba MJ, Dupéré S, Fagerlin A, Giguere AM, Haslett L, Hoffman AS, Ivers NM, Légaré F, Légaré J, Levin CA, Menear M, Renaud JS, Stacey D, Volk RJ, Witteman HO: Involving members of vulnerable populations in the development of patient decision aids: a mixed methods sequential explanatory study. BMC Med Inform Decis Mak; 2017 Jan 19;17(1):12

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Involving members of vulnerable populations in the development of patient decision aids: a mixed methods sequential explanatory study.
  • BACKGROUND: Patient decision aids aim to present evidence relevant to a health decision in understandable ways to support patients through the process of making evidence-informed, values-congruent health decisions.
  • METHODS: To describe and compare the development practices of research teams that did and did not specifically involve members of vulnerable populations in the development of patient decision aids, we conducted a secondary analysis of data from a systematic review about the development processes of patient decision aids.
  • CONCLUSIONS: There are a small number of key differences in the development processes for patient decision aids in which members of vulnerable populations were or were not specifically involved.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 28103862.001).
  • [ISSN] 1472-6947
  • [Journal-full-title] BMC medical informatics and decision making
  • [ISO-abbreviation] BMC Med Inform Decis Mak
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Keywords] NOTNLM ; Decision aids / Marginalized populations / Patient engagement / Shared decision making / Vulnerable populations
  •  go-up   go-down


59. Ataide R, Ashley EA, Powell R, Chan JA, Malloy MJ, O'Flaherty K, Takashima E, Langer C, Tsuboi T, Dondorp AM, Day NP, Dhorda M, Fairhurst RM, Lim P, Amaratunga C, Pukrittayakamee S, Hien TT, Htut Y, Mayxay M, Faiz MA, Beeson JG, Nosten F, Simpson JA, White NJ, Fowkes FJ: Host immunity to &lt;i&gt;Plasmodium falciparum&lt;/i&gt; and the assessment of emerging artemisinin resistance in a multinational cohort. Proc Natl Acad Sci U S A; 2017 Mar 28;114(13):3515-3520

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Antibodies specific to 12 <i>Plasmodium falciparum</i> sporozoite and blood-stage antigens were determined in 959 patients (from 11 sites in Southeast Asia) participating in a multinational cohort study assessing parasite clearance half-life (PCt<sub>1/2</sub>) after artesunate treatment and <i>kelch13</i> mutations.
  • Linear mixed-effects modeling of pooled individual patient data assessed the association between antibody responses and PCt<sub>1/2.
  • Naturally acquired immunity accelerates the clearance of artemisinin-resistant parasites in patients with falciparum malaria and may confound the current working definition of artemisinin resistance.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] N Engl J Med. 2014 Jul 31;371(5):411-23 [25075834.001]
  • [Cites] N Engl J Med. 2009 Jul 30;361(5):455-67 [19641202.001]
  • [Cites] Malar J. 2012 Mar 22;11:79 [22439695.001]
  • [Cites] Immunity. 2015 Mar 17;42(3):580-90 [25786180.001]
  • [Cites] BMC Med. 2014 Jul 01;12:108 [24980799.001]
  • [Cites] N Engl J Med. 2008 Dec 11;359(24):2619-20 [19064625.001]
  • [Cites] Trends Parasitol. 2013 Jul;29(7):313-7 [23623760.001]
  • [Cites] Blood. 2011 Jan 13;117(2):381-92 [20852127.001]
  • [Cites] PLoS One. 2011;6(11):e26005 [22102856.001]
  • [Cites] Nature. 2014 Jan 2;505(7481):50-5 [24352242.001]
  • [Cites] BMC Med. 2015 Sep 07;13:212 [26343145.001]
  • [Cites] Malar J. 2007 Nov 16;6:153 [18021388.001]
  • [Cites] PLoS Med. 2010 Jan 19;7(1):e1000218 [20098724.001]
  • [Cites] Lancet Infect Dis. 2012 Nov;12(11):851-8 [22940027.001]
  • [Cites] Malar J. 2009 Nov 18;8:258 [19922664.001]
  • [Cites] Cell Mol Life Sci. 2014 Oct;71(19):3633-57 [24691798.001]
  • [Cites] Lancet Infect Dis. 2015 Apr;15(4):415-21 [25704894.001]
  • [Cites] Infect Immun. 2006 May;74(5):2887-93 [16622227.001]
  • [Cites] Am J Trop Med Hyg. 2003 Nov;69(5):558-63 [14695097.001]
  • [Cites] Malar J. 2011 Sep 22;10:278 [21939506.001]
  • [Cites] PLoS One. 2012;7(12):e52571 [23285095.001]
  • [Cites] Am J Trop Med Hyg. 2001 Dec;65(6):918-23 [11791999.001]
  • [Cites] Malar J. 2011 Nov 10;10:339 [22074219.001]
  • [Cites] Clin Exp Immunol. 1982 Mar;47(3):635-44 [7044626.001]
  • [Cites] J Infect Dis. 2013 Jun 1;207(11):1655-63 [23448727.001]
  • [Cites] J Clin Invest. 2004 Apr;113(8):1084-92 [15085184.001]
  • [Cites] PLoS One. 2013;8(3):e57689 [23520478.001]
  • [Cites] J Exp Med. 1990 Dec 1;172(6):1633-41 [2258697.001]
  • [Cites] Nat Genet. 2015 Mar;47(3):226-34 [25599401.001]
  • [Cites] Infect Immun. 2005 Apr;73(4):2116-22 [15784553.001]
  • [Cites] Clin Microbiol Rev. 2009 Jan;22(1):13-36, Table of Contents [19136431.001]
  • [Cites] Lancet. 2012 May 26;379(9830):1960-6 [22484134.001]
  • [Cites] J Infect Dis. 2015 Jan 15;211(2):290-7 [25183768.001]
  • [Cites] J Infect Dis. 2009 Jul 15;200(2):299-306 [19500037.001]
  • [Cites] PLoS Biol. 2015 Apr 22;13(4):e1002132 [25901609.001]
  • [Cites] J Infect Dis. 2002 May 15;185(10):1538-41 [11992295.001]
  • [Cites] Clin Microbiol Rev. 2011 Apr;24(2):377-410 [21482730.001]
  • [Cites] Malar J. 2012 Aug 16;11:278 [22898135.001]
  • (PMID = 28289193.001).
  • [ISSN] 1091-6490
  • [Journal-full-title] Proceedings of the National Academy of Sciences of the United States of America
  • [ISO-abbreviation] Proc. Natl. Acad. Sci. U.S.A.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Keywords] NOTNLM ; artemisinin / drug resistance / immunity / malaria / serology
  •  go-up   go-down


60. Nguyen KT, Olgin JE, Pletcher MJ, Ng M, Kaye L, Moturu S, Gladstone RA, Malladi C, Fann AH, Maguire C, Bettencourt L, Christensen MA, Marcus GM: Smartphone-Based Geofencing to Ascertain Hospitalizations. Circ Cardiovasc Qual Outcomes; 2017 Mar;10(3)

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: Ascertainment of hospitalizations is critical to assess quality of care and the effectiveness and adverse effects of various therapies.
  • An in-person study included consecutive consenting patients scheduled for electrophysiology and cardiac catheterization procedures.
  • Of 22 eligible in-person patients, 17 hospitalizations were detected (sensitivity 77%; 95% confidence interval, 55%-92%).
  • This first proof of concept may ultimately be applicable to geofencing other types of prespecified locations to facilitate healthcare research and patient care.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] © 2017 American Heart Association, Inc.
  • [Cites] J Biomed Inform. 2009 Apr;42(2):377-81 [18929686.001]
  • [Cites] Telemed J E Health. 2016 Aug;22(8):655-65 [26958742.001]
  • [Cites] J Am Coll Cardiol. 2012 Aug 14;60(7):569-80 [22796257.001]
  • [Cites] J Vasc Surg. 2014 Jul;60(1):98-105 [24636641.001]
  • [Cites] Am J Epidemiol. 1998 May 15;147(10):969-77 [9596475.001]
  • [Cites] Med Care Res Rev. 2006 Apr;63(2):217-35 [16595412.001]
  • [Cites] J Clin Epidemiol. 1990;43(1):87-91 [2319285.001]
  • [Cites] Gerontologist. 2016 Oct;56(5):807-16 [26035900.001]
  • [Cites] Patient Prefer Adherence. 2016 Jan 27;10:99-106 [26869773.001]
  • [Cites] Am J Hypertens. 2007 Sep;20(9):942-8 [17765133.001]
  • [Cites] JMIR Mhealth Uhealth. 2016 Apr 19;4(2):e41 [27095507.001]
  • [Cites] Soc Sci Med. 2008 Jul;67(1):128-36 [18396367.001]
  • [Cites] AIDS. 2006 Jan 9;20(2):253-60 [16511419.001]
  • [Cites] Lancet. 2012 Dec 15;380(9859):2197-223 [23245608.001]
  • [Cites] Am J Epidemiol. 2004 Dec 15;160(12):1152-8 [15583367.001]
  • [Cites] Biotechnol Adv. 2016 May-Jun;34(3):291-304 [26952640.001]
  • [Cites] Lancet. 2014 Jul 5;384(9937):45-52 [24996589.001]
  • [Cites] Heart Rhythm. 2016 Jan;13(1):3-9 [26340844.001]
  • [Cites] JMIR Mhealth Uhealth. 2014 May 01;2(2):e19 [25099179.001]
  • [Cites] BMJ Open. 2015 Dec 23;5(12):e008896 [26700275.001]
  • [Cites] Health Serv Res. 2002 Jun;37(3):751-74 [12132604.001]
  • (PMID = 28325751.001).
  • [ISSN] 1941-7705
  • [Journal-full-title] Circulation. Cardiovascular quality and outcomes
  • [ISO-abbreviation] Circ Cardiovasc Qual Outcomes
  • [Language] eng
  • [Grant] United States / NIMHD NIH HHS / MD / R25 MD006832; United States / NCATS NIH HHS / TR / TL1 TR000144; United States / NIBIB NIH HHS / EB / U2C EB021881
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Keywords] NOTNLM ; fast food / hospitalization / internet / pharmacies / smartphone
  •  go-up   go-down


61. Sauser Zachrison K, Levine DA, Fonarow GC, Bhatt DL, Cox M, Schulte P, Smith EE, Suter RE, Xian Y, Schwamm LH: Timely Reperfusion in Stroke and Myocardial Infarction Is Not Correlated: An Opportunity for Better Coordination of Acute Care. Circ Cardiovasc Qual Outcomes; 2017 Mar;10(3)

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Timely Reperfusion in Stroke and Myocardial Infarction Is Not Correlated: An Opportunity for Better Coordination of Acute Care.
  • The degree to which hospital performance is correlated on emergent STEMI and AIS care is unknown.
  • Primary objective of this study was to determine whether there was a positive correlation between hospital performance on door-to-balloon (D2B) time for STEMI and door-to-needle (DTN) time for AIS, with and without controlling for patient and hospital differences.
  • METHODS AND RESULTS: Prospective study of all hospitals in both Get With The Guidelines-Stroke and Get With The Guidelines-Coronary Artery Disease from 2006 to 2009 and treating ≥10 patients.
  • There were 43 hospitals with 1976 AIS and 59 823 STEMI patients.
  • There was no correlation between hospitals' proportion of eligible patients treated within target time windows for AIS and STEMI (median DTN time <60 minutes: 21% [interquartile range, 11-30]; median D2B time <90 minutes: 68% [interquartile range, 62-79]; ρ=-0.14; <i>P</i>=0.36).
  • Opportunities exist to improve hospitals' performance of time-critical care processes for AIS and STEMI in a coordinated approach.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] © 2017 American Heart Association, Inc.
  • [Cites] Lancet. 2004 Mar 6;363(9411):768-74 [15016487.001]
  • [Cites] J Am Coll Cardiol. 2011 Aug 2;58(6):637-44 [21798428.001]
  • [Cites] J Stroke Cerebrovasc Dis. 2013 Feb;22(2):154-60 [22155116.001]
  • [Cites] Circulation. 1999 Jul 6;100(1):14-20 [10393675.001]
  • [Cites] Neurology. 2000 Dec 12;55(11):1649-55 [11113218.001]
  • [Cites] Am Heart J. 2004 Nov;148(5 Suppl):S46-8 [15514634.001]
  • [Cites] JAMA Neurol. 2014 Sep;71(9):1155-61 [25023407.001]
  • [Cites] Stroke. 2010 Jul;41(7):1431-9 [20522809.001]
  • [Cites] Circulation. 2009 Jan 6;119(1):107-15 [19075103.001]
  • [Cites] Circulation. 2014 Mar 11;129(10):1152-60 [24615963.001]
  • [Cites] JAMA. 2013 Jun 19;309(23):2480-8 [23780461.001]
  • [Cites] Circulation. 2004 Mar 16;109(10):1223-5 [15007008.001]
  • [Cites] Circulation. 2011 Aug 30;124(9):1038-45 [21859971.001]
  • [Cites] Lancet. 2010 May 15;375(9727):1695-703 [20472172.001]
  • [Cites] Crit Pathw Cardiol. 2006 Dec;5(4):179-86 [18340235.001]
  • [Cites] Am Heart J. 2010 Feb;159(2):207-14 [20152218.001]
  • [Cites] J Am Coll Cardiol. 2006 Jun 6;47(11):2180-6 [16750682.001]
  • [Cites] JAMA. 2014 Apr 23-30;311(16):1632-40 [24756513.001]
  • [Cites] Stroke. 2009 Nov;40(11):3580-4 [19797701.001]
  • [Cites] Stroke. 2013 Mar;44(3):870-947 [23370205.001]
  • [Cites] Am Heart J. 2009 Oct;158(4):546-53 [19781413.001]
  • (PMID = 28283469.001).
  • [ISSN] 1941-7705
  • [Journal-full-title] Circulation. Cardiovascular quality and outcomes
  • [ISO-abbreviation] Circ Cardiovasc Qual Outcomes
  • [Language] eng
  • [Grant] United States / NIA NIH HHS / AG / K23 AG040278
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Keywords] NOTNLM ; American Heart Association / fibrinolysis / myocardial infarction / stroke / tissue-type plasminogen activator
  •  go-up   go-down


62. Silverman P, Colella F, McQuigg B, Hines H, Ciarallo S, Whittington L, Belcher S: Elective chemotherapy admission pilot and work-flow improvements to reduce excess days. J Clin Oncol; 2012 Dec;30(34_suppl):101

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • : 101 Background: The Inpatient (Inpt) Oncology Service at University Hospitals Seidman Cancer Center, a large urban academic NCI Comprehensive Cancer Center was charged with identifying opportunities to link patient (pt) quality improvement and decreased length of stay (LOS) in pts admitted for elective chemotherapy (EC).
  • METHODS: A 2-month pilot was conducted, using an intervention group (IG) and control (C) group representing usual care (UC).
  • Census was taken above cap to accommodate IG patients.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 28146956.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


63. Lewis H, Adamson J, Atherton K, Bailey D, Birtwistle J, Bosanquet K, Clare E, Delgadillo J, Ekers D, Foster D, Gabe R, Gascoyne S, Haley L, Hargate R, Hewitt C, Holmes J, Keding A, Lilley-Kelly A, Maya J, McMillan D, Meer S, Meredith J, Mitchell N, Nutbrown S, Overend K, Pasterfield M, Richards D, Spilsbury K, Torgerson D, Traviss-Turner G, Trépel D, Woodhouse R, Ziegler F, Gilbody S: CollAborative care and active surveillance for Screen-Positive EldeRs with subthreshold depression (CASPER): a multicentred randomised controlled trial of clinical effectiveness and cost-effectiveness. Health Technol Assess; 2017 Feb;21(8):1-196

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] CollAborative care and active surveillance for Screen-Positive EldeRs with subthreshold depression (CASPER): a multicentred randomised controlled trial of clinical effectiveness and cost-effectiveness.
  • Less attention has been paid to those with mild disorders/subthreshold depression, but these patients also suffer significant impairments in their quality of life and level of functioning.
  • There is currently no clear evidence-based guidance regarding treatment for this patient group.
  • OBJECTIVES: To establish the clinical effectiveness and cost-effectiveness of a low-intensity intervention of collaborative care for primary care older adults who screened positive for subthreshold depression.
  • INTERVENTIONS: Participants in the intervention group received a low-intensity intervention of collaborative care, which included behavioural activation delivered by a case manager for an average of six sessions over 7-8 weeks, alongside usual GP care.
  • Control-arm participants received only usual GP care.
  • MAIN OUTCOME MEASURES: The primary outcome measure was a self-reported measure of depression severity, the Patient Health Questionnaire-9 items PHQ-9 score at 4 months post randomisation.
  • Secondary outcome measures included the European Quality of Life-5 Dimensions, Short Form questionnaire-12 items, Patient Health Questionnaire-15 items, Generalised Anxiety Disorder seven-item scale, Connor-Davidson Resilience Scale two-item version, a medication questionnaire and objective data.
  • RESULTS: In total, 705 participants were randomised (collaborative care <i>n</i> = 344, usual care <i>n</i> = 361), with 586 participants (83%; collaborative care 76%, usual care 90%) followed up at 4 months and 519 participants (74%; collaborative care 68%, usual care 79%) followed up at 12 months.
  • Attrition was markedly greater in the collaborative care arm.
  • Model estimates at the primary end point of 4 months revealed a statistically significant effect in favour of collaborative care compared with usual care [mean difference 1.31 score points, 95% confidence interval (CI) 0.67 to 1.95 score points; <i>p</i> < 0.001].
  • On average, participants allocated to collaborative care displayed significantly higher QALYs than those allocated to the control group (annual difference in adjusted QALYs of 0.044, 95% bias-corrected CI 0.015 to 0.072; <i>p</i> = 0.003).
  • CONCLUSIONS: Collaborative care has been shown to be clinically effective and cost-effective for older adults with subthreshold depression and to reduce the proportion of people who go on to develop case-level depression at 12 months.
  • Important future work would include investigating the longer-term effect of collaborative care on the CASPER population, which could be conducted by introducing an extension to follow-up, and investigating the impact of collaborative care on managing multimorbidities in people with subthreshold depression.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 28248154.001).
  • [ISSN] 2046-4924
  • [Journal-full-title] Health technology assessment (Winchester, England)
  • [ISO-abbreviation] Health Technol Assess
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


64. Goodship TH, Cook HT, Fakhouri F, Fervenza FC, Frémeaux-Bacchi V, Kavanagh D, Nester CM, Noris M, Pickering MC, Rodríguez de Córdoba S, Roumenina LT, Sethi S, Smith RJ, Conference Participants: Atypical hemolytic uremic syndrome and C3 glomerulopathy: conclusions from a "Kidney Disease: Improving Global Outcomes" (KDIGO) Controversies Conference. Kidney Int; 2017 Mar;91(3):539-551
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • In order to help guide clinicians who are caring for such patients, recommendations for best treatment strategies were discussed at length, providing the evidence base underpinning current treatment options.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright © 2016 International Society of Nephrology. Published by Elsevier Inc. All rights reserved.
  • (PMID = 27989322.001).
  • [ISSN] 1523-1755
  • [Journal-full-title] Kidney international
  • [ISO-abbreviation] Kidney Int.
  • [Language] eng
  • [Grant] United Kingdom / Medical Research Council / / G1002528
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Keywords] NOTNLM ; C3 glomerulopathy / anti-complement therapies / atypical hemolytic uremic syndrome / complement / glomerulonephritis / kidney disease
  • [Investigator] Alpers CE; Appel GB; Ardissino G; Ariceta G; Arici M; Bagga A; Bajema IM; Blasco M; Burke L; Cairns TD; Carratala M; D'Agati VD; Daha MR; De Vriese AS; Dragon-Durey MA; Fogo AB; Galbusera M; Gale DP; Haller H; Johnson S; Józsi M; Karpman D; Lanning L; Le Quintrec M; Licht C; Loirat C; Monfort F; Morgan BP; Noël LH; O'Shaughnessy MM; Rabant M; Rondeau E; Ruggenenti P; Sheerin NS; Smith J; Spoleti F; Thurman JM; van de Kar NC; Vivarelli M; Zipfel PF
  •  go-up   go-down


65. Kadokura M, Ishida Y, Tatsumi A, Takahashi E, Shindo H, Amemiya F, Takano S, Fukasawa M, Sato T, Enomoto N: Performance status and neutrophil-lymphocyte ratio are important prognostic factors in elderly patients with unresectable pancreatic cancer. J Gastrointest Oncol; 2016 Dec;7(6):982-988

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Performance status and neutrophil-lymphocyte ratio are important prognostic factors in elderly patients with unresectable pancreatic cancer.
  • BACKGROUND: The usefulness of various prognostic factors for pancreatic cancer (PC) has been reported, but the number of elderly patients in these studies is disproportionately fewer compared with those in everyday practice.
  • The purpose of this study was to investigate the prognostic factors for unresectable PC in elderly patients.
  • METHODS: We retrospectively analyzed 67 elderly (age ≥75 years) patients with unresectable PC who underwent chemotherapy between January 2006 and December 2014 at our hospital.
  • CONCLUSIONS: The two prognostic factors identified herein are useful in the identification of patients with a poor prognosis and subsequent administration of supportive care alone, which may help avoid the unnecessary adverse effects and complications of systemic chemotherapy.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Int J Cancer. 2015 Mar 1;136(5):E359-86 [25220842.001]
  • [Cites] JAMA. 1986 Jun 27;255(24):3385-90 [3712698.001]
  • [Cites] J Clin Invest. 2010 Apr;120(4):1151-64 [20237412.001]
  • [Cites] Hepatogastroenterology. 2013 Sep;60(126):1479-83 [23933941.001]
  • [Cites] Cancer Chemother Pharmacol. 2011 Oct;68(4):1017-26 [21327930.001]
  • [Cites] Oncologist. 2015 Feb;20(2):143-50 [25582141.001]
  • [Cites] Hepatobiliary Pancreat Dis Int. 2014 Oct;13(5):474-81 [25308357.001]
  • [Cites] Pancreas. 2015 Apr;44(3):471-7 [25423560.001]
  • [Cites] J Gastrointest Cancer. 2013 Dec;44(4):404-9 [23765155.001]
  • [Cites] Mol Clin Oncol. 2013 Jul;1(4):788-792 [24649248.001]
  • [Cites] PLoS One. 2014 Aug 18;9(8):e104730 [25133546.001]
  • [Cites] N Engl J Med. 1999 Dec 30;341(27):2061-7 [10615079.001]
  • [Cites] Cancer Cell. 2009 Sep 8;16(3):183-94 [19732719.001]
  • [Cites] PLoS One. 2013 Nov 04;8(11):e78225 [24223776.001]
  • [Cites] Cancer. 1995 Nov 1;76(9):1671-7 [8635074.001]
  • [Cites] Jpn J Clin Oncol. 2015 Jan;45(1):61-6 [25341546.001]
  • [Cites] Yonsei Med J. 2013 May 1;54(3):643-9 [23549809.001]
  • [Cites] Pancreas. 2008 Apr;36(3):e16-21 [18362833.001]
  • [Cites] J Clin Oncol. 2013 May 1;31(13):1640-8 [23547081.001]
  • [Cites] Br J Cancer. 2013 Jul 23;109(2):416-21 [23799847.001]
  • [Cites] World J Gastroenterol. 2014 Aug 21;20(31):10802-12 [25152583.001]
  • [Cites] J Gastrointest Cancer. 2016 Mar;47(1):15-9 [26545612.001]
  • [Cites] CA Cancer J Clin. 2014 Jan-Feb;64(1):9-29 [24399786.001]
  • [Cites] Cancer Med. 2014 Apr;3(2):406-15 [24519894.001]
  • [Cites] J Am Geriatr Soc. 1985 Sep;33(9):585-9 [4031335.001]
  • [Cites] Oncology. 2011;80(3-4):175-80 [21701231.001]
  • [Cites] Pancreas. 2016 Feb;45(2):211-7 [26495775.001]
  • [Cites] Sci Rep. 2015 Jul 31;5:11026 [26226887.001]
  • [Cites] Pancreas. 2014 Mar;43(2):306-10 [24518512.001]
  • [Cites] J BUON. 2012 Jan-Mar;17(1):102-5 [22517701.001]
  • [Cites] Med Oncol. 2012 Dec;29(5):3101-7 [22729400.001]
  • [Cites] Br J Cancer. 2014 Jan 7;110(1):183-8 [24201751.001]
  • [Cites] Int J Clin Oncol. 2013 Oct;18(5):839-46 [22996141.001]
  • [Cites] Cytokine Growth Factor Rev. 2007 Feb-Apr;18(1-2):171-82 [17329145.001]
  • [Cites] Jpn J Clin Oncol. 2008 Nov;38(11):755-61 [18845521.001]
  • [Cites] World J Gastroenterol. 2011 Aug 14;17(30):3497-502 [21941416.001]
  • (PMID = 28078122.001).
  • [ISSN] 2078-6891
  • [Journal-full-title] Journal of gastrointestinal oncology
  • [ISO-abbreviation] J Gastrointest Oncol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] China
  • [Keywords] NOTNLM ; Pancreatic cancer (PC) / elderly patient / neutrophil-lymphocyte ratio (NLR) / prognostic factor
  •  go-up   go-down


66. Fordyce CB, Al-Khalidi HR, Jollis JG, Roettig ML, Gu J, Bagai A, Berger PB, Corbett CC, Dauerman HL, Fox K, Garvey JL, Henry TD, Rokos IC, Sherwood MW, Wilson BH, Granger CB, STEMI Systems Accelerator Project: Association of Rapid Care Process Implementation on Reperfusion Times Across Multiple ST-Segment-Elevation Myocardial Infarction Networks. Circ Cardiovasc Interv; 2017 Jan;10(1)

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Association of Rapid Care Process Implementation on Reperfusion Times Across Multiple ST-Segment-Elevation Myocardial Infarction Networks.
  • BACKGROUND: The Mission: Lifeline STEMI Systems Accelerator program, implemented in 16 US metropolitan regions, resulted in more patients receiving timely reperfusion.
  • We assessed whether implementing key care processes was associated with system performance improvement.
  • METHODS AND RESULTS: Hospitals (n=167 with 23 498 ST-segment-elevation myocardial infarction patients) were surveyed before (March 2012) and after (July 2014) program intervention.
  • Data were merged with patient-level clinical data over the same period.
  • For reperfusion, hospitals were grouped by whether a specific process of care was implemented, preexisting, or never implemented.
  • Uptake of 4 key care processes increased after intervention: prehospital catheterization laboratory activation (62%-91%; P<0.001), single call transfer protocol from an outside facility (45%-70%; P<0.001), and emergency department bypass for emergency medical services direct presenters (48%-59%; P=0.002) and transfers (56%-79%; P=0.001).
  • Similarly, patients treated at hospitals implementing single call transfer protocols had shorter median first medical contact-to-device times (112 versus 128 versus 152 minutes; P<0.001).
  • CONCLUSIONS: The Accelerator program increased uptake of key care processes, which were associated with improved system performance.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] © 2017 American Heart Association, Inc.
  • (PMID = 28082714.001).
  • [ISSN] 1941-7632
  • [Journal-full-title] Circulation. Cardiovascular interventions
  • [ISO-abbreviation] Circ Cardiovasc Interv
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Keywords] NOTNLM ; ST-segment–elevation myocardial infarction / percutaneous coronary intervention / quality improvement / reperfusion times / systems of care
  •  go-up   go-down


67. Dobrolecki LE, Airhart SD, Alferez DG, Aparicio S, Behbod F, Bentires-Alj M, Brisken C, Bult CJ, Cai S, Clarke RB, Dowst H, Ellis MJ, Gonzalez-Suarez E, Iggo RD, Kabos P, Li S, Lindeman GJ, Marangoni E, McCoy A, Meric-Bernstam F, Piwnica-Worms H, Poupon MF, Reis-Filho J, Sartorius CA, Scabia V, Sflomos G, Tu Y, Vaillant F, Visvader JE, Welm A, Wicha MS, Lewis MT: Patient-derived xenograft (PDX) models in basic and translational breast cancer research. Cancer Metastasis Rev; 2016 Dec;35(4):547-573
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Patient-derived xenograft (PDX) models in basic and translational breast cancer research.
  • Patient-derived xenograft (PDX) models of a growing spectrum of cancers are rapidly supplanting long-established traditional cell lines as preferred models for conducting basic and translational preclinical research.
  • Many of these models are well-characterized with respect to genomic, transcriptomic, and proteomic features, metastatic behavior, and treatment response to a variety of standard-of-care and experimental therapeutics.
  • This review summarizes current experiences related to PDX generation across participating groups, efforts to develop data standards for annotation and dissemination of patient clinical information that does not compromise patient privacy, efforts to develop complementary data standards for annotation of PDX characteristics and biology, and progress toward "credentialing" of PDX models as surrogates to represent individual patients for use in preclinical and co-clinical translational research.

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Microsc Res Tech. 2001 Jan 15;52(2):224-30 [11169869.001]
  • [Cites] Nature. 2015 Feb 19;518(7539):422-6 [25470049.001]
  • [Cites] J Infect Dis. 2013 Nov;208 Suppl 2:S125-30 [24151318.001]
  • [Cites] Mol Oncol. 2014 Mar;8(2):431-43 [24394560.001]
  • [Cites] Blood. 1997 Jun 15;89(12):4307-16 [9192753.001]
  • [Cites] Breast Cancer Res Treat. 2015 Nov;154(1):13-22 [26438141.001]
  • [Cites] Nat Protoc. 2006;1(1):206-14 [17406234.001]
  • [Cites] Cancer J Sci Am. 1996 Sep-Oct;2(5):291-300 [9166547.001]
  • [Cites] Breast Cancer Res. 2002;4(4):155-64 [12100741.001]
  • [Cites] Am J Pathol. 1985 Sep;120(3):464-77 [2412448.001]
  • [Cites] Curr Protoc Mouse Biol. 2013 Mar 01;3(1):21-9 [26069021.001]
  • [Cites] Nat Med. 2008 Dec;14(12):1384-9 [19029987.001]
  • [Cites] Ann Oncol. 2016 Jul;27(7):1190-8 [26912558.001]
  • [Cites] Nat Commun. 2016 Jun 06;7:11908 [27264733.001]
  • [Cites] Leukemia. 1998 Dec;12(12):2029-33 [9844934.001]
  • [Cites] Methods Mol Biol. 2010;596:33-45 [19949919.001]
  • [Cites] Breast Cancer Res Treat. 2010 Jun;121(2):301-9 [19603265.001]
  • [Cites] Stem Cells. 2015 Jun;33(6):1696-704 [25694194.001]
  • [Cites] Cell. 2010 Jan 8;140(1):62-73 [20074520.001]
  • [Cites] Anticancer Res. 1995 Jan-Feb;15(1):1-7 [7733618.001]
  • [Cites] Breast Cancer Res. 2015 Jan 09;17:3 [25572662.001]
  • [Cites] Cancer Res. 1983 May;43(5):2223-39 [6831445.001]
  • [Cites] Blood. 2002 Nov 1;100(9):3175-82 [12384415.001]
  • [Cites] Genome Biol. 2007;8(5):R76 [17493263.001]
  • [Cites] Biochim Biophys Acta. 2010 Jan;1805(1):105-17 [19931353.001]
  • [Cites] Br J Cancer. 1985 Mar;51(3):347-56 [3970811.001]
  • [Cites] Oncotarget. 2015 May 30;6(15):12890-908 [25973541.001]
  • [Cites] Breast Cancer Res Treat. 2010 May;121(1):53-64 [19593635.001]
  • [Cites] Cancer Res. 2013 Aug 1;73(15):4885-97 [23737486.001]
  • [Cites] Breast Cancer Res Treat. 2010 Jul;122(1):35-43 [19701706.001]
  • [Cites] Cancer Res. 2012 Jun 15;72(12):3010-9 [22523036.001]
  • [Cites] Nature. 1994 Nov 3;372(6501):103-7 [7969402.001]
  • [Cites] Expert Rev Mol Diagn. 2013 Mar;13(2):151-65 [23477556.001]
  • [Cites] J Natl Cancer Inst. 1960 Apr;24:953-69 [13821714.001]
  • [Cites] Blood. 2010 Jul 15;116(2):193-200 [20404133.001]
  • [Cites] Br J Cancer. 1980 Oct;42(4):524-9 [6254552.001]
  • [Cites] Clin Cancer Res. 2007 Jul 1;13(13):3989-98 [17606733.001]
  • [Cites] J Natl Cancer Inst. 1979 Dec;63(6):1331-7 [92586.001]
  • [Cites] Proc Natl Acad Sci U S A. 2012 Feb 21;109 (8):2766-71 [21768359.001]
  • [Cites] Development. 2000 Jun;127(11):2269-82 [10804170.001]
  • [Cites] Eur J Immunol. 1995 Feb;25(2):631-4 [7875225.001]
  • [Cites] Contemp Top Lab Anim Sci. 2003 Nov;42(6):33-5 [14615958.001]
  • [Cites] Cancer Res. 2007 Mar 15;67(6):2649-56 [17363585.001]
  • [Cites] Breast Care (Basel). 2016 Apr;11(2):108-15 [27239172.001]
  • [Cites] PLoS One. 2015 Sep 01;10(9):e0136851 [26325287.001]
  • [Cites] J Clin Oncol. 2009 Mar 10;27(8):1160-7 [19204204.001]
  • [Cites] Hum Immunol. 2009 May;70(5):325-30 [19236898.001]
  • [Cites] J Pathol. 2016 Nov;240(3):256-261 [27447842.001]
  • [Cites] Nature. 2014 Aug 14;512(7513):155-60 [25079324.001]
  • [Cites] Nature. 2011 Apr 7;472(7341):90-4 [21399628.001]
  • [Cites] Breast Cancer Res Treat. 2012 Sep;135(2):415-32 [22821401.001]
  • [Cites] Cancer. 2015 Jan 1;121(1):8-16 [25043972.001]
  • [Cites] Oncotarget. 2016 Jul 26;7(30):48206-48219 [27374081.001]
  • [Cites] Cancer Res. 1959 Jun;19(5):515-20 [13663040.001]
  • [Cites] Arch Pathol Lab Med. 2014 Feb;138(2):241-56 [24099077.001]
  • [Cites] Int J Cancer. 2003 Jul 1;105(4):444-53 [12712433.001]
  • [Cites] Nature. 2000 Aug 17;406(6797):747-52 [10963602.001]
  • [Cites] Cancer Cell. 2006 Dec;10(6):529-41 [17157792.001]
  • [Cites] J Exp Med. 1988 Mar 1;167(3):1016-33 [3280724.001]
  • [Cites] Blood. 2013 Mar 21;121(12):e90-7 [23349390.001]
  • [Cites] Genet Res. 1966 Dec;8(3):295-309 [5980117.001]
  • [Cites] Breast Cancer Res. 2015 Feb 10;17:17 [25849559.001]
  • [Cites] Cell. 1995 Mar 10;80(5):813-23 [7889575.001]
  • [Cites] Adv Exp Med Biol. 2016;882:169-89 [26987535.001]
  • [Cites] J Exp Med. 1971 Sep 1;134(3 Pt 1):681-92 [15776569.001]
  • [Cites] Nature. 2010 Apr 15;464(7291):999-1005 [20393555.001]
  • [Cites] Nature. 2009 Jun 18;459(7249):1005-9 [19421193.001]
  • [Cites] Oncotarget. 2016 May 3;7(18):26107-19 [27034166.001]
  • [Cites] Proc Natl Acad Sci U S A. 2004 Apr 6;101(14):4966-71 [15051869.001]
  • [Cites] Biomed Pharmacother. 2005 Oct;59 Suppl 2:S375-9 [16507413.001]
  • [Cites] Breast Cancer Res. 2009;11(5):R66 [19735549.001]
  • [Cites] N Engl J Med. 2012 Mar 22;366(12):1090-8 [22417201.001]
  • [Cites] Genes Dev. 2000 Jan 15;14(2):142-6 [10702024.001]
  • [Cites] Cancer Discov. 2014 Sep;4(9):998-1013 [25185190.001]
  • [Cites] Stem Cells. 2011 Jan;29(1):11-9 [21280155.001]
  • [Cites] PLoS One. 2016 Mar 08;11(3):e0151121 [26953790.001]
  • [Cites] Breast Cancer Res. 2006;8(2):R21 [16611371.001]
  • [Cites] Nat Protoc. 2016 Mar;11(3):616 [26914320.001]
  • [Cites] Cell. 2012 May 25;149(5):994-1007 [22608083.001]
  • [Cites] Cancer Cell. 2003 Jun;3(6):537-49 [12842083.001]
  • [Cites] Curr Protoc Pharmacol. 2012 Dec;Chapter 14:Unit 14.22 [23258598.001]
  • [Cites] J Immunol. 1995 Jan 1;154(1):180-91 [7995938.001]
  • [Cites] Cancer Res. 2002 Feb 1;62(3):917-23 [11830552.001]
  • [Cites] Br J Cancer. 2001 May 18;84(10):1424-31 [11355958.001]
  • [Cites] Cancer Lett. 2014 Mar 1;344(1):13-9 [24513265.001]
  • [Cites] Clin Exp Metastasis. 1995 Jan;13(1):3-15 [7820953.001]
  • [Cites] Cancer Res. 2014 Mar 1;74(5):1463-74 [24425047.001]
  • [Cites] Mol Oncol. 2011 Feb;5(1):5-23 [21147047.001]
  • [Cites] Cancer Discov. 2011 Jun;1(1):54-67 [22039576.001]
  • [Cites] Curr Opin Immunol. 2010 Apr;22(2):231-7 [20144856.001]
  • [Cites] Neoplasia. 2015 Sep;17(9):735-41 [26476081.001]
  • [Cites] Nat Protoc. 2012 May 03;7(6):1024-41 [22555242.001]
  • [Cites] Am J Pathol. 1995 Apr;146(4):888-902 [7717456.001]
  • [Cites] Mol Cell Biol. 1992 Nov;12(11):5152-8 [1406687.001]
  • [Cites] Am J Pathol. 1996 Jan;148(1):313-9 [8546221.001]
  • [Cites] Proc Natl Acad Sci U S A. 2008 Sep 2;105(35):13081-6 [18723673.001]
  • [Cites] Nat Med. 2011 Oct 23;17(11):1514-20 [22019887.001]
  • [Cites] PLoS One. 2008 Apr 02;3(4):e1908 [18382681.001]
  • [Cites] PLoS One. 2016 Jun 16;11(6):e0157368 [27310713.001]
  • [Cites] Cancer Res. 2007 Mar 1;67(5):2062-71 [17332335.001]
  • [Cites] Br J Cancer. 1999 Dec;81(8):1328-34 [10604729.001]
  • [Cites] Cell Rep. 2013 Sep 26;4(6):1116-30 [24055055.001]
  • [Cites] Genome Res. 2013 Dec;23(12):2115-25 [24056532.001]
  • [Cites] Cancer Lett. 1981 Dec;14(3):309-16 [7332907.001]
  • [Cites] Nat Med. 2010 Sep;16(9):974-5 [20823880.001]
  • [Cites] PLoS One. 2010 Aug 16;5(8):e12180 [20808935.001]
  • [Cites] Cancer Res. 1980 Jan;40(1):95-100 [6243091.001]
  • [Cites] Nat Biotechnol. 2014 Apr;32(4):364-72 [24633240.001]
  • [Cites] Nat Med. 2016 Aug;22(8):933-9 [27322743.001]
  • [Cites] Cancer Lett. 1980 Aug;10(2):177-89 [7459836.001]
  • [Cites] Br J Cancer. 1988 Jan;57(1):19-31 [3348947.001]
  • [Cites] Cancer Biol Ther. 2009 Jun;8(11):1010-7 [19398888.001]
  • [Cites] J Natl Cancer Inst. 2008 May 7;100(9):672-9 [18445819.001]
  • [Cites] Exp Cell Biol. 1979;47(4):281-93 [467773.001]
  • [Cites] Breast Cancer Res. 2014 May 20;16(3):210 [25928070.001]
  • [Cites] Eur J Cancer. 2004 Apr;40(6):845-51 [15120040.001]
  • [Cites] Nature. 1979 Mar 29;278(5703):451-3 [313007.001]
  • [Cites] Cancer Immunol Immunother. 2007 Mar;56(3):271-85 [16819631.001]
  • [Cites] Cell Cycle. 2009 Aug;8(15):2317-8 [19625762.001]
  • [Cites] Cancer Cell. 2013 Jul 8;24(1):120-9 [23845444.001]
  • [Cites] Cell Growth Differ. 1993 Jul;4(7):563-9 [8398896.001]
  • [Cites] Cancer Res. 2013 Dec 15;73(24):7290-300 [24142344.001]
  • [Cites] Nature. 2009 Oct 8;461(7265):809-13 [19812674.001]
  • [Cites] J Mammary Gland Biol Neoplasia. 2000 Oct;5(4):379-91 [14973383.001]
  • [Cites] Nature. 2012 Apr 04;486(7403):395-9 [22495314.001]
  • [Cites] Am J Pathol. 1977 Nov;89(2):413-30 [200144.001]
  • [Cites] Trends Immunol. 2016 Jul;37(7):462-76 [27216414.001]
  • [Cites] Mod Pathol. 1998 Feb;11(2):155-68 [9504686.001]
  • [Cites] J Mammary Gland Biol Neoplasia. 2016 Dec;21(3-4):99-109 [27680982.001]
  • [Cites] Cancer Res. 2012 Jun 1;72(11):2705-13 [22467173.001]
  • [Cites] Cancer Res. 1985 Feb;45(2):584-90 [3967234.001]
  • [Cites] Int J Cancer. 1988 May 15;41(5):713-9 [3366492.001]
  • [Cites] J Immunol. 1993 May 1;150(9):3817-24 [8473734.001]
  • [Cites] Cancer Cell. 2006 Dec;10(6):515-27 [17157791.001]
  • [Cites] Immunol Lett. 2012 Aug 30;146(1-2):1-7 [22507217.001]
  • [Cites] Nat Rev Drug Discov. 2010 Apr;9(4):253-4 [20369394.001]
  • [Cites] Cell Immunol. 1996 Aug 1;171(2):186-99 [8806787.001]
  • [Cites] Clin Cancer Res. 2015 Apr 1;21(7):1688-98 [25208879.001]
  • [Cites] Cell. 2012 Mar 2;148(5):873-85 [22385957.001]
  • [Cites] Nature. 2014 Oct 2;514(7520):54-8 [25079331.001]
  • [Cites] J Steroid Biochem Mol Biol. 2006 Dec;102(1-5):71-8 [17049443.001]
  • [Cites] Cancer Cell. 2016 Mar 14;29(3):407-22 [26947176.001]
  • [Cites] J Cancer Res Clin Oncol. 1992;119(1):35-40 [1400563.001]
  • [Cites] Nat Med. 2006 Nov;12(11):1294-300 [17057710.001]
  • [Cites] Nat Rev Immunol. 2007 Feb;7(2):118-30 [17259968.001]
  • [Cites] Cancer Cell. 2007 Mar;11(3):259-73 [17349583.001]
  • [Cites] J Cancer. 2014 Jan 23;5(2):156-65 [24563670.001]
  • [Cites] Breast Cancer Res. 2014 Apr 07;16(2):R36 [24708766.001]
  • [Cites] Nature. 1983 Feb 10;301(5900):527-30 [6823332.001]
  • [Cites] Genome Res. 2014 Nov;24(11):1881-93 [25060187.001]
  • [Cites] Cancer Cell. 2008 May;13(5):394-406 [18455123.001]
  • [Cites] Prostate. 2015 May;75(6):585-92 [25585936.001]
  • [Cites] Cancer. 1978 Jan;41(1):239-44 [626933.001]
  • [Cites] Nature. 2012 Apr 18;486(7403):346-52 [22522925.001]
  • [Cites] Lancet Oncol. 2007 Dec;8(12):1071-8 [18024211.001]
  • [Cites] Nature. 2012 Oct 4;490(7418):61-70 [23000897.001]
  • [Cites] J Endocrinol. 2006 Mar;188(3):589-601 [16522738.001]
  • [Cites] Nature. 2012 May 16;486(7403):400-4 [22722201.001]
  • [Cites] Arch Pathol Lab Med. 2010 Jun;134(6):907-22 [20524868.001]
  • [Cites] Proc Natl Acad Sci U S A. 2011 Nov 15;108(46):18708-13 [22068913.001]
  • [Cites] Cancer Discov. 2011 Nov;1(6):508-23 [22586653.001]
  • [Cites] Breast Dis. 2006-2007;26:139-47 [17473372.001]
  • [Cites] Nat Commun. 2016 May 10;7:11479 [27161491.001]
  • [Cites] Cancer Cell. 2008 Jan;13(1):23-35 [18167337.001]
  • [Cites] Breast Cancer Res. 2010;12(5):R68 [20813035.001]
  • [Cites] Nature. 1988 Sep 15;335(6187):256-9 [2970594.001]
  • [Cites] Genome Res. 2009 Feb;19(2):167-77 [19056696.001]
  • [Cites] Clin Cancer Res. 2008 Jan 15;14(2):370-8 [18223211.001]
  • [Cites] Clin Chem. 2014 Jan;60(1):122-33 [24298072.001]
  • [Cites] Nat Med. 2015 Nov;21(11):1318-25 [26479923.001]
  • [Cites] J Cell Physiol. 1995 Apr;163(1):51-60 [7896900.001]
  • [Cites] Nature. 2012 Jun 20;486(7403):405-9 [22722202.001]
  • [Cites] Nature. 2007 Oct 4;449(7162):557-63 [17914389.001]
  • [Cites] Nature. 2005 Jul 28;436(7050):518-24 [16049480.001]
  • [Cites] Proc Natl Acad Sci U S A. 2003 Apr 1;100(7):3983-8 [12629218.001]
  • [Cites] Adv Immunol. 2006;90:1-50 [16730260.001]
  • [Cites] J Natl Cancer Inst. 1997 Jul 16;89(14):1059-65 [9230888.001]
  • [Cites] J Clin Oncol. 2014 Jul 20;32(21):2255-69 [24868023.001]
  • [Cites] J Natl Cancer Inst. 1993 Nov 3;85(21):1725-32 [8411256.001]
  • [Cites] Curr Protoc Pharmacol. 2013 Mar;Chapter 14:Unit14.23 [23456611.001]
  • [Cites] Cancer Cell. 2010 Nov 16;18(5):485-98 [21035406.001]
  • [Cites] Blood. 1996 Nov 15;88(10):3731-40 [8916937.001]
  • [Cites] Cell. 1992 Mar 6;68(5):869-77 [1547488.001]
  • [Cites] Nat Med. 2009 Aug;15(8):907-13 [19648928.001]
  • [Cites] Breast Cancer Res Treat. 2012 Oct;135(3):913-22 [22941572.001]
  • [Cites] Cancer. 1980 Apr 15;45(8):2160-5 [7370957.001]
  • [Cites] Clin Cancer Res. 2010 Feb 1;16(3):876-87 [20103682.001]
  • [Cites] J Immunol. 2005 May 15;174(10):6477-89 [15879151.001]
  • [Cites] BMC Cancer. 2003 Apr 24;3:13 [12713671.001]
  • [Cites] Clin Cancer Res. 2016 Aug 1;22(15):3764-73 [26957554.001]
  • [Cites] Cell. 2006 Jan 27;124(2):263-6 [16439202.001]
  • [Cites] J Clin Oncol. 2014 Jul 1;32(19):2100-8 [24799487.001]
  • [Cites] Breast Cancer Res. 2004;6(1):22-30 [14680482.001]
  • [Cites] Nat Methods. 2014 Apr;11(4):396-8 [24633410.001]
  • [Cites] Cancer Metastasis Rev. 2010 Jun;29(2):309-16 [20405169.001]
  • [Cites] Int J Cancer. 2011 Nov 1;129(9):2194-206 [21544806.001]
  • [Cites] Science. 1976 Oct 1;194(4260):23-8 [959840.001]
  • [Cites] J Clin Oncol. 2015 Jun 10;33(17 ):1974-82 [25605845.001]
  • [Cites] Am J Pathol. 1998 May;152(5):1299-311 [9588898.001]
  • [Cites] Breast Cancer Res. 2016 Jan 27;18(1):13 [26818199.001]
  • [Cites] Curr Drug Targets. 2010 Sep;11(9):1041-2 [20545615.001]
  • [Cites] Breast Cancer Res Treat. 2012 Jun;133(2):595-606 [22002565.001]
  • [Cites] Breast Cancer Res. 2016 Jun 28;18(1):68 [27349894.001]
  • [Cites] Proc Natl Acad Sci U S A. 2001 Sep 11;98(19):10869-74 [11553815.001]
  • [Cites] J Cell Biochem. 2006 Jul 1;98(4):966-80 [16795075.001]
  • [Cites] Cancer Res. 2011 Jan 15;71(2):614-24 [21224357.001]
  • [Cites] J Natl Cancer Inst. 1975 Dec;55(6):1461-6 [1206764.001]
  • [Cites] Breast Cancer Res Treat. 1996;39(1):69-86 [8738607.001]
  • [Cites] BioDrugs. 2009;23(5):277-87 [19754218.001]
  • [Cites] Mol Oncol. 2007 Jun;1(1):84-96 [18516279.001]
  • (PMID = 28025748.001).
  • [ISSN] 1573-7233
  • [Journal-full-title] Cancer metastasis reviews
  • [ISO-abbreviation] Cancer Metastasis Rev.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / R01 CA112305; United States / NCI NIH HHS / CA / R01 CA172764; United States / NCI NIH HHS / CA / R01 CA173903; United States / NCI NIH HHS / CA / R01 CA129765; United States / NCI NIH HHS / CA / K08 CA164048; United States / NCI NIH HHS / CA / R01 CA140985; United States / NCI NIH HHS / CA / P30 CA034196; United States / NCRR NIH HHS / RR / UL1 RR024992; United States / NCI NIH HHS / CA / P30 CA008748; United States / NCI NIH HHS / CA / P30 CA125123; United States / NCI NIH HHS / CA / R01 CA166422; United States / NCI NIH HHS / CA / R21 CA185460; United States / NCI NIH HHS / CA / R01 CA101860; United States / NCI NIH HHS / CA / P50 CA058183; United States / NCATS NIH HHS / TR / UL1 TR000448; United States / NCI NIH HHS / CA / U01 CA214172; United States / NCI NIH HHS / CA / U54 CA149196; United States / NCI NIH HHS / CA / R21 CA187890
  • [Publication-type] Journal Article
  • [Publication-country] Netherlands
  • [Keywords] NOTNLM ; Breast cancer / Immunocompromised/immunodeficient mice / PDX consortium / Patient-derived xenograft / Translational research
  •  go-up   go-down


68. Yang K, Downey C, Suter N, Gott L, Naughton L, Aufiero K, Day S, McGovern N, Brock J, Andreou K, Strasser J, Koprowski C, Raben A, Chen H, Mourtada F: SU-F-J-35: Moving Towards Isocentric Prone Breast Setup with Contralateral Leveling Tattoo and Couch Move Assistant (CMA). Med Phys; 2016 Jun;43(6):3413-3414

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • PURPOSE: Large setup variability has been observed for prone breast patients due to rotation error.
  • METHODS: Daily CBCT is used to evaluate the prone breast patient positioning uncertainty of proposed isocentric technique against our routine manual clinical setup.
  • While the proposed isocentric prone breast method features an additional contralateral leveling tattoo positioned at mid-level of torso during CT simulation to determine correct patient obliqueness, and an automatic couch shift using Elekta CMA to correct both known distance from 2PT to the iso and daily setup uncertainty.
  • Summary statistics were calculated for a cohort of prone breast patients from our clinic (n=5), and will be updated as more patients get administrated.
  • CONCLUSION: Contralateral leveling tattoo is essential to determine correct patient obliqueness.
  • More consistent and accurate isocentric prone breast patient positioning is achievable on Elekta linac with CMA and CBCT.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] © 2016 American Association of Physicists in Medicine.
  • (PMID = 28047378.001).
  • [ISSN] 2473-4209
  • [Journal-full-title] Medical physics
  • [ISO-abbreviation] Med Phys
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Keywords] NOTNLM ; Cone beam computed tomography / Linear accelerators / Medical imaging
  •  go-up   go-down


69. Gilbody S, Lewis H, Adamson J, Atherton K, Bailey D, Birtwistle J, Bosanquet K, Clare E, Delgadillo J, Ekers D, Foster D, Gabe R, Gascoyne S, Haley L, Hamilton J, Hargate R, Hewitt C, Holmes J, Keding A, Lilley-Kelly A, Meer S, Mitchell N, Overend K, Pasterfield M, Pervin J, Richards DA, Spilsbury K, Traviss-Turner G, Trépel D, Woodhouse R, Ziegler F, McMillan D: Effect of Collaborative Care vs Usual Care on Depressive Symptoms in Older Adults With Subthreshold Depression: The CASPER Randomized Clinical Trial. JAMA; 2017 02 21;317(7):728-737
MedlinePlus Health Information. consumer health - Depression.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Effect of Collaborative Care vs Usual Care on Depressive Symptoms in Older Adults With Subthreshold Depression: The CASPER Randomized Clinical Trial.
  • Objective: To evaluate whether a collaborative care intervention can reduce depressive symptoms and prevent more severe depression in older people.
  • Design, Setting, and Participants: Randomized clinical trial conducted from May 24, 2011, to November 14, 2014, in 32 primary care centers in the United Kingdom among 705 participants aged 65 years or older with Diagnostic and Statistical Manual of Mental Disorders (Fourth Edition) subthreshold depression; participants were followed up for 12 months.
  • Interventions: Collaborative care (n=344) was coordinated by a case manager who assessed functional impairments relating to mood symptoms.
  • The control group received usual primary care (n=361).
  • Main Outcomes and Measures: The primary outcome was self-reported depression severity at 4-month follow-up on the 9-item Patient Health Questionnaire (PHQ-9; score range, 0-27).
  • Four-month retention was 83%, with higher loss to follow-up in collaborative care (82/344 [24%]) vs usual care (37/361 [10%]).
  • Collaborative care resulted in lower PHQ-9 scores vs usual care at 4-month follow-up (mean score with collaborative care, 5.36 vs with usual care, 6.67; mean difference, -1.31; 95% CI, -1.95 to -0.67; P < .001).
  • Treatment differences remained at 12 months (mean PHQ-9 score with collaborative care, 5.93 vs with usual care, 7.25; mean difference, -1.33; 95% CI, -2.10 to -0.55).
  • Conclusions and Relevance: Among older adults with subthreshold depression, collaborative care compared with usual care resulted in a statistically significant difference in depressive symptoms at 4-month follow-up, of uncertain clinical importance.
  • [MeSH-minor] Aged. Antidepressive Agents / therapeutic use. Comorbidity. Female. Follow-Up Studies. Humans. Male. Patient Care Team. Patient Dropouts / statistics & numerical data. Primary Health Care. Psychiatry. Quality of Life. Sample Size. Self Report. Time Factors. United Kingdom

  • Genetic Alliance. consumer health - Depression.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] JAMA. 2017 Feb 21;317(7):702-704 [28241337.001]
  • (PMID = 28241357.001).
  • [ISSN] 1538-3598
  • [Journal-full-title] JAMA
  • [ISO-abbreviation] JAMA
  • [Language] eng
  • [Databank-accession-numbers] ISRCTN/ ISRCTN02202951
  • [Publication-type] Journal Article; Multicenter Study; Pragmatic Clinical Trial; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antidepressive Agents
  •  go-up   go-down


70. Scott CB, Gonzalez ML, Einhorn J, Yan H, Sullivan M, Srinivas S, Zhong F, Crump B, Paz-Querubin ER, McPherson M, DeMarco C, Kasimis B: Patient-reported outcomes for determining prognostic groups in veterans with stage IV solid tumors starting systemic therapy. J Clin Oncol; 2014 Nov;32(31_suppl):48

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Patient-reported outcomes for determining prognostic groups in veterans with stage IV solid tumors starting systemic therapy.
  • : 48 Background: A Recursive Partitioning Analysis (RPA) prognostic algorithm based on quality of life and symptoms predicted 4 groups with distinct median survivals in patients with metastatic solid tumors receiving chemotherapy (ASCO 2013, Abst 9567).
  • We analyzed records of patients with stage IV metastatic solid tumors enrolled through June 2013, and determined survival as of June 15, 2014.
  • RESULTS: There were 97 patients(pts).
  • The patient in group 1 had uterine sarcoma.
  • CONCLUSIONS: These preliminary findings suggest that this algorithm is capable of dividing patients with metastatic solid tumor who are starting systemic therapy into prognostic groups.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 28142847.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


71. Atri M, Zhang Z, Dehdashti F, Lee SI, Marques H, Ali S, Koh WJ, Mannel RS, DiSilvestro P, King SA, Pearl M, Zhou X, Plante M, Moxley KM, Gold M: Utility of PET/CT to Evaluate Retroperitoneal Lymph Node Metastasis in High-Risk Endometrial Cancer: Results of ACRIN 6671/GOG 0233 Trial. Radiology; 2017 May;283(2):450-459
Genetic Alliance. consumer health - Endometrial cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Patients underwent PET/CT and pelvic and abdominal lymphadenectomy.
  • Two hundred seven of 215 enrolled patients had PET/CT and pathologic examination results for the abdomen and pelvis.
  • Mean patient age was 62.7 years ± 9.6 (standard deviation).
  • Data in all 23 patients with a positive abdominal examination and in 26 randomly selected patients with a negative abdominal examination were used for this central reader study.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Abdom Imaging. 2015 Oct;40(7):2472-85 [25680500.001]
  • [Cites] Gynecol Oncol. 2008 Mar;108(3):486-92 [18201753.001]
  • [Cites] Eur Radiol. 2009 Jun;19(6):1529-36 [19184037.001]
  • [Cites] Am J Obstet Gynecol. 1999 Jul;181(1):31-4 [10411790.001]
  • [Cites] Obstet Gynecol. 2010 Nov;116(5):1141-9 [20966700.001]
  • [Cites] J Obstet Gynaecol (Tokyo 1995). 1995 Dec;21(6):551-6 [8640464.001]
  • [Cites] Int J Gynecol Cancer. 2013 Nov;23 (9):1536-43 [24172090.001]
  • [Cites] Gynecol Oncol. 2004 Dec;95(3):546-51 [15581961.001]
  • [Cites] Int J Gynecol Cancer. 2007 Jul-Aug;17 (4):890-6 [17343574.001]
  • [Cites] Radiology. 2004 May;231(2):372-8 [15031434.001]
  • [Cites] J Nucl Med. 2008 Dec;49(12):1928-35 [18997054.001]
  • [Cites] AJR Am J Roentgenol. 2008 Jun;190(6):1652-8 [18492920.001]
  • [Cites] Ann Oncol. 2010 May;21 Suppl 5:v41-5 [20555100.001]
  • [Cites] J Clin Oncol. 2005 Apr 20;23(12):2813-21 [15837995.001]
  • [Cites] Cancer. 1987 Oct 15;60(8 Suppl):2035-41 [3652025.001]
  • [Cites] Gynecol Oncol. 2013 Aug;130(2):306-11 [23707673.001]
  • [Cites] J Bone Joint Surg Am. 2003 Apr;85-A(4):760; author reply 760 [12672856.001]
  • [Cites] Obstet Gynecol. 2000 May;95(5):692-6 [10775731.001]
  • [Cites] Biometrics. 1988 Sep;44(3):837-45 [3203132.001]
  • [Cites] Gynecol Oncol. 2002 Oct;87(1):112-7 [12468351.001]
  • [Cites] Int J Gynecol Cancer. 2007 Jan-Feb;17(1):188-96 [17291252.001]
  • [Cites] J Nucl Med. 2009 Jul;50(7):1187-93 [19525463.001]
  • [Cites] Radiology. 1991 Jun;179(3):829-32 [2028000.001]
  • [Cites] Eur J Radiol. 2012 Nov;81(11):3511-7 [22305013.001]
  • [Cites] Anticancer Res. 2014 Feb;34(2):585-92 [24510987.001]
  • [Cites] Radiology. 2006 Jan;238(1):272-9 [16304090.001]
  • (PMID = 28051912.001).
  • [ISSN] 1527-1315
  • [Journal-full-title] Radiology
  • [ISO-abbreviation] Radiology
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / U10 CA027469; United States / NCI NIH HHS / CA / U10 CA037517; United States / NCI NIH HHS / CA / U10 CA079778; United States / NCI NIH HHS / CA / U10 CA080098
  • [Publication-type] Clinical Trial; Journal Article; Multicenter Study
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Radiopharmaceuticals; 0Z5B2CJX4D / Fluorodeoxyglucose F18
  •  go-up   go-down


72. Bosnic-Anticevich S, Callan C, Chrystyn H, Lavorini F, Nikolaou V, Kritikos V, Dekhuijzen PNR, Roche N, Bjermer L, Rand C, Zwar N, Price DB: Inhaler technique mastery and maintenance in healthcare professionals trained on different devices. J Asthma; 2017 Mar 23;:1-10
figshare. supplemental materials - Supporting Data and Materials for the article .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • OBJECTIVE: Healthcare professionals (HCPs) are required to assess and train patients in the correct use of inhalers but are often unable to demonstrate correct technique themselves.
  • METHODS: We conducted a randomized, un-blinded, crossover study in undergraduate HCPs who undertook a six-step training procedure (intuitive use, patient information leaflet, instructional video, individual tuition from expert, then two repeats of individual tuition) for the use of Turbuhaler® (an established device) and Spiromax® (a newer device, reportedly easier to use).
  • The implications on clinical practice, device education delivery, and patient outcomes require further evaluation.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 28332886.001).
  • [ISSN] 1532-4303
  • [Journal-full-title] The Journal of asthma : official journal of the Association for the Care of Asthma
  • [ISO-abbreviation] J Asthma
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Keywords] NOTNLM ; Asthma / clinical trial / device mastery / device mastery maintenance / dry powder inhaler / handling errors
  •  go-up   go-down


73. Baynam G, Broley S, Bauskis A, Pachter N, McKenzie F, Townshend S, Slee J, Kiraly-Borri C, Vasudevan A, Hawkins A, Schofield L, Helmholz P, Palmer R, Kung S, Walker CE, Molster C, Lewis B, Mina K, Beilby J, Pathak G, Poulton C, Groza T, Zankl A, Roscioli T, Dinger ME, Mattick JS, Gahl W, Groft S, Tifft C, Taruscio D, Lasko P, Kosaki K, Wilhelm H, Melegh B, Carapetis J, Jana S, Chaney G, Johns A, Owen PW, Daly F, Weeramanthri T, Dawkins H, Goldblatt J: Initiating an undiagnosed diseases program in the Western Australian public health system. Orphanet J Rare Dis; 2017 May 03;12(1):83

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: New approaches are required to address the needs of complex undiagnosed diseases patients.
  • However, complementary cross-disciplinary approaches are also critical to address those patients with multisystem disorders who traverse the bounds of multiple specialties and remain undiagnosed despite existing intra-specialty and genomic-focused approaches.
  • Herein, we describe the initiation and summary outcomes of a public health system approach for complex undiagnosed patients - the Undiagnosed Diseases Program-Western Australia (UDP-WA).
  • ii) delivered within a public health system to support equitable access to health care, including for those from remote and regional areas;.
  • iii) providing diagnoses and improved patient care;.
  • vii) designed to integrate with clinical translational research; and viii) is supporting greater connectedness for patients, families and medical staff.
  • The UDP-WA supports the provision of equitable and sustainable diagnostics and simultaneously supports capacity building in clinical care and translational research, for those with undiagnosed, typically rare, conditions.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] JAMA. 2015 Nov 3;314(17):1797-8 [26375289.001]
  • [Cites] Mol Genet Metab. 2015 Dec;116(4):223-5 [26596705.001]
  • [Cites] Orphanet J Rare Dis. 2016 Jun 11;11(1):77 [27287197.001]
  • [Cites] Orphanet J Rare Dis. 2016 Mar 24;11:30 [27012247.001]
  • [Cites] JAMA. 2014 Nov 12;312(18):1880-7 [25326637.001]
  • [Cites] Curr Opin Pediatr. 2014 Dec;26(6):626-33 [25313974.001]
  • [Cites] Genet Med. 2016 Nov;18(11):1102-1110 [27031083.001]
  • (PMID = 28468665.001).
  • [ISSN] 1750-1172
  • [Journal-full-title] Orphanet journal of rare diseases
  • [ISO-abbreviation] Orphanet J Rare Dis
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Keywords] NOTNLM ; Clinical best practice / Diagnosis / Diagnostic odyssey / Genomics / Phenomics / Policy / Precision public health / Undiagnosed
  •  go-up   go-down


74. Hirose T, Kimbara F, Shinozaki M, Mizushima Y, Yamamoto H, Kishi M, Kiguchi T, Shiono S, Noborio M, Fuke A, Akimoto H, Kimura T, Kaga S, Horiuchi T, Shimazu T: Screening for hereditary angioedema (HAE) at 13 emergency centers in Osaka, Japan: A prospective observational study. Medicine (Baltimore); 2017 Feb;96(6):e6109
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The objective is to study the incidence of HAE among patients who visit the emergency department.This was a 3-year prospective observational screening study involving 13 urban tertiary emergency centers in Osaka prefecture, Japan.
  • Patients were included if they met the following criteria: unexplained edema of the body, upper airway obstruction accompanied by edema, anaphylaxis, acute abdomen with intestinal edema (including ileus and acute pancreatitis), or asthma attack.
  • C1-INH activity and C4 level were measured at the time of emergency department admission during the period between July 2011 and June 2014.This study comprised 66 patients with a median age of 54.0 (IQR: 37.5-68.3) years.
  • Three patients were newly diagnosed as having HAE, and 1 patient had already been diagnosed as having HAE.
  • C1-INH activity levels of the patients with HAE were below the detection limit (<25%), whereas those of non-HAE patients (n = 62) were 106% (IQR: 85.5%-127.0%) (normal range, 70%-130%).
  • The median level of C4 was significantly lower in the patients with HAE compared with those without HAE (1.2 [IQR: 1-3] mg/dL vs 22 [IQR: 16.5-29.5] mg/dL, P < 0.01) (normal range, 17-45 mg/dL).Three patients with undiagnosed HAE were diagnosed as having HAE in the emergency department during the 3-year period.
  • If patients have signs and symptoms suspicious of HAE, the levels of C1-INH activity and C4 should be measured.
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Complement C1 Inhibitor Protein / analysis. Complement C4 / analysis. Female. Humans. Japan. Male. Middle Aged. Prospective Studies. Tertiary Care Centers

  • Genetic Alliance. consumer health - Hereditary angioedema.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Annu Rev Immunol. 1988;6:595-628 [3289579.001]
  • [Cites] Arerugi. 2014 Jun;63(6):749-53 [24953732.001]
  • [Cites] Am J Med Sci. 2012 Mar;343(3):210-4 [21934598.001]
  • [Cites] Eur Ann Allergy Clin Immunol. 2013 Feb;45(1):7-16 [23678554.001]
  • [Cites] N Engl J Med. 1996 Jun 20;334(25):1666-7 [8628365.001]
  • [Cites] Ann Allergy Asthma Immunol. 2010 Mar;104(3):211-4 [20377110.001]
  • [Cites] Eur J Emerg Med. 2012 Aug;19(4):271-4 [22008588.001]
  • [Cites] Mayo Clin Proc. 2000 Apr;75(4):349-54 [10761488.001]
  • [Cites] Clin Rev Allergy Immunol. 2016 Oct;51(2):183-92 [27207174.001]
  • [Cites] Ann Allergy Asthma Immunol. 2013 Nov;111(5):329-36 [24125136.001]
  • [Cites] Allergy Asthma Clin Immunol. 2014 Oct 24;10(1):50 [25352908.001]
  • [Cites] Lancet. 2012 Aug 25;380(9843):730 [22920751.001]
  • [Cites] Allergy Asthma Proc. 2004 Mar-Apr;25(2):127-31 [15176498.001]
  • [Cites] N Engl J Med. 2008 Sep 4;359(10):1027-36 [18768946.001]
  • [Cites] Allergy Asthma Clin Immunol. 2010 Jul 28;6(1):24 [20667127.001]
  • [Cites] Am J Emerg Med. 2015 Dec;33(12):1840.e1-2 [25913082.001]
  • [Cites] Arch Intern Med. 2001 Nov 12;161(20):2417-29 [11700154.001]
  • [Cites] J Allergy Clin Immunol. 2012 Sep;130(3):692-7 [22841766.001]
  • [Cites] BMC Gastroenterol. 2013 Aug 02;13:123 [23915279.001]
  • [Cites] Allergol Int. 2012 Dec;61(4):559-62 [23093794.001]
  • [Cites] J Allergy Clin Immunol. 2004 Sep;114(3 Suppl):S51-131 [15356535.001]
  • [Cites] Am J Med. 2006 Mar;119(3):267-74 [16490473.001]
  • [Cites] Transfusion. 2014 Nov;54(11):2989-96; quiz 2988 [24735226.001]
  • (PMID = 28178173.001).
  • [ISSN] 1536-5964
  • [Journal-full-title] Medicine
  • [ISO-abbreviation] Medicine (Baltimore)
  • [Language] eng
  • [Publication-type] Journal Article; Multicenter Study; Observational Study
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Complement C1 Inhibitor Protein; 0 / Complement C4
  •  go-up   go-down


75. McCord J, Cabrera R, Lindahl B, Giannitsis E, Evans K, Nowak R, Frisoli T, Body R, Christ M, deFilippi CR, Christenson RH, Jacobsen G, Alquezar A, Panteghini M, Melki D, Plebani M, Verschuren F, French J, Bendig G, Weiser S, Mueller C, TRAPID-AMI Investigators: Prognostic Utility of a Modified HEART Score in Chest Pain Patients in the Emergency Department. Circ Cardiovasc Qual Outcomes; 2017 Feb;10(2)

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prognostic Utility of a Modified HEART Score in Chest Pain Patients in the Emergency Department.
  • METHODS AND RESULTS: Twelve centers evaluated 1282 patients in the emergency department for possible AMI from 2011 to 2013.
  • Low-risk patients had an m-HS≤3 and had either hs-cTnT<14 ng/L over serial testing or had AMI excluded by the 1-hour protocol.
  • By the 1-hour protocol, 777 (60%) patients had an AMI excluded.
  • Of those 777 patients, 515 (66.3%) patients had an m-HS≤3, with 1 (0.2%) patient having a MACE, and 262 (33.7%) patients had an m-HS≥4, with 6 (2.3%) patients having MACEs (P=0.007).
  • Over 4 to 14 hours, 661 patients had a hs-cTnT<14 ng/L.
  • Of those 661 patients, 413 (62.5%) patients had an m-HS≤3, with 1 (0.2%) patient having a MACE, and 248 (37.5%) patients had an m-HS≥4, with 5 (2.0%) patients having MACEs (P=0.03).

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] © 2017 American Heart Association, Inc.
  • (PMID = 28167641.001).
  • [ISSN] 1941-7705
  • [Journal-full-title] Circulation. Cardiovascular quality and outcomes
  • [ISO-abbreviation] Circ Cardiovasc Qual Outcomes
  • [Language] eng
  • [Grant] United Kingdom / Department of Health / / PDF-2012-05-193
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Keywords] NOTNLM ; mortality / myocardial i / nfarction / patient discharge / prognosis / troponin-T
  • [Investigator] Twerenbold R; Katus HA; Popp S; Ordóñez-Llanos J; Santalo-Bel M; Horner D; Dolci A; Jernberg T; Zaninotto M; Manara A; Dinkel C; Menassanch-Volker S; Jarausch J; Zaugg C
  •  go-up   go-down


76. Udy AA, Dulhunty JM, Roberts JA, Davis JS, Webb SAR, Bellomo R, Gomersall C, Shirwadkar C, Eastwood GM, Myburgh J, Paterson DL, Starr T, Paul SK, Lipman J, BLING-II Investigators, ANZICS Clinical Trials Group: Association between augmented renal clearance and clinical outcomes in patients receiving β-lactam antibiotic therapy by continuous or intermittent infusion: a nested cohort study of the BLING-II randomised, placebo-controlled, clinical trial. Int J Antimicrob Agents; 2017 May;49(5):624-630

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Association between augmented renal clearance and clinical outcomes in patients receiving β-lactam antibiotic therapy by continuous or intermittent infusion: a nested cohort study of the BLING-II randomised, placebo-controlled, clinical trial.
  • This substudy of the BLING-II trial aimed to explore the association between ARC and patient outcomes in a large randomised clinical trial.
  • Patients receiving any form of renal replacement therapy were excluded.
  • A total of 254 patients were included, among which 45 (17.7%) manifested ARC [median (IQR) CL<sub>Cr</sub> 165 (144-198) mL/min].
  • ARC patients were younger (P <0.001), more commonly male (P = 0.04) and had less organ dysfunction (P <0.001).
  • There were no statistically significant differences in clinical outcomes in ARC patients according to the dosing strategy employed.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright © 2017 Elsevier B.V. and International Society of Chemotherapy. All rights reserved.
  • (PMID = 28286115.001).
  • [ISSN] 1872-7913
  • [Journal-full-title] International journal of antimicrobial agents
  • [ISO-abbreviation] Int. J. Antimicrob. Agents
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Netherlands
  • [Keywords] NOTNLM ; Augmented renal clearance / Critical illness / Sepsis / β-Lactams
  • [Investigator] Bellomo R; Eastwood G; Peck L; Young H; Boschert C; Fletcher J; Smith J; Nand K; Sara T; Shirwadkar C; Harney A; Rodgers H; Van Haren F; Clarke S; Durham D; Hannan C; Matheson E; Schwartz K; Thomas K; Bone A; Cattigan C; Elderkin T; Salerno T; Cameron R; Ellis K; Hatter S; Davis J; Sanap M; Soar N; Wood J; Chan K; Heffernan A; Lai NA; Moss C; Sheehy K; Duroux M; Ratcliffe M; Shone S; Warhurst T; Dulhunty J; Dunlop R; Lipman J; Paterson D; Roberts J; Starr T; Stuart J; Udy A; Cooper D; McAllister R; Webb S; Cheng A; Inskip D; Miller J; Myburgh J; Knowles S; Reynolds C; Rudham S; Baker S; Hepburn K; Roberts B; Woods P; Chatterjee I; Smith J; Cullen M; Kong J; Nayyar V; Whitehead C; Gomersall C; Leung P; Gilder E; McCarthy L; McGuiness S; Parke R; Benefield K; Chen Y; McArthur C; Newby L; Henderson S; Mehrtens J; Noble S; Chadwick L; Freebain R; Hogan C; Kazemi A; Rust L; Song R; Tilsley A; Williams A; Durning J; Frengley R; La Pine M; McCracken G; Sharma SB; Andrews L; Dinsdale R; Hunt A; Hurford S; Mackle D; Ongley J; Young P; Lipman J; Bellomo R; Davis J; Dulhunty J; Eastwood G; Gomersall C; Myburgh J; Paterson D; Roberts J; Shirwadkar C; Starr T; Webb S; Kollef M; Turnidge J; Paul S
  •  go-up   go-down


77. Powell JT, Sweeting MJ, Ulug P, Blankensteijn JD, Lederle FA, Becquemin JP, Greenhalgh RM, EVAR-1, DREAM, OVER and ACE Trialists: Meta-analysis of individual-patient data from EVAR-1, DREAM, OVER and ACE trials comparing outcomes of endovascular or open repair for abdominal aortic aneurysm over 5 years. Br J Surg; 2017 Feb;104(3):166-178
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Meta-analysis of individual-patient data from EVAR-1, DREAM, OVER and ACE trials comparing outcomes of endovascular or open repair for abdominal aortic aneurysm over 5 years.
  • METHODS: An individual-patient data meta-analysis of four multicentre randomized trials of EVAR versus open repair was conducted to a prespecified analysis plan, reporting on mortality, aneurysm-related mortality and reintervention.
  • RESULTS: The analysis included 2783 patients, with 14 245 person-years of follow-up (median 5·5 years).
  • Patients with moderate renal dysfunction or previous coronary artery disease had no early survival advantage under EVAR.
  • Over 5 years, patients of marginal fitness had no early survival advantage from EVAR compared with open repair.
  • Aneurysm-related mortality and patients with low ankle : brachial pressure index contributed to the erosion of the early survival advantage for the EVAR group.
  • Trial registration numbers: EVAR-1, ISRCTN55703451; DREAM (Dutch Randomized Endovascular Aneurysm Management), NCT00421330; ACE (Anévrysme de l'aorte abdominale, Chirurgie versus Endoprothèse), NCT00224718; OVER (Open Versus Endovascular Repair Trial for Abdominal Aortic Aneurysms), NCT00094575.

  • Faculty of 1000. commentaries/discussion - See the articles recommended by F1000Prime's Faculty of more than 8,000 leading experts in Biology and Medicine. (subscription/membership/fee required).
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] © 2017 The Authors. BJS published by John Wiley & Sons Ltd on behalf of BJS Society Ltd.
  • [Cites] Br J Surg. 2013 Apr;100(5):638-44 [23334950.001]
  • [Cites] N Engl J Med. 2005 Jun 9;352(23):2398-405 [15944424.001]
  • [Cites] Ann Intern Med. 1999 Mar 16;130(6):461-70 [10075613.001]
  • [Cites] J Endovasc Ther. 2015 Dec;22(6):897-904 [26403831.001]
  • [Cites] N Engl J Med. 2012 Nov 22;367 (21):1988-97 [23171095.001]
  • [Cites] Control Clin Trials. 1986 Sep;7(3):177-88 [3802833.001]
  • [Cites] J Vasc Surg. 2013 Oct;58(4):879-85 [23683383.001]
  • [Cites] Eur J Vasc Endovasc Surg. 2004 Apr;27(4):372-81 [15015186.001]
  • [Cites] Cochrane Database Syst Rev. 2014 Jan 23;(1):CD004178 [24453068.001]
  • [Cites] Lancet. 2004 Sep 4-10;364(9437):843-8 [15351191.001]
  • [Cites] Eur J Vasc Endovasc Surg. 2010 Jan;39(1):55-61 [19775919.001]
  • [Cites] JAMA. 2012 Nov 7;308(17):1795-801 [23117780.001]
  • [Cites] BMJ. 2003 Sep 6;327(7414):557-60 [12958120.001]
  • [Cites] Ann Surg. 2010 Nov;252(5):805-12 [21037436.001]
  • [Cites] J Vasc Surg. 2009 Oct;50(4):880-96 [19786241.001]
  • [Cites] J Cardiovasc Surg (Torino). 2002 Jun;43(3):379-84 [12055570.001]
  • [Cites] Atherosclerosis. 2006 Nov;189(1):61-9 [16620828.001]
  • [Cites] N Engl J Med. 2015 Jul 23;373(4):328-38 [26200979.001]
  • [Cites] Surgery. 1969 May;65(5):763-71 [5777227.001]
  • [Cites] N Engl J Med. 2010 May 20;362(20):1863-71 [20382983.001]
  • [Cites] J Vasc Surg. 2011 May;53(5):1167-1173.e1 [21276681.001]
  • [Cites] Lancet. 2005 Jun 25-Jul 1;365(9478):2156-8 [15978908.001]
  • (PMID = 28160528.001).
  • [ISSN] 1365-2168
  • [Journal-full-title] The British journal of surgery
  • [ISO-abbreviation] Br J Surg
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Investigator] Greenhalgh RM; Beard JD; Buxton MJ; Brown LC; Harris PL; Powell JT; Rose JD; Russell IT; Sculpher MJ; Thompson SG; Lilford RJ; Bell PR; Greenhalgh RM; Whitaker SC; Poole-Wilson TL; Ruckley CV; Campbell WB; Dean MR; Ruttley MS; Coles EC; Powell JT; Halliday A; Gibbs SJ; Brown LC; Epstein D; Sculpher MJ; Thompson SG; Hannon RJ; Johnston L; Bradbury AW; Henderson MJ; Parvin SD; Shepherd DF; Greenhalgh RM; Mitchell AW; Edwards PR; Abbott GT; Higman DJ; Vohra A; Ashley S; Robottom C; Wyatt MG; Rose JD; Byrne D; Edwards R; Leiberman DP; McCarter DH; Taylor PR; Reidy JF; Wilkinson AR; Ettles DF; Clason AE; Leen GL; Wilson NV; Downes M; Walker SR; Lavelle JM; Gough MJ; McPherson S; Scott DJ; Kessell DO; Naylor R; Sayers R; Fishwick NG; Harris PL; Gould DA; Walker MG; Chalmers NC; Garnham A; Collins MA; Beard JD; Gaines PA; Ashour MY; Uberoi R; Braithwaite B; Whitaker SC; Davies JN; Travis S; Hamilton G; Platts A; Shandall A; Sullivan BA; Sobeh M; Matson M; Fox AD; Orme R; Yusef W; Doyle T; Horrocks M; Hardman J; Blair PH; Ellis PK; Morris G; Odurny A; Vohra R; Duddy M; Thompson M; Loosemore TM; Belli AM; Morgan R; Adiseshiah M; Brookes JA; McCollum CN; Ashleigh R; Aukett M; Baker S; Barbe E; Batson N; Bell J; Blundell J; Boardley D; Boyes S; Brown O; Bryce J; Carmichael M; Chance T; Coleman J; Cosgrove C; Curran G; Dennison T; Devine C; Dewhirst N; Errington B; Farrell H; Fisher C; Fulford P; Gough M; Graham C; Hooper R; Horne G; Horrocks L; Hughes B; Hutchings T; Ireland M; Judge C; Kelly L; Kemp J; Kite A; Kivela M; Lapworth M; Lee C; Linekar L; Mahmood A; March L; Martin J; Matharu N; McGuigen K; Morris-Vincent P; Murray S; Murtagh A; Owen G; Ramoutar V; Rippin C; Rowley J; Sinclair J; Spencer S; Taylor V; Tomlinson C; Ward S; Wealleans V; West J; White K; Williams J; Wilson L; Grobbee DE; Blankensteijn JD; Bak AA; Buth J; Pattynama PM; Verhoeven EL; van Voorthuisen AE; Blankensteijn JD; Balm R; Buth J; Cuypers PW; Grobbee DE; Prinssen M; van Sambeek MR; Verhoeven EL; Baas AF; Hunink MG; van Engelshoven JM; Jacobs MJ; de Mol BA; van Bockel JH; Balm R; Reekers J; Tielbeek X; Verhoeven EL; Wisselink W; Boekema N; Heuveling LM; Sikking I; Prinssen M; Balm R; Blankensteijn JD; Buth J; Cuypers PW; van Sambeek MR; Verhoeven EL; de Bruin JL; Baas AF; Blankensteijn JD; Prinssen M; Buth J; Tielbeek AV; Blankensteijn JD; Balm R; Reekers JA; van Sambeek MR; Pattynama P; Verhoeven EL; Prins T; van der Ham AC; van der Velden JJ; van Sterkenburg SM; Ten Haken GB; Bruijninckx CM; van Overhagen H; Tutein Nolthenius RP; Hendriksz TR; Teijink JA; Odink HF; de Smet AA; Vroegindeweij D; van Loenhout RM; Rutten MJ; Hamming JF; Lampmann LE; Bender MH; Pasmans H; Vahl AC; de Vries C; Mackaay AJ; van Dortmont LM; van der Vliet AJ; Schultze Kool LJ; Boomsma JH; van Dop HR; de Mol van Otterloo JC; de Rooij TP; Smits TM; Yilmaz EN; Wisselink W; van den Berg FG; Visser MJ; van der Linden E; Schurink GW; de Haan M; Smeets HJ; Stabel P; van Elst F; Poniewierski J; Vermassen FE; Lederle FA; Freischlag JA; Kohler TR; Latts E; Matsumura J; Padberg FT Jr; Kyriakides TC; Swanson KM; Guarino P; Peduzzi P; Antonelli M; Cushing C; Davis E; Durant L; Joyner S; Kossack TL; Kyriakides TC; LeGwin M; McBride V; O'Connor T; Poulton J; Stratton TL; Zellner S; Snodgrass AJ; Thornton J; Swanson KM; Haakenson CM; Stroupe KT; Jonk Y; Hallett JW; Hertzer N; Towne J; Katz DA; Karrison T; Matts JP; Marottoli R; Kasl S; Mehta R; Feldman R; Farrell W; Allore H; Perry E; Niederman J; Randall F; Zeman M; Beckwith TL; O'Leary TJ; Huang GD; Latts E; Bader M; Ketteler ER; Kingsley DD; Marek JM; Massen RJ; Matteson BD; Pitcher JD; Langsfeld M; Corson JD; Goff JM Jr; Kasirajan K; Paap C; Robertson DC; Salam A; Veeraswamy R; Milner R; Kasirajan K; Guidot J; Lal BK; Busuttil SJ; Lilly MP; Braganza M; Ellis K; Patterson MA; Jordan WD; Whitley D; Taylor S; Passman M; Kerns D; Inman C; Poirier J; Ebaugh J; Raffetto J; Chew D; Lathi S; Owens C; Hickson K; Dosluoglu HH; Eschberger K; Kibbe MR; Baraniewski HM; Matsumura J; Endo M; Busman A; Meadows W; Evans M; Giglia JS; El Sayed H; Reed AB; Ruf M; Ross S; Jean-Claude JM; Pinault G; Kang P; White N; Eiseman M; Jones TL; Timaran CH; Modrall JG; Welborn MB 3rd; Lopez J; Nguyen T; Chacko JK; Granke K; Vouyouka AG; Olgren E; Chand P; Allende B; Ranella M; Yales C; Whitehill TA; Krupski TL; Nehler MR; Johnson SP; Jones DN; Strecker P; Bhola MA; Shortell CK; Gray JL; Lawson JH; McCann R; Sebastian MW; Kistler Tetterton J; Blackwell C; Prinzo PA; Lee N; Padberg FT Jr; Cerveira JJ; Lal BK; Zickler RW; Hauck KA; Berceli SA; Lee WA; Ozaki CK; Nelson PR; Irwin AS; Baum R; Aulivola B; Rodriguez H; Littooy FN; Greisler H; O'Sullivan MT; Kougias P; Lin PH; Bush RL; Guinn G; Bechara C; Cagiannos C; Pisimisis G; Barshes N; Pillack S; Guillory B; Cikrit D; Lalka SG; Lemmon G; Nachreiner R; Rusomaroff M; O'Brien E; Cullen JJ; Hoballah J; Sharp WJ; McCandless JL; Beach V; Minion D; Schwarcz TH; Kimbrough J; Ashe L; Rockich A; Warner-Carpenter J; Moursi M; Eidt JF; Brock S; Bianchi C; Bishop V; Gordon IL; Fujitani R; Kubaska SM 3rd; Behdad M; Azadegan R; Ma Agas C; Zalecki K; Hoch JR; Carr SC; Acher C; Schwarze M; Tefera G; Mell M; Dunlap B; Rieder J; Stuart JM; Weiman DS; Abul-Khoudoud O; Garrett HE; Walsh SM; Wilson KL; Seabrook GR; Cambria RA; Brown KR; Lewis BD; Framberg S; Kallio C; Barke RA; Santilli SM; d'Audiffret AC; Oberle N; Proebstle C; Johnson LL; Jacobowitz GR; Cayne N; Rockman C; Adelman M; Gagne P; Nalbandian M; Caropolo LJ; Pipinos II; Johanning J; Lynch T; DeSpiegelaere H; Purviance G; Zhou W; Dalman R; Lee JT; Safadi B; Coogan SM; Wren SM; Bahmani DD; Maples D; Thunen S; Golden MA; Mitchell ME; Fairman R; Reinhardt S; Wilson MA; Tzeng E; Muluk S; Peterson NM; Foster M; Edwards J; Moneta GL; Landry G; Taylor L; Yeager R; Cannady E; Treiman G; Hatton-Ward S; Salabsky TL; Kansal N; Owens E; Estes M; Forbes BA; Sobotta C; Rapp JH; Reilly LM; Perez SL; Yan K; Sarkar R; Dwyer SS; Perez S; Chong K; Kohler TR; Hatsukami TS; Glickerman DG; Sobel M; Burdick TS; Pedersen K; Cleary P; Back M; Bandyk D; Johnson B; Shames M; Reinhard RL; Thomas SC; Hunter GC; Leon LR Jr; Westerband A; Guerra RJ; Riveros M; Mills JL Sr; Hughes JD; Escalante AM; Psalms SB; Day NN; Macsata R; Sidawy A; Weiswasser J; Arora S; Jasper BJ; Dardik A; Gahtan V; Muhs BE; Sumpio BE; Gusberg RJ; Spector M; Pollak J; Aruny J; Kelly EL; Wong J; Vasilas P; Joncas C; Gelabert HA; DeVirgillio C; Rigberg DA; Cole L; Becquemin JP; Marzelle J; Becquemin JP; Sapoval M; Becquemin JP; Favre JP; Watelet J; Lermusiaux P; Sapoval M; Lepage E; Hemery F; Dolbeau G; Hawajry N; Cunin P; Harris P; Stockx L; Chatellier G; Mialhe C; Fiessinger JN; Pagny L; Kobeiter H; Boissier C; Lacroix P; Ledru F; Pinot JJ; Deux JF; Tzvetkov B; Duvaldestin P; Watelet J; Jourdain C; David V; Enouf D; Ady N; Krimi A; Boudjema N; Jousset Y; Enon B; Blin V; Picquet J; L'Hoste P; Thouveny F; Borie H; Kowarski S; Pernes JM; Auguste M; Becquemin JP; Desgranges P; Allaire E; Marzelle J; Kobeiter H; Meaulle PY; Chaix D; Juliae P; Fabiani JN; Chevalier P; Combes M; Seguin A; Belhomme D; Sapoval M; Baque J; Pellerin O; Favre JP; Barral X; Veyret C; Watelet J; Peillon C; Plissonier D; Thomas P; Clavier E; Lermusiaux P; Martinez R; Bleuet F; C D; Verhoye JP; Langanay T; Heautot JF; Koussa M; Haulon S; Halna P; Destrieux L; Lions C; Wiloteaux S; Beregi JP; Bergeron P; Pinot JJ; Patra P; Costargent A; Chaillou P; D'Alicourt A; Goueffic Y; Cheysson E; Parrot A; Garance P; Demon A; Tyazi A; Pillet JC; Lescalie F; Tilly G; Steinmetz E; Favier C; Brenot R; Krause D; Cercueil JP; Vahdat O; Sauer M; Soula P; Querian A; Garcia O; Levade M; Colombier D; Cardon JM; Joyeux A; Borrelly P; Dogas G; Magnan PÉ; Branchereau A; Bartoli JM; Hassen-Khodja R; Batt M; Planchard PF; Bouillanne PJ; Haudebourg P; Bayne J; Gouny P; Badra A; Braesco J; Nonent M; Lucas A; Cardon A; Kerdiles Y; Rolland Y; Kassab M; Brillu C; Goubault F; Tailboux L; Darrieux H; Briand O; Maillard JC; Varty K; Cousins C
  •  go-up   go-down


78. Dámaso Fernández-Ginés F, Cortiñas-Sáenz M, Mateo-Carrasco H, de Aranda AN, Navarro-Muñoz E, Rodríguez-Carmona R, Fernández-Sánchez C, Sierra-García F, Morales-Molina JA: Efficacy and safety of topical sevoflurane in the treatment of chronic skin ulcers. Am J Health Syst Pharm; 2017 May 01;74(9):e176-e182

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • PURPOSE: Results of efficacy and safety assessments of topical sevoflurane use in patients with long-term treatment-refractory vascular ulcers are reported.
  • METHODS: Patients were randomly assigned to receive sevoflurane instillations (1 mL per cm<sup>2</sup> of ulcer area 1-4 times daily) plus standard wound care (ulcer cleaning, debridement, and dressing changes) or standard care only.
  • The primary efficacy measures were debridement-related and overall pain (assessed using a 10-point visual analog scale), daily opioid use, and ulcer size; secondary measures were patient and clinician impressions of improvement and ulcer-related admissions during treatment.
  • RESULTS: Compared with the group receiving standard care alone (<i>n</i> = 5), the sevoflurane group (<i>n</i> = 10) had significant (<i>p</i> = 0.001) reductions in mean ± S.D. scores for debridement-related pain on day 1 of treatment and at subsequent time points; the sevoflurane group also had significant reductions in overall pain, daily opioid use, and ulcer size.
  • Outcomes in terms of patient- and clinician-rated improvement and emergency admissions also favored the sevoflurane group.
  • Mild localized reddening in the area surrounding ulcers occurred in 4 sevoflurane-treated patients.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright © 2017 by the American Society of Health-System Pharmacists, Inc. All rights reserved.
  • (PMID = 28438822.001).
  • [ISSN] 1535-2900
  • [Journal-full-title] American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists
  • [ISO-abbreviation] Am J Health Syst Pharm
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Keywords] NOTNLM ; opioid skin ulcer / pain / sevoflurane / topical drug administration
  •  go-up   go-down


79. Tzoran I, Papadakis M, Brenner B, Fidalgo Á, Rivas A, Wells PS, Gavín O, Adarraga MD, Moustafa F, Monreal M, Registro Informatizado de Enfermedad TromboEmbólica Investigators: Outcome of Patients with Venous Thromboembolism and Factor V Leiden or Prothrombin 20210 Carrier Mutations During the Course of Anticoagulation. Am J Med; 2017 Apr;130(4):482.e1-482.e9
MedlinePlus Health Information. consumer health - Blood Thinners.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Outcome of Patients with Venous Thromboembolism and Factor V Leiden or Prothrombin 20210 Carrier Mutations During the Course of Anticoagulation.
  • However, the influence of these polymorphisms on patient outcome during anticoagulant therapy has not been consistently explored.
  • METHODS: We used the Registro Informatizado de Enfermedad TromboEmbólica database to compare rates of venous thromboembolism recurrence and bleeding events occurring during the anticoagulation course in factor V Leiden carriers, prothrombin mutation carriers, and noncarriers.
  • RESULTS: Between March 2001 and December 2015, 10,139 patients underwent thrombophilia testing.
  • During the anticoagulation course, 160 patients developed recurrent deep vein thrombosis and 94 patients developed pulmonary embolism (16 died); 154 patients had major bleeding (10 died), and 291 patients had nonmajor bleeding.

  • Genetic Alliance. consumer health - Prothrombin.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright © 2017. Published by Elsevier Inc.
  • (PMID = 27986523.001).
  • [ISSN] 1555-7162
  • [Journal-full-title] The American journal of medicine
  • [ISO-abbreviation] Am. J. Med.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Anticoagulants; 0 / factor V Leiden; 9001-24-5 / Factor V; 9001-26-7 / Prothrombin; Thrombophilia due to Activated Protein C Resistance
  • [Keywords] NOTNLM ; Anticoagulant therapy / Bleeding / Thrombophilia / Venous thromboembolism
  • [Investigator] Decousus H; Prandoni P; Brenner B; Barba R; Di Micco P; Bertoletti L; Tzoran I; Reis A; Bosevski M; Bounameaux H; Malý R; Wells P; Papadakis M; Adarraga MD; Aibar MA; Alfonso M; Arcelus JI; Barba R; Barrón M; Barrón-Andrés B; Bascuñana J; Blanco-Molina A; Bueso T; Cañada G; Cañas I; Chic N; Del Pozo R; Del Toro J; Díaz-Pedroche MC; Díaz-Peromingo JA; Falgá C; Fernández-Capitán C; Fidalgo MA; Font C; Font L; Gallego P; García A; García MA; García-Bragado F; García-Brotons P; Gavín O; Gómez C; Gómez V; González J; González-Marcano D; Grau E; Grimón A; Guijarro R; Gutiérrez J; Hernández-Comes G; Hernández-Blasco L; Hermosa-Los Arcos MJ; Jara-Palomares L; Jaras MJ; Jiménez D; Joya MD; Llamas P; Lecumberri R; Lobo JL; López P; López-Jiménez L; López-Reyes R; López-Sáez JB; Lorente MA; Lorenzo A; Maestre A; Marchena PJ; Martín-Martos F; Monreal M; Nieto JA; Nieto S; Núñez A; Núñez MJ; Odriozola M; Otero R; Pedrajas JM; Pérez G; Pérez-Ductor C; Peris ML; Porras JA; Reig O; Riera-Mestre A; Riesco D; Rivas A; Rodríguez C; Rodríguez-Dávila MA; Rosa V; Ruiz-Giménez N; Sahuquillo JC; Sala-Sainz MC; Sampériz A; Sánchez-Martínez R; Sánchez Simón-Talero R; Sanz O; Soler S; Suriñach JM; Torres MI; Trujillo-Santos J; Uresandi F; Valero B; Valle R; Vela J; Vicente MP; Villalobos A; Vanassche T; Verhamme P; Wells P; Hirmerova J; Malý R; Tomko T; Del Pozo G; Salgado E; Sánchez GT; Bertoletti L; Bura-Riviere A; Mahé I; Merah A; Moustafa F; Papadakis M; Braester A; Brenner B; Tzoran I; Antonucci G; Barillari G; Bilora F; Bortoluzzi C; Cattabiani C; Ciammaichella M; Di Biase J; Di Micco P; Duce R; Ferrazzi P; Giorgi-Pierfranceschi M; Grandone E; Imbalzano E; Lodigiani C; Maida R; Mastroiacovo D; Pace F; Pesavento R; Pinelli M; Poggio R; Prandoni P; Rota L; Tiraferri E; Tonello D; Tufano A; Visonà A; Zalunardo B; Gibietis V; Skride A; Vitola B; Monteiro P; Ribeiro JL; Sousa MS; Bosevski M; Zdraveska M; Bounameaux H; Calanca L; Erdmann A; Mazzolai L
  •  go-up   go-down


80. Lehrnbecher T, Robinson P, Fisher B, Alexander S, Ammann RA, Beauchemin M, Carlesse F, Groll AH, Haeusler GM, Santolaya M, Steinbach WJ, Castagnola E, Davis BL, Dupuis LL, Gaur AH, Tissing WJE, Zaoutis T, Phillips R, Sung L: Guideline for the Management of Fever and Neutropenia in Children With Cancer and Hematopoietic Stem-Cell Transplantation Recipients: 2017 Update. J Clin Oncol; 2017 May 01;:JCO2016717017
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Methods The International Pediatric Fever and Neutropenia Guideline Panel is a multidisciplinary and multinational group of experts in pediatric oncology and infectious diseases that includes a patient advocate.
  • Key differences from our 2012 FN CPG included the listing of a fourth-generation cephalosporin for empirical therapy in high-risk FN, refinement of risk stratification to define patients with high-risk invasive fungal disease (IFD), changes in recommended biomarkers and radiologic investigations for the evaluation of IFD in prolonged FN, and a weak recommendation to withhold empirical antifungal therapy in IFD low-risk patients with prolonged FN.
  • Conclusion Changes to the updated FN CPG recommendations will likely influence the care of pediatric patients with cancer and those undergoing hematopoietic stem-cell transplantation.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 28459614.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


81. van der Zee J, Gijselinck I, Van Mossevelde S, Perrone F, Dillen L, Heeman B, Bäumer V, Engelborghs S, De Bleecker J, Baets J, Gelpi E, Rojas-García R, Clarimón J, Lleó A, Diehl-Schmid J, Alexopoulos P, Perneczky R, Synofzik M, Just J, Schöls L, Graff C, Thonberg H, Borroni B, Padovani A, Jordanova A, Sarafov S, Tournev I, de Mendonça A, Miltenberger-Miltényi G, Simões do Couto F, Ramirez A, Jessen F, Heneka MT, Gómez-Tortosa E, Danek A, Cras P, Vandenberghe R, De Jonghe P, De Deyn PP, Sleegers K, Cruts M, Van Broeckhoven C, Goeman J, Nuytten D, Smets K, Robberecht W, Damme PV, Bleecker J, Santens P, Dermaut B, Versijpt J, Michotte A, Ivanoiu A, Deryck O, Bergmans B, Delbeck J, Bruyland M, Willems C, Salmon E, Pastor P, Ortega-Cubero S, Benussi L, Ghidoni R, Binetti G, Hernández I, Boada M, Ruiz A, Sorbi S, Nacmias B, Bagnoli S, Sorbi S, Sanchez-Valle R, Llado A, Santana I, Rosário Almeida M, Frisoni GB, Maetzler W, Matej R, Fraidakis MJ, Kovacs GG, Fabrizi GM, Testi S: TBK1 Mutation Spectrum in an Extended European Patient Cohort with Frontotemporal Dementia and Amyotrophic Lateral Sclerosis. Hum Mutat; 2017 Mar;38(3):297-309
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] TBK1 Mutation Spectrum in an Extended European Patient Cohort with Frontotemporal Dementia and Amyotrophic Lateral Sclerosis.
  • : We investigated the mutation spectrum of the TANK-Binding Kinase 1 (TBK1) gene and its associated phenotypic spectrum by exonic resequencing of TBK1 in a cohort of 2,538 patients with frontotemporal dementia (FTD), amyotrophic lateral sclerosis (ALS), or FTD plus ALS, ascertained within the European Early-Onset Dementia Consortium.
  • Although missense mutations were also present in controls, over three times more mutations affecting TBK1 functioning were found in the mutation fraction observed in patients only, suggesting high-risk alleles (P = 0.03).

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] © 2016 The Authors. **Human Mutation published by Wiley Periodicals, Inc.
  • (PMID = 28008748.001).
  • [ISSN] 1098-1004
  • [Journal-full-title] Human mutation
  • [ISO-abbreviation] Hum. Mutat.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Keywords] NOTNLM ; ALS / FTD / NFκB luciferase reporter assay / TANK-Binding Kinase 1 / TBK1 / amyotrophic lateral sclerosis / frontotemporal dementia / mutations
  •  go-up   go-down


82. Blecha S, Harth M, Schlachetzki F, Zeman F, Blecha C, Flora P, Burger M, Denzinger S, Graf BM, Helbig H, Pawlik MT: Changes in intraocular pressure and optic nerve sheath diameter in patients undergoing robotic-assisted laparoscopic prostatectomy in steep 45° Trendelenburg position. BMC Anesthesiol; 2017 Mar 11;17(1):40

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Changes in intraocular pressure and optic nerve sheath diameter in patients undergoing robotic-assisted laparoscopic prostatectomy in steep 45° Trendelenburg position.
  • BACKGROUND: To evaluate changes in intraocular pressure (IOP) and intracerebral pressure (ICP) reflected by the optic nerve sheath diameter (ONSD) in patients undergoing robotic-assisted laparoscopic prostatectomy (RALP) in permanent 45° steep Trendelenburg position (STP).
  • METHODS: Fifty-one patients undergoing RALP under a standardised anaesthesia.
  • IOP was perioperatively measured in awake patients (T0) and IOP and ONSD 20 min after induction of anaesthesia (T1), after insufflation of the abdomen in supine position (T2), after 30 min in STP (T3), when controlling Santorini's plexus in STP (T4) and before awakening while supine (T5).
  • We investigated the influence of respiratory and circulatory parameters as well as patient-specific and time-dependent factors on IOP and ONSD.
  • Patients aged <63 years showed a 0.21 mm wider ONSD on average (p = 0.017) and greater variations in diameter than older patients.
  • Differences in the ONSD were age-related, showing higher output values as well as better autoregulation and compliance in STP for patients aged <63 years.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Urol. 2016 Jul;196(1):9-10 [27086181.001]
  • [Cites] J Neuroophthalmol. 2007 Dec;27(4):285-7 [18090562.001]
  • [Cites] BMC Anesthesiol. 2015 Mar 31;15:43 [25861241.001]
  • [Cites] Acta Anaesthesiol Scand. 2011 Jul;55(6):644-52 [21463263.001]
  • [Cites] J Neurosurg Anesthesiol. 2015 Apr;27(2):155-9 [25105824.001]
  • [Cites] Br J Ophthalmol. 2014 Mar;98(3):305-8 [24064941.001]
  • [Cites] Anesth Analg. 2009 Aug;109(2):473-8 [19608821.001]
  • [Cites] Eur Urol. 2009 May;55(5):1037-63 [19185977.001]
  • [Cites] J Endourol. 2014 Jul;28(7):801-6 [24517270.001]
  • [Cites] Emerg Med J. 2009 Sep;26(9):630-4 [19700575.001]
  • [Cites] J Clin Ultrasound. 2003 Jun;31(5):258-73 [12767021.001]
  • [Cites] J Neurosurg Anesthesiol. 2009 Jan;21(1):16-20 [19098619.001]
  • [Cites] PLoS One. 2015 Apr 23;10(4):e0123361 [25906167.001]
  • [Cites] Br J Anaesth. 1998 Feb;80(2):243-4 [9602594.001]
  • [Cites] Ultraschall Med. 2014 Oct;35(5):422-31 [24647767.001]
  • [Cites] Anesth Analg. 1985 May;64(5):520-30 [3158256.001]
  • [Cites] J Neurol Neurosurg Psychiatry. 2016 Jun;87(6):650-5 [26285586.001]
  • [Cites] Minerva Anestesiol. 2012 May;78(5):596-604 [22415437.001]
  • [Cites] AANA J. 2011 Apr;79(2):115-21 [21560974.001]
  • [Cites] Curr Opin Anaesthesiol. 2013 Jun;26(3):375-81 [23614957.001]
  • [Cites] AANA J. 2014 Jun;82(3):203-11 [25109158.001]
  • [Cites] Acta Anaesthesiol Scand. 2002 Jul;46(6):703-6 [12059895.001]
  • [Cites] Eur Urol. 2013 Apr;63(4):606-14 [22840353.001]
  • [Cites] Acta Ophthalmol. 2011 Sep;89(6):e528-32 [21518306.001]
  • [Cites] J Urol. 2016 Jul;196(1):76-81 [26860793.001]
  • [Cites] J Urol. 2015 Apr;193(4):1213-9 [25444990.001]
  • [Cites] Intensive Care Med. 2008 Nov;34(11):2062-7 [18509619.001]
  • (PMID = 28284189.001).
  • [ISSN] 1471-2253
  • [Journal-full-title] BMC anesthesiology
  • [ISO-abbreviation] BMC Anesthesiol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Keywords] NOTNLM ; Intraocular pressure / Optic nerve sheath diameter / Robotic-assisted laparoscopic prostatectomy / steep Trendelenburg position
  •  go-up   go-down


83. Magdon-Ismail Z, Benesch C, Cushman JT, Brissette I, Southerland AM, Brandler ES, Sozener CB, Flor S, Hemmitt R, Wales K, Parrigan K, Levine SR: Establishing Recommendations for Stroke Systems in the Thrombectomy Era: The Upstate New York Stakeholder Proceedings. Stroke; 2017 May 11;

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Implementation may vary based on geographic need/capacity and be contingent on establishing standard care practices.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] © 2017 American Heart Association, Inc.
  • (PMID = 28495830.001).
  • [ISSN] 1524-4628
  • [Journal-full-title] Stroke
  • [ISO-abbreviation] Stroke
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Keywords] NOTNLM ; emergency medical services / feedback / goals / patient transfer / stroke / thrombectomy / triage
  •  go-up   go-down


84. Mittal R, Harris IA, Adie S, Naylor JM, CROSSBAT Study Group: Surgery for Type B Ankle Fracture Treatment: a Combined Randomised and Observational Study (CROSSBAT). BMJ Open; 2017 Mar 27;7(3):e013298

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Primary outcomes Patient-reported ankle function using the American Academy of Orthopaedic Surgeons Foot and Ankle Outcomes Questionnaire (FAOQ) and the physical component score (PCS) of the SF-12v2 General Health Survey at 12 months postinjury.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://www.bmj.com/company/products-services/rights-and-licensing/.
  • [Cites] J Orthop Surg (Hong Kong). 2011 Dec;19(3):309-13 [22184160.001]
  • [Cites] J Bone Joint Surg Am. 2004 May;86-A(5):902-9 [15118030.001]
  • [Cites] J Bone Joint Surg Am. 1985 Jan;67(1):67-78 [3881447.001]
  • [Cites] Foot Ankle Clin. 2008 Dec;13(4):593-610 [19013398.001]
  • [Cites] J Bone Joint Surg Br. 2001 May;83(4):525-9 [11380123.001]
  • [Cites] Acta Orthop Scand. 1998 Feb;69(1):43-7 [9524517.001]
  • [Cites] J Bone Joint Surg Am. 1995 Jan;77(1):142-52 [7822349.001]
  • [Cites] Clin Orthop Relat Res. 1985 Oct;(199):17-27 [3930121.001]
  • [Cites] J Orthop Trauma. 2007 Aug;21(7):449-55 [17762475.001]
  • [Cites] J Bone Joint Surg Am. 2004 Nov;86-A(11):2393-8 [15523008.001]
  • [Cites] Injury. 2011 Nov;42(11):1226-9 [20869055.001]
  • [Cites] J Bone Joint Surg Am. 2002 Feb;84-A(2):208-15 [11861726.001]
  • [Cites] Injury. 2004 Aug;35(8):805-8 [15246805.001]
  • [Cites] J Orthop Trauma. 2012 Mar;26(3):129-34 [22330975.001]
  • [Cites] J Bone Joint Surg Am. 2009 May;91(5):1042-9 [19411451.001]
  • [Cites] Arch Orthop Trauma Surg. 2012 Feb;132(2):257-63 [21959696.001]
  • [Cites] Cochrane Database Syst Rev. 2012 Aug 15;(8):CD008470 [22895975.001]
  • [Cites] Health Aff (Millwood). 2005 Jan-Feb;24(1):18-28 [15647212.001]
  • [Cites] Cochrane Database Syst Rev. 2012 Nov 14;11:CD005595 [23152232.001]
  • [Cites] J Orthop Trauma. 2007 May;21(5):307-15 [17485995.001]
  • [Cites] Foot Ankle Int. 2014 Oct;35(10):988-95 [24962527.001]
  • [Cites] Osteoporos Int. 1999;9(1):29-37 [10367027.001]
  • [Cites] Med Care. 1996 Mar;34(3):220-33 [8628042.001]
  • [Cites] Injury. 2011 Apr;42(4):403-7 [21163480.001]
  • [Cites] Bone Joint J. 2014 Aug;96-B(8):1062-9 [25086122.001]
  • [Cites] Foot Ankle Int. 2011 Dec;32(12 ):1103-9 [22381193.001]
  • [Cites] Ann Surg. 2004 Aug;240(2):205-13 [15273542.001]
  • [Cites] J Nurs Meas. 2001 Fall;9(2):151-61 [11696939.001]
  • [Cites] Injury. 2006 Aug;37(8):691-7 [16814787.001]
  • [Cites] J Bone Joint Surg Br. 1986 Aug;68(4):610-3 [3090049.001]
  • [Cites] J Orthop Trauma. 2012 Nov;26(11):652-8 [22473067.001]
  • (PMID = 28348185.001).
  • [ISSN] 2044-6055
  • [Journal-full-title] BMJ open
  • [ISO-abbreviation] BMJ Open
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Keywords] NOTNLM ; ORTHOPAEDIC & TRAUMA SURGERY
  • [Investigator] Allcock P; Alttahir M; Balogh Z; Bhimani A; Bourne R; Boyle R; Broe D; Bucknill A; Chehade M; Chin R; Clout A; Connon F; Cooke C; Dave C; Dave J; Dekkers M; Drobetz H; Farrugia R; Fritsch B; Gupta S; Hoffman C; Holt M; Horseley M; Hutchinson S; Jeyaprakash P; Kent S; King D; Ko V; Kulkarni V; Laird M; Lieu D; Loefler A; Lunz D; Lynch G; Malisano L; Meakin I; Molnar R; Morrey C; Mulford J; Munsif A; Muscio P; Narayan A; Nicholls A; Nouh F; O'Carrigan T; O'Leary E; Lorentzos P; Pant S; Perriman D; Petchell J; Pirpiris M; Pohl T; Punjabi V; Randhawa S; Rau M; Scarvell J; Schuetz M; Scwartz B; Smith P; Sivakumar B; Solomon B; Spencer J; Stalley P; Steele M; Suthersan M; Szomor Z; Tamblyn P; Tarrant S; Tetsworth K; Viswanathan S; Walker R
  •  go-up   go-down


85. Hida T, Nokihara H, Kondo M, Kim YH, Azuma K, Seto T, Takiguchi Y, Nishio M, Yoshioka H, Imamura F, Hotta K, Watanabe S, Goto K, Satouchi M, Kozuki T, Shukuya T, Nakagawa K, Mitsudomi T, Yamamoto N, Asakawa T, Asabe R, Tanaka T, Tamura T: Alectinib versus crizotinib in patients with ALK-positive non-small-cell lung cancer (J-ALEX): an open-label, randomised phase 3 trial. Lancet; 2017 May 10;
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Alectinib versus crizotinib in patients with ALK-positive non-small-cell lung cancer (J-ALEX): an open-label, randomised phase 3 trial.
  • BACKGROUND: Alectinib, a potent, highly selective, CNS-active inhibitor of anaplastic lymphoma kinase (ALK), showed promising efficacy and tolerability in the single-arm phase 1/2 AF-001JP trial in Japanese patients with ALK-positive non-small-cell lung cancer.
  • METHODS: J-ALEX was a randomised, open-label, phase 3 trial that recruited ALK inhibitor-naive Japanese patients with ALK-positive non-small-cell lung cancer, who were chemotherapy-naive or had received one previous chemotherapy regimen, from 41 study sites in Japan.
  • Patients were randomly assigned (1:1) via an interactive web response system using a permuted-block method stratified by Eastern Cooperative Oncology Group performance status, treatment line, and disease stage to receive oral alectinib 300 mg twice daily or crizotinib 250 mg twice daily until progressive disease, unacceptable toxicity, death, or withdrawal.
  • The efficacy analysis was done in the intention-to-treat population, and safety analyses were done in all patients who received at least one dose of the study drug.
  • The study is ongoing and patient recruitment is closed.
  • FINDINGS: Between Nov 18, 2013, and Aug 4, 2015, 207 patients were recruited and assigned to the alectinib (n=103) or crizotinib (n=104) groups.
  • At data cutoff for the second interim analysis, 24 patients in the alectinib group had discontinued treatment compared with 61 in the crizotinib group, mostly due to lack of efficacy or adverse events.
  • Dose interruptions due to adverse events were also more prevalent with crizotinib (77 [74%] of 104) than with alectinib (30 [29%] of 103), and more patients receiving crizotinib (21 [20%]) than alectinib (nine [9%]) discontinued the study drug because of an adverse event.
  • INTERPRETATION: These results provide the first head-to-head comparison of alectinib and crizotinib and have the potential to change the standard of care for the first-line treatment of ALK-positive non-small-cell lung cancer.

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright © 2017 Elsevier Ltd. All rights reserved.
  • (PMID = 28501140.001).
  • [ISSN] 1474-547X
  • [Journal-full-title] Lancet (London, England)
  • [ISO-abbreviation] Lancet
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


86. Robinson D, Humbert M, Buhl R, Cruz AA, Inoue H, Korom S, Hanania NA, Nair P: Revisiting Type 2-high and Type 2-low airway inflammation in asthma: current knowledge and therapeutic implications. Clin Exp Allergy; 2017 Feb;47(2):161-175

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • : Asthma is a complex respiratory disorder characterized by marked heterogeneity in individual patient disease triggers and response to therapy.
  • Endotypes further describe the functional or pathophysiologic mechanisms underlying the patient's disease. type 2-driven asthma is an emerging nomenclature for a common subtype of asthma and is characterized by the release of signature cytokines IL-4, IL-5 and IL-13 from cells of both the innate and adaptive immune systems.
  • These type 2 cytokines are targets for pharmaceutical intervention, and a number of therapeutic options are under clinical investigation for the management of patients with uncontrolled severe asthma.
  • Anticipating and understanding the heterogeneity of asthma and subsequent improved characterization of different phenotypes and endotypes must guide the selection of treatment to meet individual patients' needs.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] © 2017 The Authors. Clinical & Experimental Allergy Published by John Wiley & Sons Ltd.
  • (PMID = 28036144.001).
  • [ISSN] 1365-2222
  • [Journal-full-title] Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology
  • [ISO-abbreviation] Clin. Exp. Allergy
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  •  go-up   go-down


87. Bruns BR, Morris DS, Zielinski M, Mowery NT, Miller PR, Arnold K, Phelan HA, Murry J, Turay D, Fam J, Oh JS, Gunter OL, Enniss T, Love JD, Skarupa D, Benns M, Fathalizadeh A, Leung PS, Carrick MM, Jewett B, Sakran J, O'Meara L, Herrera AV, Chen H, Scalea TM, Diaz JJ: Stapled versus hand-sewn: A prospective emergency surgery study. An American Association for the Surgery of Trauma multi-institutional study. J Trauma Acute Care Surg; 2017 Mar;82(3):435-443

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: Data from the trauma patient population suggests handsewn (HS) anastomoses are superior to stapled (ST).
  • A recent retrospective study in emergency general surgery (EGS) patients had similar findings.
  • The aim of the current study was to evaluate HS and ST anastomoses in EGS patients undergoing urgent/emergent operations.
  • Patients undergoing urgent/emergent bowel resection for EGS pathology were prospectively enrolled from July 22, 2013 to December 31, 2015.
  • Patients were grouped by HS/ST anastomoses, and variables were collected.
  • RESULTS: Fifteen institutions enrolled a total of 595 patients with 649 anastomoses (253 HS and 396 ST).
  • Hospital and intensive care unit days, as well as mortality, were greater in the HS group.
  • On multivariate regression, the presence of contamination at initial resection (odds ratio, 1.965; 95% confidence interval, 1.183-3.264) and the patient being managed with open abdomen (odds ratio, 2.529; 95% confidence interval, 1.492-4.286) were independently associated with anastomotic failure, while the type of anastomosis was not.
  • CONCLUSION: EGS patients requiring bowel resection and anastomosis are at high risk for anastomotic failure.
  • The current study illustrates an apparent bias among acute care surgeons to perform HS techniques in higher-risk patients.
  • Despite the individualized application of technique for differing patient populations, the risk of anastomotic failure was equivalent when comparing HS and ST anastomoses.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 28030492.001).
  • [ISSN] 2163-0763
  • [Journal-full-title] The journal of trauma and acute care surgery
  • [ISO-abbreviation] J Trauma Acute Care Surg
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


88. Weiss CR, Akinwande O, Paudel K, Cheskin LJ, Holly B, Hong K, Fischman AM, Patel RS, Shin EJ, Steele KE, Moran TH, Kaiser K, Park A, Shade DM, Kraitchman DL, Arepally A: Clinical Safety of Bariatric Arterial Embolization: Preliminary Results of the BEAT Obesity Trial. Radiology; 2017 May;283(2):598-608
Genetic Alliance. consumer health - Obesity.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Purpose To conduct a pilot prospective clinical trial to evaluate the feasibility, safety, and short-term efficacy of bariatric embolization, a recently developed endovascular procedure for the treatment of obesity, in patients with severe obesity.
  • Five severely obese patients (four women, one man) who were 31-49 years of age and who had a mean body mass index of 43.8 kg/m<sup>2</sup> ± 2.9 with no clinically important comorbidities were enrolled in this study.
  • Results The left gastric artery, with or without the gastroepiploic artery, was embolized in five patients, with a technical success rate of 100%.
  • A hospital stay of less than 48 hours for routine supportive care was provided for three patients.
  • Conclusion Bariatric embolization is feasible and appears to be well tolerated in severely obese patients.
  • In this small patient cohort, it appears to induce appetite suppression and may induce weight loss.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Diabetes. 2001 Aug;50(8):1714-9 [11473029.001]
  • [Cites] Cardiovasc Intervent Radiol. 2012 Dec;35(6):1460-6 [22367009.001]
  • [Cites] Obes Surg. 2015 Mar;25(3):550-8 [25511751.001]
  • [Cites] Adv Ther. 2012 Nov;29(11):970-8 [23149862.001]
  • [Cites] JACC Cardiovasc Interv. 2015 Oct;8(12):1641-4 [26493259.001]
  • [Cites] Am J Prev Med. 2008 Aug;35(2):118-26 [18617080.001]
  • [Cites] Ann Surg. 2006 Jan;243(1):108-14 [16371744.001]
  • [Cites] Gastroenterology. 2007 May;132(6):2253-71 [17498516.001]
  • [Cites] Obesity (Silver Spring). 2008 Jun;16(6):1413-20 [18421273.001]
  • [Cites] Radiology. 2008 Oct;249(1):127-33 [18796671.001]
  • [Cites] N Engl J Med. 2002 May 23;346(21):1623-30 [12023994.001]
  • [Cites] Ann Surg. 2007 Nov;246(5):780-5 [17968169.001]
  • [Cites] Ann Pharmacother. 2000 Sep;34(9):1066-9 [10981254.001]
  • [Cites] J Obes. 2014;2014:185349 [25349724.001]
  • [Cites] Int J Obes (Lond). 2009 Apr;33 Suppl 1:S33-40 [19363506.001]
  • [Cites] N Engl J Med. 2011 Oct 27;365(17):1597-604 [22029981.001]
  • [Cites] J Radiol Case Rep. 2015 Sep 30;9(9):36-43 [26629307.001]
  • [Cites] Arch Surg. 2006 Mar;141(3):262-8 [16549691.001]
  • [Cites] Int J Obes (Lond). 2014 Sep;38(9):1147-52 [24352292.001]
  • [Cites] Radiology. 2013 Feb;266(2):471-9 [23204538.001]
  • [Cites] Trends Endocrinol Metab. 2010 Jun;21(6):337-44 [20133150.001]
  • [Cites] Nat Med. 2012 May 04;18(5):666-7 [22561823.001]
  • [Cites] J Am Diet Assoc. 2010 Apr;110(4):571-84 [20338283.001]
  • [Cites] Arch Surg. 2003 Apr;138(4):389-96 [12686525.001]
  • [Cites] Nat Med. 2012 May 04;18(5):668-9 [22561824.001]
  • [Cites] J Vasc Interv Radiol. 2014 Mar;25(3):455-61 [24462005.001]
  • [Cites] Radiology. 2007 Jul;244(1):138-43 [17581899.001]
  • (PMID = 28195823.001).
  • [ISSN] 1527-1315
  • [Journal-full-title] Radiology
  • [ISO-abbreviation] Radiology
  • [Language] eng
  • [Grant] United States / NIBIB NIH HHS / EB / R01 EB017615; United States / NIBIB NIH HHS / EB / T32 EB006351
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Hemostatics
  •  go-up   go-down


89. Ro J, Andre F, Loi S, Verma S, Iwata H, Harbeck N, Loibl S, Bartlett CH, Zhang K, Giorgetti C, Randolph S, Koehler M, Cristofanilli M: PALOMA3: A double-blind, phase III trial of fulvestrant with or without palbociclib in pre- and post-menopausal women with hormone receptor-positive, HER2-negative metastatic breast cancer that progressed on prior endocrine therapy. J Clin Oncol; 2015 Jun 20;33(18_suppl):LBA502

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Resistance to endocrine treatment remains a major clinical problem for patients with hormone receptor positive breast cancer.
  • METHODS: In this double-blind phase 3 study women with HR positive/HER2 negative advanced metastatic BC whose cancer had relapsed or progressed on prior endocrine therapy, were randomized 2:1 to palbociclib (Palbo, 125 mg/d orally for 3 wk followed by 1 wk off) and fulvestrant (F, 500 mg per standard of care) or placebo (PLB) and F.
  • Secondary endpoints included overall survival (OS), response assessment, patient-reported outcomes, and safety and tolerability.
  • CONCLUSIONS: Palbociclib combined with fulvestrant improved progression free survival in hormone receptor positive advanced breast cancer that had progressed on prior endocrine therapy, and can be considered as a treatment option for these patients.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 28147719.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


90. Petkovic J, Barton JL, Flurey C, Goel N, Bartels CM, Barnabe C, de Wit MP, Lyddiatt A, Lacaille D, Welch V, Boonen A, Shea B, Christensen R, Maxwell LJ, Campbell W, Jull J, Toupin-April K, Singh JA, Goldsmith CH, Sreih AG, Pohl C, Hofstetter C, Beaton DE, Buchbinder R, Guillemin F, Tugwell PS: Health Equity Considerations for Developing and Reporting Patient-reported Outcomes in Clinical Trials: A Report from the OMERACT Equity Special Interest Group. J Rheumatol; 2017 Feb 15;

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Health Equity Considerations for Developing and Reporting Patient-reported Outcomes in Clinical Trials: A Report from the OMERACT Equity Special Interest Group.
  • OBJECTIVE: Despite advances integrating patient-centered outcomes into rheumatologic studies, concerns remain regarding their representativeness across diverse patient groups and how this affects equity.
  • METHODS: We surveyed current and previous OMERACT meeting attendees and members of the Campbell and Cochrane Equity Group regarding whether to address equity issues within the OMERACT Filter 2.0 Core Outcome Sets and how to assess the appropriateness of domains, instruments, and measurement properties among diverse patients.
  • RESULTS: We proposed 6 moments for which an equity lens could be added to the development, selection, or testing of patient-reported outcome measures (PROM):.
  • CONCLUSION: There is a need to (1) conduct a systematic review to assess how equity and population characteristics have been considered in PROM development and whether these differences influence the ranking of importance of outcome domains or a patient's response to questionnaire items, and (2) conduct the same survey described above with patients representing groups experiencing health inequities.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 28202740.001).
  • [ISSN] 0315-162X
  • [Journal-full-title] The Journal of rheumatology
  • [ISO-abbreviation] J. Rheumatol.
  • [Language] eng
  • [Grant] United States / NIAMS NIH HHS / AR / K23 AR064372
  • [Publication-type] Journal Article
  • [Publication-country] Canada
  •  go-up   go-down


91. Van Fleet H, Dunn DK, McNinch NL, Volsko TA: Evaluation of Functional Characteristics of 4 Oscillatory Positive Pressure Devices in a Simulated Cystic Fibrosis Model. Respir Care; 2017 Apr;62(4):451-458

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • METHODS: The ASL 5000 was scripted to simulate pulmonary mechanics of a pediatric cystic fibrosis patient with moderate to severe lung disease.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright © 2017 by Daedalus Enterprises.
  • (PMID = 28292973.001).
  • [ISSN] 1943-3654
  • [Journal-full-title] Respiratory care
  • [ISO-abbreviation] Respir Care
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Keywords] NOTNLM ; OPEP / airway clearance / simulated model
  •  go-up   go-down


92. Taqui A, Cerejo R, Itrat A, Briggs FB, Reimer AP, Winners S, Organek N, Buletko AB, Sheikhi L, Cho SM, Buttrick M, Donohue MM, Khawaja Z, Wisco D, Frontera JA, Russman AN, Hustey FM, Kralovic DM, Rasmussen P, Uchino K, Hussain MS, Cleveland Pre-Hospital Acute Stroke Treatment (PHAST) Group: Reduction in time to treatment in prehospital telemedicine evaluation and thrombolysis. Neurology; 2017 Apr 04;88(14):1305-1312

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • OBJECTIVE: To compare the times to evaluation and thrombolytic treatment of patients treated with a telemedicine-enabled mobile stroke treatment unit (MSTU) vs those among patients brought to the emergency department (ED) via a traditional ambulance.
  • A vascular neurologist evaluated each patient via telemedicine and a neuroradiologist and vascular neurologist remotely assessed images obtained by the MSTU CT.
  • The evaluation and treatment of the first 100 MSTU patients (July 18, 2014-November 1, 2014) was compared to a control group of 53 patients brought to the ED via a traditional ambulance in 2014.
  • RESULTS: Patient and stroke severity characteristics were similar between 100 MSTU and 53 ED control patients (initial NIH Stroke Scale score 6 vs 7, <i>p</i> = 0.679).
  • Sixteen patients evaluated on MSTU received thrombolysis, 25% of whom received it within 60 minutes of symptom onset.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] © 2017 American Academy of Neurology.
  • (PMID = 28275084.001).
  • [ISSN] 1526-632X
  • [Journal-full-title] Neurology
  • [ISO-abbreviation] Neurology
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Investigator] Taqui A; Cerejo R; Itrat A; Briggs FB; Reimer AP; Winners S; Organek N; Buletko AB; Sheikhi L; Cho SM; Buttrick M; Donohue MM; Khawaja Z; Wisco D; Frontera J; Russman A; Hustey FM; Kralovic D; Rasmussen P; Uchino K; Hussain MS
  •  go-up   go-down


93. Dreber H, Reynisdottir S, Angelin B, Tynelius P, Rasmussen F, Hemmingsson E: Mental distress in treatment seeking young adults (18-25 years) with severe obesity compared with population controls of different body mass index levels: cohort study. Clin Obes; 2017 Feb;7(1):1-10
MedlinePlus Health Information. consumer health - Obesity.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Young adults (18-25) with severe obesity constitute a challenging patient group, and there is limited evidence about their mental health status compared to population controls.

  • Genetic Alliance. consumer health - Obesity.
  • MedlinePlus Health Information. consumer health - Mental Disorders.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] © 2017 World Obesity Federation.
  • (PMID = 28058812.001).
  • [ISSN] 1758-8111
  • [Journal-full-title] Clinical obesity
  • [ISO-abbreviation] Clin Obes
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] England
  • [Keywords] NOTNLM ; Clinical care (major topic) / mental distress (major topic) / severe obesity (major topic) / young adult (major topic)
  •  go-up   go-down


94. Yoshida EM, Kwo P, Agarwal K, Duvoux C, Durand F, Peck-Radosavljevic M, Lilly L, Willems B, Vargas H, Kumar P, Brown RS Jr, Horsmans Y, De-Oertel S, Arterburn S, Dvory-Sobol H, Brainard DM, McHutchison JG, Terrault N, Rizzetto M, Müllhaupt B: Persistence of Virologic Response after Liver Transplant in Hepatitis C Patients Treated with Ledipasvir / Sofosbuvir Plus Ribavirin Pretransplant. Ann Hepatol; 2017 May - Jun;16(3):375-381

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Persistence of Virologic Response after Liver Transplant in Hepatitis C Patients Treated with Ledipasvir / Sofosbuvir Plus Ribavirin Pretransplant.
  • INTRODUCTION: Recurrence of HCV infection in patients with chronic hepatitis C virus (HCV) at the time of liver transplantation is nearly universal and reduces the likelihood of graft and patient survival.
  • MATERIALS AND METHODS: We evaluated outcomes of 17 patients (16 with HCV genotype 1 and 1 with genotype 4) who received up to 12 or 24 weeks of ledipasvir/sofosbuvir plus ribavirin prior to or up to the time of liver transplant in the SOLAR-1 and SOLAR-2 trials.
  • In all patients, HCV RNA was < 15 IU/mL prior to transplant.
  • At screening, 6 patients were Child-Pugh-Turcotte (CPT) class B and 11 were CPT class C.
  • Seven patients underwent transplant prior to completing assigned treatment, with 4 treated for < 12 weeks.
  • The primary endpoint was posttransplant virologic response 12 weeks after transplant (pTVR12) in patients with HCV RNA < 15 IU/mL at their last measurement prior to transplant.
  • The single patient who did not achieve pTVR12 discontinued study drug on day 21 and underwent liver transplant the following day.
  • The patient had HCV RNA < 15 IU/mL at post-transplant week 2 but died 15 days post-transplant because of multi-organ failure and septic shock.
  • CONCLUSION: Among a small population of HCV patients with decompensated cirrhosis, virologic response to ledipasvir / sofosbuvir plus ribavirin prior to liver transplantation was maintained after transplantation, even if treatment was stopped early.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 28425407.001).
  • [ISSN] 1665-2681
  • [Journal-full-title] Annals of hepatology
  • [ISO-abbreviation] Ann Hepatol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Mexico
  •  go-up   go-down


95. Bailly S, Leroy O, Azoulay E, Montravers P, Constantin JM, Dupont H, Guillemot D, Lortholary O, Mira JP, Perrigault PF, Gangneux JP, Timsit JF, AmarCAND2 Study Group: Impact of echinocandin on prognosis of proven invasive candidiasis in ICU: A post-hoc causal inference model using the AmarCAND2 study. J Infect; 2017 Jan 16;
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • OBJECTIVE: guidelines recommend first-line systemic antifungal therapy (SAT) with echinocandins in invasive candidiasis (IC), especially in critically ill patients.
  • This study aimed at assessing the impact of echinocandins compared to azoles as initial SAT on the 28-day prognosis in adult ICU patients.
  • METHODS: From the prospective multicenter AmarCAND2 cohort (835 patients), we selected those with documented IC and treated with echinocandins (ECH) or azoles (AZO).
  • RESULTS: 397 patients were selected, treated with echinocandins (242 patients, 61%) or azoles (155 patients, 39%); septic shock: 179 patients (45%).
  • However, echinocandin tended to benefit patients with septic shock (HR: 0.46 [0.19; 1.07]; p = 0.07).
  • CONCLUSION: Patients who received echinocandins were more severely ill.
  • Echinocandin use was associated with a non-significant 7% decrease of 28-day mortality and a trend to a beneficial effect for patient with septic shock.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright © 2017 The British Infection Association. Published by Elsevier Ltd. All rights reserved.
  • (PMID = 28104387.001).
  • [ISSN] 1532-2742
  • [Journal-full-title] The Journal of infection
  • [ISO-abbreviation] J. Infect.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Keywords] NOTNLM ; Echinocandin / Fluconazole / IPTW estimator / Invasive candidiasis / Patient prognosis
  • [Investigator] Aait H; Adda; Allaouchiche; Ammenouche; Angel; Argaud; Badetti; Baldesi; Barthet; Bastien; Baudin; Bellec; Blasco; Bollaert; Bonadona; Bretonnière; Brocas; Brua; Bruder; Brunin; Cabaret; Carpentier; Cartier; Cerf; Chabanne; Charles; Cheval; Cinotti; Cohen; Constantin; Cousson; Delpierre; Demory; Diconne; Du Cheyron; Dubost; Dumenil; Durand; Duroy; Forel; Foucher-Lezla; Fratea; Gally; Gaudard; Geffe; Gergaud; Gette; Girault; Goubaux; Gouin; Grenot; Grossmith; Guelon; Guerin-Robardey; Guervilly; Hayl-Slayman; Hilbert; Houissa; Hraiech; Ichai; Jung; Kaidomar; Karoubi; Kherchache; Lambiotte; Lamhaut; Launoy; Lebreton; Lefrant; Lemaire; Lepape; Lepoivre; Leroy; Lesieur; Levy; Luyt; Mahe; Mahul; Mateu; Megarbane; Merle; Mira; Montcriol; Mootien; Navellou; Ouattara; Page; Perrigault; Petitpas; Plantefeve; Quinart; Quintard; Ragonnet; Roquilly; Ruiz; Saliba; Samba; Schmitt; Seguin; Sejourne; Tellier; Thevenot; Tonnelier; Van Grunderbeek; Vincent; Wiramus; Zogheib
  •  go-up   go-down


96. Rantner B, Kollerits B, Roubin GS, Ringleb PA, Jansen O, Howard G, Hendrikse J, Halliday A, Gregson J, Eckstein HH, Calvet D, Bulbulia R, Bonati LH, Becquemin JP, Algra A, Brown MM, Mas JL, Brott TG, Fraedrich G: Early Endarterectomy Carries a Lower Procedural Risk Than Early Stenting in Patients With Symptomatic Stenosis of the Internal Carotid Artery: Results From 4 Randomized Controlled Trials. Stroke; 2017 Apr 28;

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Early Endarterectomy Carries a Lower Procedural Risk Than Early Stenting in Patients With Symptomatic Stenosis of the Internal Carotid Artery: Results From 4 Randomized Controlled Trials.
  • BACKGROUND AND PURPOSE: Patients undergoing carotid endarterectomy (CEA) for symptomatic stenosis of the internal carotid artery benefit from early intervention.
  • METHODS: We investigated the association between timing of treatment (0-7 days and >7 days after the qualifying neurological event) and the 30-day risk of stroke or death after CAS or CEA in a pooled analysis of individual patient data from 4 randomized trials by the Carotid Stenosis Trialists' Collaboration.
  • RESULTS: Among a total of 4138 patients, a minority received their allocated treatment within 7 days after symptom onset (14% CAS versus 11% CEA).
  • Among patients treated within 1 week of symptoms, those treated by CAS had a higher risk of stroke or death compared with those treated with CEA: 8.3% versus 1.3%, risk ratio, 6.7; 95% confidence interval, 2.1 to 21.9 (adjusted for age at treatment, sex, and type of qualifying event).

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] © 2017 American Heart Association, Inc.
  • (PMID = 28455318.001).
  • [ISSN] 1524-4628
  • [Journal-full-title] Stroke
  • [ISO-abbreviation] Stroke
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Keywords] NOTNLM ; carotid artery / carotid artery diseases / endarterectomy, carotid / stent / stroke
  •  go-up   go-down


97. Kato A, Fujimaki Y, Fujimori S, Isogawa A, Onishi Y, Suzuki R, Yamauchi T, Ueki K, Kadowaki T, Hashimoto H: Psychological and behavioural patterns of stigma among patients with type 2 diabetes: a cross-sectional study. BMJ Open; 2017 Mar 29;7(3):e013425

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Psychological and behavioural patterns of stigma among patients with type 2 diabetes: a cross-sectional study.
  • OBJECTIVES: The aim of this study was to test the psychological and behavioural patterns of stigma (self-esteem and social participation) and their relationship to self-stigma, patient activation for engaging in self-care and glycaemic control among patients with type 2 diabetes mellitus (T2DM).
  • OUTCOME MEASURES: Study measures included a self-administered questionnaire to assess the Rosenberg Self-Esteem Scale (SES), the 3 subscales of 36-question Short Form Health Survey (SF-36; Social Function, Role Physical, Role Emotional), Self-Stigma Scale and Patient Activation Measure (PAM-13).
  • In our previous qualitative study, we found that psychological and behavioural patterns of stigma varied according to patients' levels of illness-related self-esteem as well as attitudes towards social participation.
  • CONCLUSIONS: The psychological and behavioural pattern of group D was found to be associated with higher levels of self-stigma and poorer patient activation for self-care.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://www.bmj.com/company/products-services/rights-and-licensing/.
  • [Cites] Diabetes Educ. 2015 Feb;41(1):86-94 [25398722.001]
  • [Cites] Diabetes Educ. 2009 Mar-Apr;35(2):285-92 [19204101.001]
  • [Cites] Health Qual Life Outcomes. 2014 Dec 12;12:179 [25495723.001]
  • [Cites] J Psychosom Res. 2007 May;62(5):589-94 [17467414.001]
  • [Cites] J Clin Nurs. 2003 Jan;12(1):149-50 [12519263.001]
  • [Cites] Occup Med (Lond). 2015 Jan;65(1):67-71 [25342711.001]
  • [Cites] BMJ Open. 2013 Nov 18;3(11):e003384 [24247325.001]
  • [Cites] Patient Educ Couns. 2016 Jul;99(7):1233-1239 [27873575.001]
  • [Cites] Res Nurs Health. 2007 Oct;30(5):508-17 [17893932.001]
  • [Cites] J Diabetes Investig. 2014 Mar 23;5(2):162-9 [24843756.001]
  • [Cites] J Ambul Care Manage. 2005 Jul-Sep;28(3):262-73 [15968219.001]
  • [Cites] Eur Psychiatry. 2005 Dec;20(8):529-39 [16171984.001]
  • [Cites] Health Serv Res. 2004 Aug;39(4 Pt 1):1005-26 [15230939.001]
  • [Cites] Health Commun. 2016 Jul;31(7):806-14 [26605947.001]
  • [Cites] Psychiatr Serv. 2001 Dec;52(12):1621-6 [11726753.001]
  • [Cites] Health Serv Res. 2007 Aug;42(4):1443-63 [17610432.001]
  • [Cites] Diabet Med. 2015 Jan;32(1):120-8 [25081181.001]
  • [Cites] Am J Orthopsychiatry. 2010 Apr;80(2):267-81 [20553520.001]
  • [Cites] Health Serv Res. 2005 Dec;40(6 Pt 1):1918-30 [16336556.001]
  • [Cites] Patient. 2013;6(1):1-10 [23322536.001]
  • [Cites] BMJ Open. 2012 Nov 14;2(6):null [23151392.001]
  • [Cites] BMJ Open Diabetes Res Care. 2016 Jan 05;4(1):e000156 [26835138.001]
  • (PMID = 28360238.001).
  • [ISSN] 2044-6055
  • [Journal-full-title] BMJ open
  • [ISO-abbreviation] BMJ Open
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Keywords] NOTNLM ; Diabetes education / Psychosocial, behavioral medicine / Stigma
  •  go-up   go-down


98. Stacchiotti S, Gronchi A, Fossati P, Akiyama T, Alapetite C, Baumann M, Blay JY, Bolle S, Boriani S, Bruzzi P, Capanna R, Caraceni A, Casadei R, Colia V, Debus J, Delaney T, Desai A, Dileo P, Dijkstra S, Doglietto F, Flanagan A, Froelich S, Gardner PA, Gelderblom H, Gokaslan ZL, Haas R, Heery C, Hindi N, Hohenberger P, Hornicek F, Imai R, Jeys L, Jones RL, Kasper B, Kawai A, Krengli M, Leithner A, Logowska I, Martin Broto J, Mazzatenta D, Morosi C, Nicolai P, Norum OJ, Patel S, Penel N, Picci P, Pilotti S, Radaelli S, Ricchini F, Rutkowski P, Scheipl S, Sen C, Tamborini E, Thornton KA, Timmermann B, Torri V, Tunn PU, Uhl M, Yamada Y, Weber DC, Vanel D, Varga PP, Vleggeert-Lankamp C, Casali PG, Sommer J: Best practices for the Management of Local-regional Recurrent Chordoma. A Position Paper by the Chordoma Global Consensus Group. Ann Oncol; 2017 Feb 09;

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Until recently, there was no consensus among experts regarding appropriate clinical management of chordoma, resulting in inconsistent care and suboptimal outcomes for many patients.
  • To address this shortcoming, the European Society of Medical Oncology (ESMO) and the Chordoma Foundation, the global chordoma patient advocacy group, convened a multi-disciplinary group of chordoma specialists to define by consensus evidence-based best practices for the optimal approach to chordoma.
  • This meeting involved over 60 specialists from Europe, the US and Japan with expertise in treatment of patients with chordoma.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] © The Author 2017. Published by Oxford University Press on behalf of the European Society for Medical Oncology. All rights reserved. For permissions, please email: journals.permissions@oup.com.
  • (PMID = 28184416.001).
  • [ISSN] 1569-8041
  • [Journal-full-title] Annals of oncology : official journal of the European Society for Medical Oncology
  • [ISO-abbreviation] Ann. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Keywords] NOTNLM ; bone sarcoma / chemotherapy / chordoma / palliative treatment / radiotherapy / relapse / sarcoma / surgery / survival
  •  go-up   go-down


99. Buntrock C, Berking M, Smit F, Lehr D, Nobis S, Riper H, Cuijpers P, Ebert D: Preventing Depression in Adults With Subthreshold Depression: Health-Economic Evaluation Alongside a Pragmatic Randomized Controlled Trial of a Web-Based Intervention. J Med Internet Res; 2017 Jan 04;19(1):e5

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Participants were randomized to a Web-based guided self-help intervention (ie, cognitive-behavioral therapy and problem-solving therapy assisted by supervised graduate students or health care professionals) in addition to usual care or to usual care supplemented with Web-based psycho-education (enhanced usual care).
  • Costs measured from a societal and health care perspective were related to DFYs and quality-adjusted life years (QALYs).
  • Taking the health care perspective and assuming a willingness-to-pay of €20,000 (£17,000), the intervention's likelihood of being cost-effective was 99% for gaining a DFY and 64% or 99% for gaining an EQ-5D or a SF-6D QALY.
  • Offering the intervention has an acceptable likelihood of being more cost-effective than enhanced usual care and could therefore reach community members on a wider scale.
  • TRIAL REGISTRATION: German Clinical Trials Register: DRKS00004709; http://www.drks.de/DRKS00004709 (Archived by WebCite at http://www.webcitation.org/6kAZVUxy9).

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Lancet. 2012 Dec 15;380(9859):2163-96 [23245607.001]
  • [Cites] J Affect Disord. 2015 May 1;176:9-17 [25682378.001]
  • [Cites] Health Policy. 1996 Jul;37(1):53-72 [10158943.001]
  • [Cites] Value Health. 2013 Mar-Apr;16(2):231-50 [23538175.001]
  • [Cites] Int J Epidemiol. 2014 Apr;43(2):318-29 [24760873.001]
  • [Cites] Am J Geriatr Psychiatry. 2014 Mar;22(3):253-62 [23759290.001]
  • [Cites] Epidemiol Psychiatr Sci. 2015 Jun;24(3):210-26 [25720357.001]
  • [Cites] Med J Aust. 2002 Oct 7;177 Suppl:S122-5 [12358571.001]
  • [Cites] J Affect Disord. 2007 Feb;98(1-2):29-43 [16952399.001]
  • [Cites] J Psychosom Res. 2003 Oct;55(4):385-7 [14507551.001]
  • [Cites] Br J Psychiatry. 2010 Apr;196(4):319-25 [20357310.001]
  • [Cites] J Clin Epidemiol. 1998 Nov;51(11):1171-8 [9817135.001]
  • [Cites] Health Econ. 2004 Sep;13(9):873-84 [15362179.001]
  • [Cites] J Affect Disord. 2015 Mar 15;174:400-10 [25553400.001]
  • [Cites] Gesundheitswesen. 2005 Oct;67(10):736-46 [16235143.001]
  • [Cites] Patient Prefer Adherence. 2008 Feb 02;2:97-105 [19920949.001]
  • [Cites] Br J Psychiatry. 2004 May;184:393-403 [15123502.001]
  • [Cites] J Med Internet Res. 2004 Dec 22;6(4):e46 [15631970.001]
  • [Cites] Int J Technol Assess Health Care. 2005 Summer;21(3):298-304 [16110708.001]
  • [Cites] Med Care. 2004 Sep;42(9):851-9 [15319610.001]
  • [Cites] BMC Health Serv Res. 2013 Jun 15;13:217 [23768141.001]
  • [Cites] Med Care. 1997 Nov;35(11):1095-108 [9366889.001]
  • [Cites] Br J Psychiatry. 2010 Apr;196(4):310-8 [20357309.001]
  • [Cites] Expert Rev Pharmacoecon Outcomes Res. 2013 Apr;13(2):237-42 [23570434.001]
  • [Cites] Value Health. 2015 Mar;18(2):161-72 [25773551.001]
  • [Cites] Psychol Med. 2013 Mar;43(3):471-81 [22831756.001]
  • [Cites] PLoS One. 2011;6(8):e22884 [21853053.001]
  • [Cites] Health Econ. 1994 Sep-Oct;3(5):309-19 [7827647.001]
  • [Cites] Br J Psychiatry. 2006 Apr;188:330-6 [16582059.001]
  • [Cites] Gesundheitswesen. 2015 Jan;77(1):53-61 [25025287.001]
  • [Cites] JAMA. 2016 May 3;315(17):1854-63 [27139058.001]
  • [Cites] J Med Internet Res. 2011 Dec 31;13(4):e126 [22209829.001]
  • [Cites] J Clin Psychiatry. 1991 May;52 Suppl:28-34 [1903134.001]
  • [Cites] Psychol Med. 2007 Dec;37(12):1797-806 [17466110.001]
  • [Cites] Int Rev Psychiatry. 2007 Dec;19(6):655-70 [18092243.001]
  • [Cites] Aust N Z J Psychiatry. 2011 Jan;45(1):36-44 [21073354.001]
  • [Cites] BMC Psychiatry. 2014 Jan 31;14:25 [24485283.001]
  • [Cites] Br J Psychiatry. 2004 Jun;184:526-33 [15172947.001]
  • [Cites] J Med Internet Res. 2010 Dec 19;12(5):e53 [21169166.001]
  • [Cites] Psychol Med. 2016 Oct;46(13):2679-93 [27649340.001]
  • [Cites] Health Econ. 2006 Nov;15(11):1229-36 [16625671.001]
  • (PMID = 28052841.001).
  • [ISSN] 1438-8871
  • [Journal-full-title] Journal of medical Internet research
  • [ISO-abbreviation] J. Med. Internet Res.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Canada
  • [Keywords] NOTNLM ; Internet / cost effectiveness / early intervention / major depressive disorders / prevention
  •  go-up   go-down


100. Mataix-Cols D, Fernández de la Cruz L, Monzani B, Rosenfield D, Andersson E, Pérez-Vigil A, Frumento P, de Kleine RA, Difede J, Dunlop BW, Farrell LJ, Geller D, Gerardi M, Guastella AJ, Hofmann SG, Hendriks GJ, Kushner MG, Lee FS, Lenze EJ, Levinson CA, McConnell H, Otto MW, Plag J, Pollack MH, Ressler KJ, Rodebaugh TL, Rothbaum BO, Scheeringa MS, Siewert-Siegmund A, Smits JAJ, Storch EA, Ströhle A, Tart CD, Tolin DF, van Minnen A, Waters AM, Weems CF, Wilhelm S, Wyka K, Davis M, Rück C, and the DCS Anxiety Consortium, Altemus M, Anderson P, Cukor J, Finck C, Geffken GR, Golfels F, Goodman WK, Gutner C, Heyman I, Jovanovic T, Lewin AB, McNamara JP, Murphy TK, Norrholm S, Thuras P: D-Cycloserine Augmentation of Exposure-Based Cognitive Behavior Therapy for Anxiety, Obsessive-Compulsive, and Posttraumatic Stress Disorders: A Systematic Review and Meta-analysis of Individual Participant Data. JAMA Psychiatry; 2017 May 01;74(5):501-510

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • None of the prespecified patient-level or study-level moderators was associated with outcomes.
  • Further research is needed to identify patient and/or therapy characteristics associated with DCS response.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 28122091.001).
  • [ISSN] 2168-6238
  • [Journal-full-title] JAMA psychiatry
  • [ISO-abbreviation] JAMA Psychiatry
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down






Advertisement